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Parkinson’s Disease (PD), one of the most common human neurodegenerative 
disorders in central nervous system, has been actively studied over the last decade. 
Several gene variants, including PARK2, LRRK2, and SNCA, have been identified and 
implicated in the degeneration of midbrain dopaminergic (mDA) neurons. However, 
the molecular details of the progression of PD associated with distinct genetic 
variations have not been sufficiently clarified. Recent studies of human diseases, such 
as PD, have taken advantage of patient-derived induced pluripotent stem cells (iPSCs) 
to recapitulate aspects of the disease in vitro. These approaches to disease modeling 
can provide insights to the disease process and reveal molecular changes associated 
with disease progression. 
In this study, multiple PD iPS cell lines carrying distinct genetic variants were 
employed to identify common molecular dysregulation underlying PD progression. 
By using optimized differentiation protocols, patient-specific mDA neurons were 
successfully generated and subjected to phenotypic assays. A variety of 
methodologies in mDA neurons were developed in vitro to model key aspects of PD, 
including ageing progression and environmental factors. Defective neurite extensions 
and enhanced apoptosis commitment were illustrated as critical degenerative signs of 
PD mDA neurons. In addition, cell responses to neurotoxic substances were also 
evaluated, highlighting the overall vulnerability of PD mDA neurons towards various 
kinds of cell stress, relative to WT mDA neurons.  
 x 
Subsequently, gene expression profiling studies were performed by microarray and 
RNA-seq to identify transcripts that were consistently differentially expressed among 
the different PD cell lines, demonstrating unifying dysregulated signaling networks 
involved in ubiquitin-proteasome system and neuronal activity. Further functional 
study of candidate transcripts unraveled novel genes involved in a dysregulated 
alternative splicing network in PD mDA neurons, suggesting an important role of 
post-transcriptional regulation in PD pathology. Thus, transcriptome-wide 
identification of dynamic splicing changes in PD mDA neurons was explored. The 
splicing alterations were found enriched in genes involved in mitochondrial functions 
and neuronal activity, thus suggesting a molecular basis of oxidative stress 
vulnerability and affected neuronal activity observed in phenotypic characterization.  
Last but not the least, gene expression profiling that focus on LRRK2 G2019S 
mutation was also investigated by microarray, revealing similar dysregulation pattern 
with previous study. In addition, the major findings provide supportive information 
for the previous RNA-seq results, successfully demonstrating a concordance of 
downstream mediators across various disease mutation backgrounds. 
Overall, the results generated from transcriptome profiling provide more insights into 
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Chapter I – Introduction  
1.1 Epidemiology and clinical features of Parkinson’s disease 
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in 
the central nervous system, affecting 1% of the population over the age of 65 (Tanner, 
1992). Based on prevalence statistics, it was estimated that in 2005 the number of 
individuals aged over 50 with PD was around 4-5 million. By 2030, this number 
would be more than double to between 8 and 9 million (Dorsey et al., 2007). And this 
number is expected to go up in a rapidly aging population. As the number of patients 
with PD increases, identifying these individuals and delivering cost-effective medical 
care will be a huge public health challenge. 
The most obvious and well-known clinical features of PD include the slowness in 
initiation of voluntary movements, resting tremor and muscle stiffness, which 
progress slowly as the disease manifests (Garcia Ruiz et al., 2011). And these 
symptoms could vary substantially from one person to another, depending on the 
disease onset and progression stages. With these motor symptoms, patients with PD 
eventually suffer from various difficulties in daily life. Apart from motor symptoms, 
during the course of disease, most of the PD patients experience non-motor symptoms, 
which include depression, dementia, hallucinations, sensory dysfunction and sleep 
disorders, which also contribute to their impaired quality of life (Chaudhuri et al., 
2006; Park and Stacy, 2009). The current therapies, such as dopamine replacement 
and deep brain stimulation, are able to delay the development of more pronounced 
clinical features, however, still fail to stop or convert the neurodegenerative process. 
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And the potential therapeutic targets for PD are limited due to the inadequate 
knowledge of the underlying mechanisms of PD. Hence, there is an urgent need to 
understand the early molecular modulators in PD progression. 
1.2 Current understanding of PD pathology 
Based on the postmortem studies and functional magnetic resonance imaging (fMRI), 
it is known that, at cellular level, PD is caused by the progressive loss of 
dopaminergic (DA) neurons in the substantia nigra, a specific region in human 
midbrain. Midbrain DA neurons (mDA neurons) primarily project to the striatum and 
release neurotransmitter dopamine, exhibiting either excitatory or inhibitory roles in 
postsynaptic striatal neurons. The chronic lack of mDA neurons with PD results in the 
deficiency of dopamine in striatum and the denervation of striatum neurons. 
Subsequently, the striatal denervation gives rise to increased inhibition onto the 
glutamatergic excitation of the motor cortex, causing movement-related disorders and 
cognitive problems (Figure 1.1) (Shulman et al., 2011).  
It has become increasingly recognized that PD is a complex and multifactorial age-
related disease. It results from a mixture of genetic predisposition and environmental 
factors (Figure 1.2). Although most PD cases appear to be sporadic (non-inherited), 
there are a dozen genes identified associated with familial PD cases, which contribute 
to the genetic basis of PD pathology (Table 1.1). To summarize the discoveries so far, 
mutations in SNCA, UCHL1 and LRRK2 genes are inherited in an autosomal 
dominant pattern (Paisan-Ruiz et al., 2004; Polymeropoulos, 1997; Zimprich et al., 
2004), resulting in late-onset PD phenotype with slow progression. While mutations 
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in PARK2, DJ-1 and PINK1 genes are inherited in an autosomal recessive pattern 
(Bonifati et al., 2003; Kitada et al., 1998; Valente et al., 2004), contributing to early-
onset forms of familial PD. The function and relative genetic mutations would be 
further discussed in the next section. Besides these mutations with high penetrance 
identified in familial cases, researchers also highlighted a group of genetic variants as 
PD risk factors in sporadic cases, including GBA, MAPT, BST1, PARK16, GAK, and 
HLA. 
Figure 1.1: Adapted from (Schiff, 2010; Shulman et al., 2011) Model of proposed 
pathophysiology of PD in basal ganglia-thalamocortical circuit under normal 
(left) and PD conditions (right). In PD, dopaminergic neurons in the the substantia 
nigra pars compacta (SNc) degenerate, resulting in increased basal ganglia inhibitory 
output from globus pallidus internus (GPi) towards thalamus (THA), which 
subsequently induces decreased excitatory input to the cortical neurons. 
(See Appendix for documentation of permission to republish this material) 
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Figure 1.2: (Adapted from (Shulman et al., 2011)) Multiple disease risks interact 
to manifest PD. A model summarizing the relative impacts of different PD risk 
factors including ageing, highly penetrant Mendelian alleles that cause familial cases, 
low-penetrant genetic variants and environmental factors. 
(See Appendix for documentation of permission to republish this material) 
 
 
Table 1.1 (Adapted from (Schulte and Gasser, 2011)) Summary of main genes 
and loci underlying familial Parkinson’s disease  
Locus Gene Chromosomal 
location 










PARK2 PARK2 6q25–q27 AR EOPD E3 ubiquitin 
ligase 
PARK5 UCHL1 4p14 AD LOPD Proteosomal 
processing 
PARK6 PINK1 1p36 AR EOPD Mitochondrial 
kinase 
PARK7 DJ1 1p36 AR EOPD Oxidative 
stress 
response PARK8 LRRK2 12q12 AD + risk LOPD Cytosolic 
kinase 
AD, autosomal dominant; AR, autosomal recessive; EOPD, early-onset Parkinson’s 
disease; LOPD, late-onset Parkinson’s disease. 
(See Appendix for documentation of permission to republish this material) !
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Although there are quite a lot genetic mutation identified associated with PD based on 
the genome wide association studies (GWAS), the mechanisms of PD progression 
with these mutations are not sufficiently clarified. It is noticeable that both familial 
and sporadic PD present similar clinical features (Figure 1.3), indicating a unifying 
mechanism as downstream of these genetic backgrounds. 
 
Figure 1.3: Phenotypic commonalities in familial and sporadic PD (Corti et al., 
2011). Patients with PD from both familial and sporadic cases show a similar 
spectrum of phenotypes at cellular level, including neuronal degeneration, Lewy body 
pathology, defects in mitochondria and autophagy, and altered glutathione 
homeostasis. Mutated genes in familial PD is highlighted by SNCA and LRRK2, 
inherited in a dominant way; PARK2, PINK1, DJ1 and ATP13A2, inherited in a 
recessive way. 




So far, a number of animal models have been developed to understand the pathology 
of PD, elucidate the genetic pathways underlying PD and identify new 
pharmacological therapeutics.  For mouse models, in particular, they can be divided 
into two main categories. One group that utilizes exposure to exogenous 
environmental or synthetic neurotoxins creates strong phenotype in substantia nigra. 
The neurotoxins are able to produce an oxidative stress that causes cell death in mDA 
populations, reflecting the PD clinical features. A detailed introduction of the 
neurotoxins will be discussed in section 6.1.2. Some of the classic neurotoxins used in 
mouse model have been recognized as environmental factors for human PD 
pathogenesis. However, the drawback of the toxin mouse models is that most of them 
resemble PD at late stage, presenting striking cell death instead of progressive 
degeneration. Such acute course of neuronal death is difficult for researchers to 
monitor. Moreover, the robust destruction of mDA neurons induced by neurotoxins 
was dosage-dependent, resulting in uncertainty of cytotoxicity and downstream 
cellular response triggered at different neurotoxic doses. The other group of mouse 
model of PD adopts the in vivo expression of PD-related genetic mutations. However, 
such genetic models are less effective at killing mDA neurons compared to 
neurotoxin model. They fail to displays any significant form of mDA neuron loss or 
any type of behavioral phenotypes. Furthermore, such genetic-based mouse model has 
limitations in their power to study sporadic cases of PD with low-penetrance 
mutations or unidentified genetic risks. Most importantly, both groups of mouse 
model fail to take ageing into account as a strong risk factor for PD progression.  
Besides mouse models, the use of simple model organisms, such as fruit fly 
(Drosophila melanogaster) and zebra fish (Danio rerio), have been described, 
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recapitulating partial aspects of PD phenotypes. Nevertheless, the mutations carried in 
such simple organisms do not precisely match the mutated forms in the respective 
human genes. And the locomotive behavioral defects shared little similarity of the 
human clinical features. Unfortunately, these models have not led to any successful 
clinical trials due to species-specific differences. Hence, a human cell-based model is 
urgently needed for mechanistic studies of PD in vitro. 
1.3 iPSC-based modeling of various neurodegenerative diseases 
In 2007, human induced pluripotent stem cells (hiPSCs) were generated from skin 
fibroblasts by forced expression of a defined combination of transcriptional factors, 
Oct4, Sox2, c-Myc, and Klf4 (Takahashi et al., 2007; Yu et al., 2007). After 
reprogramming, differentiated somatic cells regained the self-renewing ground state. 
This pioneer technology enabled researchers to obtain patient specific pluripotent 
stem cells that carry respective disease genetic backgrounds for human cell-based 
disease modeling. The unique advantage that iPSCs could preserve the genetic 
integrity of the donor individual provides us unlimited access to disease-related 
genetic background for pathology studies. Patient-derived iPSCs could be expanded 
in culture and directed to differentiate into specialized cell types of interest. 
Compared to animal models, human iPSCs provide an alternative approach to 
produce more clinically relevant platforms for interrogating disease pathology. 
Moreover, the high accessibility for genetic manipulation of iPSCs has enabled the 
researchers to broaden the empirical scope of disease modeling in vitro. The recent 
advances in neural differentiation methods have inspired the studies of human iPSC 
modeling of neurological diseases, such as Alzheimer's disease (AD) (Israel et al., 
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2012; Qiang et al., 2011; Yagi et al., 2011), Parkinson's disease (PD) (Byers et al., 
2011; Cooper et al., 2012; Devine et al., 2011; Imaizumi et al., 2012; Liu et al., 2012; 
Nguyen et al., 2011; Reinhardt et al., 2013; Sanchez-Danes et al., 2012; Seibler et al., 
2011; Soldner et al., 2009), amyotrophic lateral sclerosis (ALS) (Dimos et al., 2008) 
and spinal muscular atrophy (SMA) (Ebert et al., 2009). A summary of iPSC 
modeling in PD will be discussed in more detail in the next section. 
1.4 iPSC-based modeling of PD 
The advent of human induced pluripotent stem cells (iPSCs) has facilitated the use of 
human cells as a more related model for mechanistic and pathogenesis studies 
compared to animal model. Furthermore, patient-derived iPSCs carrying defined 
phenotypes and genotypes can be employed to produce specific types of terminally 
differentiated cells including neuroectodermal lineages. In recent years, a number of 
PD patients-specific iPSC lines have been generated from patients’ somatic cells and 
reported (Byers et al., 2011; Cooper et al., 2012; Devine et al., 2011; Imaizumi et al., 
2012; Liu et al., 2012; Nguyen et al., 2011; Reinhardt et al., 2013; Sanchez-Danes et 
al., 2012; Seibler et al., 2011). Interestingly, these PD iPSC-derived neurons were 
able to recapitulate  a certain aspects of PD phenotype in vitro, including increasing 
sensitivity to oxidative stress (Byers et al., 2011; Nguyen et al., 2011) and 
mitochondrial deficits (Cooper et al., 2012).  
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1.4.1 iPSC models of dominant familial PD  
Recent developments in genome-wide association studies (GWAS) have identified a 
few genetic mutations responsible for familial forms of PD. Mutations in the leucine-
rich kinase 2 (LRRK2) are widely recognized as important factors for both late-onset 
autosomal-dominant and sporadic PD (Brice, 2005; Hernandez et al., 2005). LRRK2 
is a large multi-domain protein, which displays GTPase and kinase activity. To date, 
there have been around 80 genetic variants on LRRK2 identified with potential 
pathogenic mechanism (Nuytemans et al., 2010). However, only a few missense 
variants were proven to be PD-related dominant mutations (Figure 1.4). Among all 
the LRRK2 mutations, the LRRK2 6055G>A transition (G2019S) accounts for 1-8% 
of sporadic cases and 3-10% of familial cases (Nichols et al., 2005), and is especially 
related with autosomal dominant Parkinsonism across European populations 
(Kachergus et al., 2005). Thus, the high penetrance of the LRRK2 G2019S mutation 
suggests a substantial contribution of genetics to PD pathology.  
The recent landmark discovery of this mutant, using iPSC as a model, showed that the 
mDA neurons derived from G2019S-iPSCs exhibited increased expression of key 
oxidative stress-response genes such as HSPB1, NOX1, and MAOB along with 
accumulation of α-synuclein protein (Nguyen et al., 2011). Furthermore, the 
researchers also demonstrated that G2019S-iPSC-derived mDA neurons exhibited 
increased susceptibility to apoptosis in response to oxidative stress induced by 
hydrogen peroxide, 6-hydroxydopamine (6-OHDA) and MG-132. The comprehensive 
experimental design from this report described the first neurotoxicity assay in PD-
iPSC model. In addition, the phenotypic characterization involved in oxidative stress 
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pathways is a major milestone for further PD modeling with other genetic mutations. 
However, this pioneer study failed to address the question of ageing pathology 
underlying the PD progression. mDA neurons differentiated for 35-50 days in this 
study were highly unlikely to carry the age-related regressive changes as the patient 
neurons in vivo. Hence, researchers intended to modulate the differentiated neural 
cells to resemble certain aspects of ageing and to test whether the cells derived from 
PD iPSCs could elicit age-related disease features. 
Recently, a progressive degenerative phenotype in neural progenitor cells (NPCs) was 
showed in LRRK2 G2019S-iPSC model (Liu et al., 2012). Aberrant nuclear 
architecture was identified in later passages and started to manifest by passage 14. 
Interestingly, the later passage NPCs showed deficiency in proliferation and the 
ability to be differentiated into mature neurons. This finding indicated that passaging 
iPSC-derived NPCs in vitro resembled the ageing process at cellular level. And the 
nuclear defects involved in PD iPSC-derived NPCs manifested along with the ageing 
progression. It is the first study demonstrating that PD iPSCs could develop in vitro 
progressive phenotype. However, whether this study managed to capture the disease 
phenotype is still under debate, since the in vivo cell degeneration only happens in 
mDA neurons instead of NPCs. Moreover, the lack of transcriptome study of 
prolonged passaging raises the doubt on whether the study reproduced the ageing 
pathology as it claimed. In addition, both studies lack a clear causative PD pathogenic 
pathway underlying the phenotypes described. 
Subsequently, apart from phenotypic characterization, mechanism studies were 
further explored using gene-corrected isogenic cultures (Reinhardt et al., 2013). 
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Similar to the previous study in neurotoxicity assay, the mDA neurons derived from 
LRRK2 G2019S-iPSC showed increased sensitivity to stress in response to 6-OHDA 
relative to the isogenic control cell lines. Decreased neurite outgrowth was also 
observed compared with isogenic controls. Most importantly, global gene expression 
profiling of the mDA neurons from LRRK2 G2019S-iPSC and isogenic controls were 
examined by microarray, from which 6 genes were isolated as significantly and 
consistently dysregulated by LRRK2 G2019S. Functional annotation of these genes 
was also performed by knockdown with the use of small interfering RNA, some of 
which gave rise to phenotypic rescue. Another valuable contribution of this study was 
that it demonstrated the linkage of enhanced oxidative sensitivity and activation of 
ERK1/2 (ERK) in the mDA neurons from LRRK2 G2019S-iPSC. Based on the results 
of this study, the PD iPSC models were further validated and examined by functional 
analysis. It is also highly commendable for providing important information on 
isogenic controls and mechanism studies. 
Apart from neuronal degeneration another significant phenotype associated with PD 
is protein aggregation in neurons, described as Lewy bodies (Wakabayashi et al., 
1990). The intracellular protein inclusion is mostly composed of α-synuclein and 
ubiquitin, contributing to the etiology of PD and Alzheimer's disease (AD). α-
synuclein, encoded by SNCA, is a small cytoplasmic protein, which is highly enriched 
in presynaptic terminals. Previously, three rare point mutations were identified, 
contributing to Lewy body dementia in PD (Kruger et al., 1998; Zarranz et al., 2004). 
And duplication and triplication of SNCA locus are prevalently considered to 
influence the manifestations of early-onset PD patients. The overdose of mRNA and 
protein level of α-synuclein directly correlates with the clinical features in PD (Ibáñez 
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et al., 2004; Singleton et al., 2003). The recent efforts in PD iPSC modeling also shed 
light on the study of this particular gene. Interestingly, recent studies in SNCA 
triplication iPSC model demonstrated similar increased sensitivity to oxidative stress 
as the findings in LRRK2 mutant published by the same group, which implied that the 
enhanced stress vulnerability could be a unifying feature for familial PD iPSC model 
(Byers et al., 2011; Nguyen et al., 2011). In addition to phenotypic characterization by 
apoptosis, the expression level of oxidative stress and protein aggregation-related 
genes were also evaluated. It was showed that the elevated expression of stress-related 
genes correlated with the accumulation of α-synuclein caused by SNCA triplication. 
Although the data presented in this paper enabled us to have a better understanding of 
the dominant contribution of SNCA triplication in PD progression, the mechanism of 
pathogenic pathway underlying the enhanced genomic dosage is still not clarified. 
1.4.2 iPSC models of recessive familial PD  
Compared to the high penetrance of LRRK2 mutation and SNCA triplication, PARK2, 
phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) mutation 
and DJ-1 are more related to autosomal recessive early-onset PD(Abbas et al., 1999; 
Bonifati et al., 2005; Kitada et al., 1998; Klein et al., 2005; Pankratz et al., 2006). 
Interestingly, recent studies demonstrated that both PARK2 and PINK1 were involved 
in mitochondrial function. PARK2, as an E3 ubiquitin ligase, was translocated to 
impaired mitochondria in a PINK1-dependent manner to facilitate mitochondrial 
autophagy (Narendra et al., 2008). Therefore, the potential synergistic effects by 
PARK2 and PINK1 underlying the pathogenesis of Parkinson's disease stimulated 
great interest in further examining it in iPSC models. In iPSC-derived mDA neurons 
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with homozygous PINK1 nonsense mutation (p.Q456X), stress-induced mitochondrial 
translocation of PARK2 was disturbed due to the mutation, resulting in increased 
mitochondrial copy number (Seibler et al., 2011). This study is a significant 
contribution to the iPSC models of recessively inherited PD. However, further 
explanations are needed to verify whether there is deficiency in mitochondrial 
function due to PINK1 mutation. Another iPSC model focused on PARK2 deletion 
mutations was reported recently, intriguingly, and it demonstrated mitochondrial 
dysfunction in iPSC-derived neurons with increased oxidative stress accompanied by 
activation of the Nrf2 pathway (Imaizumi et al., 2012). Moreover, the researchers also 
combined the study of postmortem tissue with the iPSC model to illustrate the 
potential correlation between Lewy body formations in vivo with the accumulation of 
α-synuclein in PARK2 iPSC-derived neurons. However, another study with similar 
PARK2 iPSC model showed contradictive results. In this report, loss-of-function 
mutations of PARK2 significantly disrupt the spatial and temporal precision of 
dopaminergic neurotransmission by increasing spontaneous DA release and 
decreasing DA uptake, resulting in increased dopamine-induced oxidative stress 
(Jiang et al., 2012). Nonetheless, mitochondrial defects and α-synuclein 
accumulations were not identified, and this gave rise to controversial conflicts with 
previous studies, indicating that PARK2 dysfunction and protein aggregation might 
not be directly pathologically relevant.  
1.4.3 iPSC models of sporadic PD 
So far, it is widely recognized that around 90% of PD cases are sporadic with no 
family history. The generation of iPSC lines from sporadic patients with unknown 
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genetic causes offers distinct advantages in disease modeling compared to classic 
animal models. Although derivation of iPSC lines from idiopathic PD (ID-PD) 
patients without identified gene mutations has been reported, it is still not known 
whether these ID-PD iPSCs give rise to mDA neurons that exhibit native phenotypes 
related to PD in vitro (Soldner et al., 2009). To date, there is only one report on 
phenotypic characterization of sporadic iPSC models (Sanchez-Danes et al., 2012). 
Seven sporadic patients were included in the examination. After 75 days of long-term 
culture of mDA neurons directly derived from iPSCs, increased apoptosis, decreased 
number of neuritis and impaired autophagy were identified in ID-PD iPSC-derived 
neuron cultures. The experimental design from this paper provided an invaluable tool 
for further functional analysis of candidate targets or therapeutic strategy. However, 
the lack of mechanism study from this paper leaves us with the question of whether 
there is unifying pathway underlying both sporadic and familial PD pathogenesis. 
From the above review, it can be seen that the recent development of patient specific 
iPSCs has provided us with a powerful in vitro tool for PD modeling. The current PD 
iPSC models from both familial and sporadic cases have managed to capture PD 
pathological features, including increasing sensitivity to oxidative stress (Byers et al., 
2011; Nguyen et al., 2011) and mitochondrial deficits (Cooper et al., 2012). But for 
the unifying molecular mechanism, it remains unclear. On the other hand, most of the 
phenotypic characterizations were induced by neurotoxin. Therefore, it is also 
intriguing to know whether there is dysregulated cellular process in terms of neuronal 
function underlying basal condition, and whether the dysregulation could be presented 
at global transcriptome level. Nevertheless, most of the studies described in the 
literature review recruited only one monogenic form of iPSC line, which is not 
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sufficient to study a multifactorial disease such as PD. It is also debatable that 
whether the mDA neurons from these studies resemble the defected neurons in vivo 
regarding to the ageing progression. In addition, the existing studies of PD models are 
still subject to phenotypic characterization. Further studies on the unifying pathogenic 
mechanisms are imperative. Therefore, in this thesis, we reported a combination of 
iPSC modeling with comprehensive transcriptome analysis by RNA-sequencing and 
microarray to identify the novel transcripts under basal condition, which could 









Chapter II – Aims and Objectives  
The main discoveries that have shaped our understanding of PD are the previous 
identifications of genetic variants and environmental factors that contribute to PD 
pathology. However, the molecular mechanisms underlying such causes are not fully 
clarified. Recent advances in PD disease modeling have been made in terms of 
recapitulating disease-related phenotypes by recruiting patient-specific iPSCs. 
Nevertheless, these studies in PD iPSC-based models have yet to unveil the relevant 
downstream pathways that contribute to PD pathogenic mechanisms. 
In this thesis, I assess the disease-related phenotypes in mDA neurons derived from 
patient-specific iPSCs with various PD genetic backgrounds by incorporating the 
serial passaging methodology to recapitulate age-related pathology. I hypothesize that 
the effect of prolonged passaging will induce ageing-like transcriptome changes in 
both NPCs and the NPCs-derived neurons. Moreover, the “aged” mDA neuron 
cultures could recapitulate PD-relative phenotypes (Chapter IV, V and VI). The 
different genetic mutations identified from familial PD cases contribute to similar 
spectrum of clinical features and selective mDA neuronal degeneration, thus 
implicating concordant downstream signaling pathways across divergent genetic 
predispositions. Based on this, I further hypothesize that the recruitment of cell lines 
from various PD genetic backgrounds could enable us to detect the underlying early 
molecular regulators (Chapter VII and VIII). To test the overall hypotheses, an 
integrated approach utilizing disease modeling and transcriptome profiling is taken to 
advance our understanding of PD progression and the early molecular features 
involved. 
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The specific aims of the thesis project are: 
• To establish a model of PD pathogenesis by generation of PD iPSC-derived 
mDA neurons from multiple patients including both familial and sporadic cases 
(Chapter IV); 
o mDA!neuron!differentiation!protocol!will!be!adapted!to!both!WT!and!PD!iPSC!lines!with!necessary!optimization. 
o The!yield!of!mDA!neurons!in!differentiated!cultures!will!be!evaluated!based! on! the! marker! expression! and! functional! characteristics!including!dopamine!release!and!electrophysiological!activity. 
• To inaugurate a methodology for recapitulating ageing pathology of PD to 
accelerate disease progression in iPSC-based model (Chapter V); 
o Optimized! prolonged! passaging! protocol! will! be! performed! in! iPSC?derived!NPCs!for!ageing!modeling. 
o Transcriptome! analysis!will! be! performed! to! evaluate! the! passaging!effect!towards!the!NPCs. 
o Phenotypic!readouts! in! late?passage!NPCs! towards!cell! stress!will!be!compared!between!PD!versus!WT!to!evaluate!the!different!responses!of!NPCs!due!to!passaging!effects. 
• To characterize the progressive PD-relative phenotypes in differentiated 
cultures (Chapter VI); 
o Transcriptome! comparison! will! be! performed! in! early! and! late?passage! NPC?derived! neurons! to! evaluate! the! ageing?related!transcriptome!changes!that!correspond!to!passaging effect in NPCs. 
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o Such!transcriptome!changes!will!be!compared!with!the!human!ageing!brain! dataset! generated! in# vivo# to! evaluate! the! ageing?related! gene!expression!changes!and!the!validity!of!the!ageing!modeling!in#vitro. 
o Phenotypic! characterization! will! be! conducted! in! late?passage! NPC?derived! neurons! to! evaluate! the! PD?related! features! in! PD! cell! lines!versus!WT!cell! lines,! including!neurite! length!quantification,!prolong!culturing!and!neurotoxin!responses. 
• To identify by global transcriptome analysis dysregulated transcripts in PD 
mDA neurons that contribute to PD pathology (Chapter VII and VIII); 
o RNA! sequencing! and! microarray! will! be! conducted! in! WT! and! PD!iPSC?derived! mDA! neuron! cultures! to! detect! the! differential! gene!expression!and!the!corresponding!gene!ontology!clustering. 
o After! validation,! strong! candidate! genes! will! be! further! studied! to!evaluate!its!function!and!downstream!targets! in!PD!mDA!neurons!by!transcriptome!tool!and!gene!knockdown. 
o A!stringent!candidate!list!will!be!generated!for!the!further!screening!of!novel!disease?modifying!therapeutics!for!PD#in#vitro.! 
The recruitment of multiple PD iPSC lines from both dominantly and recessively 
inherited familial PD and sporadic PD enabled us to recapitulate a certain aspects of 
PD phenotypes in vitro. To date, it would be the first universal transcriptome analysis 
of PD iPSC models from different genetic backgrounds to uncover the abnormally 
regulated transcripts, serving as an innovated data resource for future work. 
Moreover, the further functional analysis of the candidate transcript contributes to a 
better understanding of the pathogenic mechanisms of PD. 
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Chapter III – Materials and Methods 
3.1 Feeder-free adaptation culture of human pluripotent stem cells 
Wild type iPSC lines GM23280 and GM23279, PD iPSC lines ND34391, ND35367, 
ND38477, ND40018, ND41181, ND41180, ND40600, ND40597, ND40599 and 
ND39896 were obtained from the Coriell Cell Repositories. Wild type iPSC line 
IR1.7 was a kind gift of Dr Irene Aksoy. All iPS cells initially were co-cultured on 
mouse embryonic fibroblast (MEF) feeder cell layers with medium consisting 
Dulbecco’s modified Eagle’s medium/ Ham’s F-12 medium (DMEM/F12) 
supplemented with 20% KnockOut Serum Replacement (KOSR), 2 mM L-glutamine, 
0.2 mM non-essential amino acids (NEAA), 0.5mg/mL Penicillin Streptomycin, 0.1 
mM 2-mercaptoethanol and recombinant human basic Fibroblast Growth Factor 
(bFGF), concentration of which was recommended by Coriell Cell Repositories (all 
from Gibco, Invitrogen). For feeder-free culture, cells were later switched to the 
chemically defined mTeSR medium (Stem Cell Technologies) on Matrigel-coated 
tissue culture plates. The cells were maintained at 37 °C with 5% CO2 in a humidified 
incubator. Confluent cultures were passaged using 1 mg/ml Dispase (Stem Cell 
Technologies) at a split ratio of 1:6 every 7 days. 
3.2 Expansion and mitotic inactivation of MEF cells 
MEF primary cells were plated on a gelatin-coated 150 cm² cell culture flask (BD 
Falcon™), and expanded in MEF medium containing Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 20% heat inactivated fetal bovine serum (HI-
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FBS), 0.5mg/mL Penicillin Streptomycin and 2 mM L-glutamine (all from Gibco, 
Invitrogen). The primary cultures were split when dishes were about 90% confluent, 
by treating with 5 ml of 0.25% Trypsin/EDTA (Gibco, Invitrogen) for 3 minutes and 
diluting with 12 ml MEF medium to inactivate the trypsin. The MEFs were reseeded 
at a ratio of 1:5 and expanded to passage 5, where they are mitotically inactivated by 
treatment with 10 µg/ml Mitomycin-C (Kyowa Hakko Kirin) diluted in MEF medium 
for 2 hours at 37 °C. The inactivated MEFs (iMEFs) were rinsed thrice with PBS 
(Gibco, Invitrogen), trypsinized as described above and cryopreserved. 
3.3 Genomic DNA sequencing and copy number validation 
In order to verify the point mutations in PD cell lines, specific primers targeting the 
mutation regions (LRRK2 G2019S and PARK2 c.255delA) were designed 
(Supplementary Table 1). PCR amplification of genomic DNA followed by 
sequencing was performed in all cell lines.  
Copy number variations (CNVs) in SNCA was validated by quantitative PCR of 
genome DNA. The dosage of SNCA exon normalized to the average of dosage in all 
the other cell lines was compared to the endogenous reference genes B2M and HBB 
(Supplementary Table 1) (Devine et al., 2011) 
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3.4 Differentiation of hPSCs into neural progenitor cells (NPCs) and midbrain 
dopaminergic neurons (mDA) 
3.4.1 Neural induction from hPSCs to neural progenitor cells 
NPCs were generated using an adapted protocol (Li et al., 2011). iPSC colonies were 
detached using 1mg/mL Dispase, and collected by pipetting once settled at the bottom 
of the dish. After wash and resuspension in mTeSR medium, small colonies were split 
1:6 and seeded on Matrigel-coated 6-well plates in the presence of 10 µM ROCK 
inhibitor. Neural induction from iPSCs into NPCs was initiated one day after 
passaging the iPSCs. For experiments comparing different iPSC lines, each line was 
seeded at the same time and differentiation was also started at the same time. At Day 
1, mTeSR medium was substituted by N2B27 medium (DMEM/F12 with 2 mM L-
glutamine and 1×N2 supplement and Neurobasal medium with 0.2 mM NEAA and 
1× B27 without Vitamin A supplement mixed in a 1:1 ratio) supplemented with 4 µM 
CHIR99021 (Cellagentech), 3 µM SB431542 (Cellagentech), 0.1 µM Compound E 
(γ-Secretase Inhibitor XXI, EMD Chemicals Inc.), 5 µg/mL BSA and 10 ng/mL hLIF 
(Sigma), for 7 days. At Day 8, cells were dissociated into single cell by Accutase 
(Millipore) and split 1:3 on Matrigel-coated 6-well plates in the presence of 10 µM 
ROCK inhibitor. Starting from Day 8, NPCs were regularly cultured in maintenance 
contained N2B27 medium supplemented with 3 µM CHIR99021, 2 µM SB431542, 5 
µg/mL BSA, 20 ng/ml bFGF and 20 ng/ml EGF (Gibco, Invitrogen).  
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3.4.2 Differentiation of NPCs into midbrain dopaminergic (mDA) neurons 
Differentiation of NPCs into mDA neurons was initiated one day after passaging the 
NPCs onto Poly-L-ornithine hydrochloride/Laminin coated 12-well plates at a density 
of 2~5 x 105 cells per well. NPC maintenance medium was substituted by mDA 
patterning medium consisting of N2B27 medium supplemented with 100 ng/ml 
Fibroblast Growth Factor 8 (FGF8) (Peprotech), 2µM Purmorphamine (Merck 
Millipore), 300ng/mL Dibutyryl cAMP (db-cAMP) (Sigma) and 200 µM L-ascorbic 
acid (L-AA, Sigma) for 14 days. This patterning medium was changed every 2 days. 
From days 14, cells were fed with maturation medium consisting of N2B27 medium 
supplemented with 20 ng/mL human GDNF, 20 ng/mL human BDNF (both from 
Peprotech), 10µM DAPT, 0.5mM db-cAMP and 200 µM L-AA. This maturation 
medium was also used as maintenance medium for differentiation cultures and 
changed every 2 days. 
The differentiation cultures were split 1:3 between day 16 to 21, and again 1:2 24hrs 
to 48hrs before confocal images by using prewarmed Accutase for no more than 10 
minutes. mDA neuron differentiation cultures were replated as single cells on about 
day 30 on Poly-L-ornithine hydrochloride/Laminin coated 14 mm Round coverslips 
for confocal images. 
3.5 Immunofluorescence microscopy and flow cytometry 
Fir immunofluorescence assays, cells were fixed in ice cold 4% paraformaldehyde 
(PFA) for 25 minutes and subsequently permeabilized by PBS solution with the 
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detergent Tween 20 (PBST) and blocked with 10% fetal bovine serum in PBST for 30 
minutes. Primary antibodies were diluted in blocking buffer and incubated overnight 
at 4 °C. Secondary antibodies conjugated with AlexaFluor-488 or AlexaFluor-594 
(Invitrogen) were diluted 1: 500 in blocking buffer and incubated for 45 minutes at 
room temperature. DAPI (0.5 µg/ml) was used to visualize cell nuclei. The respective 
primary antibodies and dilutions are provided in Supplementary table 2. Confocal 
images were taken using a Zeiss LSM 510 upright confocal microscope. Co-
localization efficiency for immunofluorescence of Tuj1 and TH was determined using 
ImageJ JACoP plugin based on Pearsons coefficient of correlation. Neurite Length 
quantification was performed by ImageJ NeuriteTracer plugin. 
For flow cytometry, live cells were were dissociated into single cell by Accutase 
(Millipore) and stained with rat anti-CORIN (R&D System; 1:200) for 10min at room 
temperature. Cells were stained,  washed and blocked with PBS containing 2% BSA 
and 2% FBS. Flow cytometry analysis was carried out with a BD FACSCalibur™ p 
flow cytometer (BD biosciences). Cells directly incubated with secondary antibody 
were used as control. 
3.6 Quantitative real-time PCR (qRT-PCR)  
Cells were washed twice with PBS, and RNA was extracted with Trizol reagent 
(Invitrogen) and purified with RNeasy Mini kit (Qiagen), according to the 
manufacturers’ instructions. RNA samples were treated with DNase I (Qiagen) for 
removal of genomic DNA contamination and eluted with DEPC-treated water. RNA 
quality was accessed by gel electrophoresis, and quantitated with the Nanodrop 
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spectrophotometer. RNA was stored at -80 °C until further use. Complementary DNA 
(cDNA) was synthesized by using 1µg of total RNA, using the High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems), according to the manufacturers’ 
instructions.  Synthesis reactions were incubated in a thermocycler at 25 °C for 10 
minutes, followed by 37 °C for 2 hours. The cDNA samples were then used for 
downstream PCR analyses. 
Real-time PCR was carried out on an ABI PRISM 7900 Real-time PCR System using 
SYBR Green Master Mix (Applied Biosystems). Primers used are listed in 
Supplementary table 3. 
For Fluidigm® BioMark™ real-time PCR system, cDNA samples were subjected to 
pre-amplification with the respective qRT-PCR primers by TaqMan® PreAmp Master 
Mix (Applied Biosystems™), followed by Exonuclease I (New England Biolabs) 
treatment. Pre-amplified cDNA mixed with SsoFast™ EvaGreen® Supermix (Bio-
Rad) and qRT-PCR primers were loaded on 96x96 Fluidigm® BioMark™ real-time 
PCR system separately according to the manufacturer's instructions.  
3.7 MEA Data Analysis 
Electrophysiologically recorded spike timing data was analyzed using custom 
MATLAB software.  Recording method was adapted from previous report (Ju et al., 
2015). Channels averaging at least 1 spike per minute (0.0167 Hz) were considered to 
be 'active' channels and were included for further analysis. Individual spike times 
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were recorded as well as mean spike rates across different time windows. Points in 
time where drugs are washed in or washed out are flagged. 
3.8 RNA sequencing and data analysis 
Total RNAs were extracted with Trizol reagent (Invitrogen) and purified with RNeasy 
Mini kit (Qiagen), according to the manufacturers’ instructions. Robosomal-RNAs 
were depleted from 4µg total RNAs by using Ribo-Zero Gold rRNA Removal Kit 
(Human/Mouse/Rat) (Epicentre Illumina). And RNA sequencing libraries were 
constructed by using 20ng ribosomal RNA-depleted total RNA samples with 
NEBNext® Ultra™ RNA Library Prep Kit for Illumina® (New England Biolabs). RNA 
sequencing at a 51bp single-end read scale was performed on an Illumina Platform 
HiSeq2000 (Genome Institute of Singapore, Singapore), using ribosomal RNA-
depleted RNA from two biological replicates of the wild type cell lines 80A, 79A and 
IR1.7 and PD iPSC lines ND34391, ND35367, ND38477 cell at NPC stage and mDA 
stage. Reads were mapped with Tophat2 to the human genome version hg19. Reads 
were counted using R, normalized reads were obtained using the regularized log-
transformation. Differentially expressed genes were identified using DESeq2. The 
OCA plot was calculated on the top 10,000 genes that showed the highest variance 
across the smaples. 
For detecting alternative splicing events, RNA sequencing libraries were generated 
from intact poly (A)+ RNAs prepared by using Oligo d(T)25 Magnetic Beads (New 
England Biolabs). RNA sequencing was conducted on an Illumina Platform 
 26 
HiSeq2000 at a 101bp paired-end read scale (Genome Institute of Singapore, 
Singapore) 
3.9 Microarray 
Midbrain dopaminergic neurons were derived from iPSC cell lines, as described 
previously. Three biological replicates of each cell line were used for microarray 
expression analysis. Total RNAs were extracted as previously described. Biotin-
labeled cRNA were synthesized from 500ng of total RNA by using TotalPrep RNA 
Amplification Kit (Ambion).  750ng of biotin-labeled cRNA were then hybridized 
with HumanHT-12 v4 Expression BeadChip (Illumina), following the manufacturer’s 
instructions. Hybridization signals were detected by staining the chips with 
streptavidin-Cy3. Scanned data from the BeadChip raw files for all samples were 
retrieved and background corrected using GenomeStudio (Illumina), and subsequent 
analyses were completed in GeneSpring 12.0 (Agilent).  
3.10 RNA interference-mediated knockdown 
Two pairs of shRNAs were designed to target RBFOX1 (Supplementary table 4) and 
incorporated into expression lentivector pLKO.1 vector (Addgene). Then, pLKO.1 
vector contains shRNA constructs was co-transfected into 293FT cells with psPax2 
and pVSV-G vectors for lenti-viral packaging using the FuGene 6 transfection reagent 
(Roche). Viral transduction was performed in mDA neuron cultures with 2µg/mL of 
polybrene. After 72 h, cells were harvested for RNA extraction. pLKO.1 - TRC 
control was a gift from David Root (Addgene plasmid # 10879) (Moffat et al., 2006). 
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3.11 Statistical analysis 
Statistical analysis was performed using Statistical Package GraphPad Prism v5.0c 
(GraphPad Software, San Diego California USA). Two-tailed unpaired Student’s t-
test with Welch’s correction was universally used for the comparison of two groups. 
Statistical testing also involved one-way analysis of variance (ANOVA) with Tukey’s 
Multiple Test (comparing within WT samples) or Dunnett’s Multiple Test for 
multiple comparisons (comparing between WT and PD samples), as indicated in the 
figure legend. Two-way ANOVA test was performed with Bonferroni posttests if two 
binomial factors were involved. Data are expressed as means ± SEM or means ± SD 









Chapter IV – Neural Differentiation of Human Pluripotent Stem Cells  
4.1 Introduction 
4.1.1 iPSC lines with various PD genetic backgrounds 
The recent development of iPSC technology provides a new method to create human 
cell-based disease model and to monitor the disease phenotype in vitro. One of the 
important advantages of utilizing iPSCs for disease modeling is that the patient-
specific genetic backgrounds are entirely preserved, which is essential for studying 
the pathology underlying specific genetic predisposition. In this study, various iPSC 
lines derived from familial PD were employed, including the mutations in SNCA, 
LRRK2 and PARK2. These PD iPSC lines were cultured with wild type iPSC lines in 
parallel for differentiation, further phenotypic characterization and transcriptome 
profiling. 
SNCA encodes a small cytoplasmic protein, called α-synuclein, which is highly 
expressed in the central nervous system and concentrated in presynaptic terminals. 
However, the function of α-synuclein is not sufficiently clarified. The PD-related 
mutations in SNCA result in misfolding of α-synuclein, leading to protein dysfunction 
and aggregation. Such intraneuronal deposits of α-synuclein protein in neurons are 
described as Lewy bodies, which contribute to PD dementia (Polymeropoulos et al., 
1996; Wakabayashi et al., 1990). Three point mutations so far have been reported in a 
few families with varying phenotypes (Farrer et al., 1998; Kruger et al., 1998; Zarranz 
et al., 2004). Compared to the rare missense variants induced by point mutations, 
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multiplications of SNCA gene have been more commonly described in a highly 
penetrant and aggressive form of PD (Ross et al., 2008; Singleton et al., 2003). This 
defect leads to pathogenic overexpression of wild type α-synuclein and subsequent 
insoluble polymerized fibrils. In this study, one patient iPSC line with SNCA 
triplication was recruited.  
Another dominantly inherited form of PD involves mutations in LRRK2, which is the 
most common genetic cause of late-onset PD with substantially high penetrance 
(Healy et al., 2008). Intriguingly, the clinical symptoms of LRRK2 missense 
mutations are indistinguishable from idiopathic PD. LRRK2 encodes a large 
multidomain protein, called Dardarin, with both GTPase and kinase functions. 
However, although LRRK2 is ubiquitously expressed in the brain, the biological 
processes that it participates in remain poorly understood. So far, in total six missense 
mutations have been identified to be pathogenically PD-relevant, including R1441C, 
R1441G, R1441H, Y1699C, G2019S, and I2020T, with various frequencies in 
different population (Figure 4.1). Among the multiple genetic variants identified, 
G2019S mutation located in the kinase domain is known to be the most common 
point mutation that uniquely contributes to both familial and sporadic PD among 
Caucasian patients (Lesage et al., 2006; Nichols et al., 2005). LRRK2 G2019S creates 
a missense mutation in exon 41, resulting in an amino acid substitution from glycine 
to serine. Unlike the other mutations, which decrease enzyme activity, only the 
G2019S mutation enhances kinase activity suggesting a gain-of-function mechanism 
for PD development (West et al., 2005). Among PD patients, G2019S could be found 
in both homozygosity and heterozygosity with no significant difference in clinical 
features. However, it remains unknown if at early stage of PD progression different 
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dosage of mutated LRRK2 might contribute to different molecular features. Therefore, 
in this study, patient-specific iPSC lines with both homozygous and heterozygous 
LRRK2 G2019S were recruited. 
 
Figure 4.1: LRRK2 mutations and domains (Cookson, 2010).  LRRK2 is a large 
multidomain protein including ankyrin-like repeats (ANK), leucine-rich repeats 
(LRR), Ras of complex protein, GTPase domain (ROC), C-terminal of ROC domain 
(COR), kinase domain (kinase), and WD40 repeats domain (WD40). The most clearly 
defined pathogenic human mutations are shown below the diagram. Both R1441 and 
Y1699 mutations decrease the modest GTPase activity of LRRK2, whereas G2019S 
increases kinase activity.  
(See Appendix for documentation of permission to republish this material) 
 
 
Autosomal-recessive PD has been clinically characterized as early-onset with slow 
disease progression, referred to as autosomal-recessive juvenile Parkinsonism (AR- 
JP).  Mutations in PARK2, PINK1 and DJ-1 have been firmly implicated in autosomal 
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recessive PD. There were multiple point mutations identified in PARK2 loci, which 
encodes an E3 ubiquitin protein ligase PARK2 (Figure 4.2). The c.255delA mutation 
was identified as the most frequent PARK2 mutation, especially in Spanish patients, 
which led to frame-shift protein truncation (Munoz, 2002). The truncated form of 
PARK2 fails to play its role in the protein ubiquitin–proteasome pathway, resulting in 
potential protein aggregation and increased oxidative stress in neurons. However, the 
PARK2-specific ubiquitinated substrate has yet to be identified. And the selective 
vulnerability towards loss-of-function of PARK2 in midbrain dopaminergic neurons 
still remains unclear. In this study, one iPSC line with PARK2 c.255delA was 
employed. 
 
Figure 4.2: Point mutations in the PARK2 gene. The hatched regions indicate the 
ubiquitin-like domain and the RING–IBR–RING finger motifs. The 6 truncating 
mutations are indicated above the sequence, and the 10 missense mutations are 
indicated below the sequence. Among these truncation mutations, c.255delA in exon2 
is highlighted. UTR, untranslated region.  




4.1.2 Directed neuronal differentiation of hiPSCs 
The central nervous system (CNS) is one of the most complex biological systems, 
comprising of an enormous array of regionally distinct neuronal and glial subtypes, 
which are organized into dynamic neural networks that form the basis of brain and 
cognitive functions. Therefore, the precise spatial and temporal expression of genes is 
exceptionally crucial for proper CNS function. During development, cells respond to 
changes in their environment in part through changes in gene expression. 
Extracellular signals such as growth factors, neurotransmitters and hormones activate 
changes in gene expression profiles in a spatially and temporally coordinated manner.  
During early embryonic development, the neuroectodermal layer gives rise to the 
central nervous system. This process is regulated by a number of important signaling 
pathways including Wnt, TGF-β, Notch and BMP pathways (Valdimarsdottir and 
Mummery, 2005; Xu et al., 2005).  By the third to fourth week of embryonic 
development, ectoderm, the surface layer of embryo, gives rise to neural plate, which 
folds up to form the neural tube (Figure 4.3 A, B, C and D). This process, called 
neurulation, relies on the active repression of BMP and Wnt signaling by exposure 
towards multiple morphogens that act as antagonists, such as noggin. Once the neural 
tube is formed, it is highly patterned along both the anterior-posterior and dorso-
ventral axes based on the different morphogen gradients including FGFs and retinoic 
acid. And the anterior end of neural tube will eventually develop into brain with 
continuously inhibition of BMP signaling, while the posterior end of neural tube will 
be ultimately specified into spinal cord (Figure 4.3 E).  
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Based on the in vivo developmental process, neural induction was performed in 
human iPSCs to achieve specific primitive progenitor cells of neural lineage for 
further expansion and differentiation in vitro. Small molecule inhibitors were used to 
induce neural progenitor cells from iPSC lines, including CHIR99021, SB431542 and 
Compound E (Li et al., 2011). CHIR99021 is one of the most selective inhibitor 
towards glycogen synthase kinase 3β (GSK3β) (Bennett et al., 2002), which is the 
important component of Wnt signaling pathway. By inhibiting GSK3β, CHIR99021 
impairs the pluripotency and self-renewal of iPSCs. SB431542 was also reported as a 
specific inhibitor of TGF-β receptor (Laping, 2002), which contributes on regulating 
the expression and activation of pluripotency related transcription factors. Compound 
E was also used to inhibit Notch signaling, and thereby promote neural induction. 
Human leukemia inhibitory factor (LIF) was also introduced to promote self-renewal 
and survival of neural progenitor cells (NPCs) generated. After neural induction, a 
pure population of NPCs could be obtained. Subsequent exposure to mitogens such as 
epidermal growth factor (EGF) and fibroblast growth factor-2 (bFGF) enables NPCs 






Figure 4.3: Nervous system develops from neuroectoderm (Modified from Siegel, 
A. and Sapru, H.N. Essential Neuroscience). A. Neural plate, B. neural groove and 
C. neural tube are formed from the dorsal surface of the embryo. The left side of each 
panel depicts the developing embryo in a dorsal view, and the right side shows cross 
sections through the nervous system cut at the levels indicated by the arrows. D. 
Anterior end of neural tube develops into central nervous system. E. Different 
signalings regulate the further specification of neural tube. BMP4 siganling further 
contributes to the epidermal ectoderm formation. Anterior neural plate requires 
continuous inhibition of BMP4. And the further exposure of FGF and retinoic acid 
induces the specification of posterior end of neural tube.  








Since the clinical symptoms of PD are primarily induced by selective degeneration of 
midbrain dopaminergic (mDA) neurons, NPCs derived from iPSCs were further 
differentiated into this neuronal subtype.  
In vivo, mDA neurons develop from a group of neuroepithelial cells that originate in 
the ventral midbrain. These neural stem cells located in the floor plate of anterior 
neural tube receive morphogens including Sonic hedgehog (SHH) and fibroblast 
growth factor 8 (FGF8) during the development of the midbrain (Figure 4.4). During 
neurulation, the notochord derived from chordomesoderm secretes high concentration 
of SHH, which induces ventral midline of the neural tube. At the same time, the 
BMP4/7 released from the epidermal ectoderm induces the formation of roof plate. 
The roof plate further develops and releases dorsalizing morphogens including TGF-
beta family of growth factors, which establish dorsal to ventral morphogen gradients. 
At the opposite side, the floor plate starts to release SHH, resulting a ventral to dorsal 
SHH gradient. These two opposing morphogen gradients along the dorso-ventral (D-
V) axis regulate the further regional specification of different neuronal subtypes. 
Along the anterior-posterior (A-P) axis, the isthmic organizer forms a boundary 
between midbrain and hindbrain and controls patterning of the midbrain and the 
anterior hindbrain.  FGF8 is released by the isthmic organizer. The specific rostral-
caudal level of FGF8 in midbrain, in combination with SHH in floor plate, activate 
genes such as FoxA2 and EN1, which encode transcription factors that increase the 
production of proteins specific to dopaminergic neurons such as tyrosine hydroxylase 
(TH), the rate-limiting enzyme for dopamine synthesis (Ferri et al., 2007). 
Subsequently, midbrain dopaminergic neurons are generated. 
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To recapitulate the in vivo signaling environment in vitro, mDA neuronal 
differentiation was performed by enforced activation of FGF8 and SHH signaling in 
NPCs. In this process, a defined concentration of FGF8 and purmorphamine were 
introduced into NPC culture. Purmorphamine activates the SHH pathway by targeting 
Smoothened, which is a critical component of the SHH signaling pathway (Sinha and 
Chen, 2006). Thus, exposure to FGF8 and purmorphamine provides NPCs suitable 
signaling environment and drives NPCs towards midbrain floor plate lineage in vitro. 
Following the above patterning process, glial cell line-derived neurotrophic factor 
(GDNF), brain-derived neurotrophic factor (BDNF), dibutyryl cAMP (db-cAMP), 
ascorbic acid and Notch inhibitor DAPT were introduced to promote survival and 










Figure 4.4: Patterning of neural tube during midbrain development. A. 
Morphogen signaling during brain development (Allodi and Hedlund, 2014). During 
embryogenesis, neurons present in the midbrain (MB), including dopamine and 
oculomotor neurons are born at the intersection of the signaling molecules Shh, Wnt1, 
and Fgf8. FP, floor plate; IsO, isthmic organizer; MB, midbrain; NC, notochord; OV, 
otic vesicle; RP, roof plate, ZLI, zona limitans intermedia, r1, rhombomer 1; r2, 
rhombomer 2; D, dorsal; V, ventral.  B. Schematics of the key players of mDA neuron 
development (Gale and Li, 2008). 






4.2.1 Characterization of iPSC lines 
We recruited a total of 12 iPSC lines into this study. Three wild type (WT) iPSC lines 
(GM23279, GM23280 and IR1.7) derived from healthy individuals were employed as 
controls. iPSC lines carrying heterozygous or homozygous G2019S mutation in 
LRRK2 (heterozygous: ND40597, ND40599, ND41181 and ND41180; homozygous: 
ND40018, ND35367), SNCA triplication (ND34391), c.255delA mutation in PARK2 
(ND38477) and sporadic case (ND39896) were studied to model relevant PD 
phenotypes (Table 4.1). In this collection of iPSC lines, WT cell lines GM23280 and 
GM23279 are two iPSC lines derived from same healthy individual. And the rest one 
WT cell line and all the PD cell lines are from different individuals. Transcriptome 
profiling in various cell stages was mostly performed with the 3 wild type cell lines 
and the following 3 PD cell lines: ND 38477 (PARK2 c.255delA), ND35367 (LRKK2 
G2019S) and ND34391 (SNCA triplication). The validation of main gene expression 






Table 2.1 Summary of iPS cell lines 
Cell Line Gender Age PD-related Mutation 
Reprogramming 
Method Race 
GM23280 Female 36 Apparently healthy Retroviral Caucasian 
GM23279 Female 36 Apparently healthy Retroviral Caucasian 
IR1.7 Male unknown Apparently healthy Retroviral Unknown 





ND35367 Male 79 Homozygous LRRK2 G2019S Retroviral Caucasian 
ND34391 Female 55 SNCA triplication Retroviral Caucasian 
ND40018 Female 60 Homozygous LRRK2 G2019S Retroviral Unknown 
ND41181 Female 66 Heterozygous LRRK2 G2019S Sendai virus Unknown 
ND41180 Male 36 Heterozygous LRRK2 G2019S Sendai virus Unknown 





ND40597 Female 66 Heterozygous LRRK2 G2019S Sendai virus Unknown 
ND40599 Male 81 Heterozygous LRRK2 G2019S Sendai virus Unknown 
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Figure 4.5: Characterization of Human WT and PD iPSC lines. A. Genomic DNA 
sequencing showing the c.255delA deletion of PARK2 gene in ND38477 cell line, 
resulting a frame shift truncation from Asn into Met. B. Genomic DNA sequencing 
showing presence of G2019S (6055G-A transition) LRRK2 mutation in PD cell line, 
but not in WT iPS cell line. C. Relative SNCA gene copy numbers quantified by 



















































































Point mutations in PARK2 and LRRK2 were confirmed by genomic DNA sequencing 
(Figure 4.5 A and B). SNCA copy number was quantified by qPCR analysis of 
genomic DNA in SNCA triplication (ND34391) cell line compared to wild type iPSCs 
(Figure 4.5 C), demonstrating increased gene dosage due to triplicated gene copy 
number.  
Immunostaining demonstrated that iPSC lines expressed the pluripotent markers 
NANOG, OCT4, SSEA4, and TRA1-60 (Figure 4.6). All the cell lines presented 
apparently normal karyotypes (Figure 4.7 A). The formation of embryoid bodies (EBs) 
followed by further in vitro spontaneous differentiation demonstrated that the iPSC 




Figure 4.6: Immunofluorescence analyses of Human iPSCs. Expression of 
pluripotency markers: TRA-1-60, OCT4, SSEA4 and NANOG in WT and PD iPS 
cell lines. Scale bar = 100µm. 
 
 43 
         
Figure 4.7: Characterization of human iPSCs showing karyotype stability and 
pluripotent differentiation ability. A. Normal karyotyping presented in both WT iPSCs 
and PD iPSCs. B. Differentiation of iPSCs through embryoid body formation in vitro 
into all three germ layers, labeled by immunostaining: α-fetoprotein (endoderm), βIII-








4.2.2 Neural induction of iPSCs into neural progenitor cells (NPCs) 
Robust populations of neural progenitor cells (NPCs) were derived from iPSCs from 
WT and PD iPSCs by introducing small molecule inhibitors into monolayer iPSC 
cultures (Li et al., 2011) (Figure 4.8 A). Starting from Day 2, iPSC colony underwent 
morphological changes (Figure 4.8 B).  Differentiated cells presented lengthening of 
the cell axis and migration from the edge of iPSC colony. At Day 7, the typical 
compact morphology of iPSC colony no longer existed. By using this protocol robust 
populations of NPCs could be rapidly derived from monolayer iPSCs with high 
efficacy within one week. Cell identity was tested by qRT-PCR and immunostaining 
for expected markers. Gene expression analysis across the course of differentiation 
process showed the complete repression of ES markers including NANOG, OCT4, 
ZFP42 and UTF1, whereas the neuroectoderm makers were up-regulated including 
NESTIN, PAX6 and VIMENTIN (Figure 4.8 C). Neural progenitor cells generated 
were also immunopositive for the respective neural markers but not for pluripotency 
marker (Figure 4.8 D). Subsequently, NPCs were maintained in culture with further 




Figure 4.8: Derivation of NPCs from iPSCs. A. Schematic representation of the 
neural induction protocol: NPCs were generated by introducing small molecule 
inhibitors into monolayer iPSC culture for 7 days; NPCs were maintained in growth 
medium supplemented with growth factors for further passaging. B. Progression of 
neural induction observed under the phase-contrast microscope. Scale bar = 200µm. C. 
Quantitative RT-PCR analysis showing the down-regulation of pluripotency markers: 
OCT4/POU5F1, NANOG, UTF1, ZFP42 and up-regulation of neural progenitors 
markers: NESTIN, PAX6, VIMENTIN, MUSASHI (MSI) during the course of neural 
induction. Data represent mean ± SD (n=3). D. Expression of NPC markers: NESTIN, 











































4.2.3 Differentiation of NPCs into functional mDA neurons 
Since PD is defined pathologically by progressive degeneration of midbrain 
dopaminergic neurons (mDA neurons) in the substantia nigra, we differentiated the 
NPCs into mDA neurons utilizing a combination of patterning and maturation factors 
(Figure 4.9 A). Exposure to FGF8 and purmorphamine drove the NPCs towards 
midbrain floor plate progenitors, which express floor plate markers CORIN and 
FOXA2 (Figure 4.9 B). The quantification of CORIN-positive population by 
fluorescence-activated cell sorting (FACS) was performed in both WT and PD cell 
lines at Day 16 after differentiation to quantify the midbrain DA precursors in the 
culture (Figure 4.9 C). Overall, 40~60% of the mDA precursors were obtained. 
Neurons generated after further maturation carried the characterisics of DA neurons 
regionally specific in substantia nigra pars compacta (SNc), indicated by expression 
of dopamine active transporter (DAT), G protein-activated inward rectifier potassium 
channel 2 (KIR3.2), vesicular monoamine transporter 2 (VMAT2), and floor plate 
marker FOXA2 (Figure 4.9 D). Furthermore, mature neuronal markers  synaptophysin 
(SYP) and postsynaptic density protein 95 (PSD95) were substantially expressed in 
the neuron population. The neuronal were further characterized by co-staining for the 
midbrain transcription factors PITX3 and NURR1 (Figure 4.9 E). To further confirm 
the dopaminergic neuron identiy, FOXA2 was used to quantify the midrain 
dopaminergic neuron population among the cultures. Quantification by nuclear 
marker FOXA2 was performed, revealing 50~60% of the cells are mDA neurons in 




Figure 4.9: Characterization of mDA neurons generated from iPSC-derived 
NPCs. A. Schematic representation of the mDA differentiation protocol: NPCs were 
patterned into ventral midbrain lineage with FGF8b and purmorphamine for 14 days; 
FP progenitors were further differentiated into mature neurons with DAPT, GDNF 














for the floor plate surface marker: CORIN. Scale bar = 200µm; fixed cells were 
stained for the floor plate marker: FOXA2. Scale bar = 100µm. C. Quantification of 
CORIN-positive mDA precursors by flow cytometry at Day 16. Data represent mean 
± SD (n=3). D. 30 days post initiation of patterning of NPCs, neurons were co-stained 
for the mDA marker DAT, KIR3.2, VMAT2 and FOXA2. E. Neurons were co-
stained for the mature neuronal markers SYP, PSD95 and mDA neuronal markers 
NURR1, PITX3. F. Quantification of FOXA2+/DAPI+ cells among differentiated 
neuronal cultures at Day 30-32. Data represent mean ± SD (n=3).  
 
qRT-PCR analysis further illustrated the upregulation of neuronal markers: Tuj1, 
MAP2, SYP and mDA specific markers: TH, NURR1, EN1 and FOXA2 compared to 
NPC stage (Figure 4.10 A). To assess the robustness of the protocol, emerging DA 
neurons from both WT and PD cell lines were characterized and quantified by co-
expression of the pan-neuronal marker TUJ1 and DA neuronal marker TH (Figure 
4.10 B and C.). More than half of the differentiated neurons were TH+ (WT: 
64.95±7.4%; ND38477: 57.61±5.6%; ND35367: 60.24±5.2%; ND34391: 
62.97±2.0%). As shown in Fig 4.10, the efficacy of DA differentiation showed no 
significant difference between WT and PD cell lines in terms of the fraction of 
neurons among total cell population and the mDA subpopulation among TUJ1+ 
neurons. Overall, based on the quantification of FOXA2-positve and TH-positive 




Figure 4.10: Differentiation efficacy of mDA neurons generated from NPCs. A. 
Quantitative RT-PCR analysis showing the expression of neuron markers: Tuj1, 
MAP2, SYP and mDA specific markers: TH, NURR1, EN1 and FOXA2. Data 
represent mean ± SD (n=3). B. Expression of pan-neuronal marker TUJ1 and DA 
neuron markers TH in iPSC-derived 35-day neurons by immunostaining. Scale bar = 
200µm. C. Quantification of mDA differentiation efficacy based on TH and TUJ1 co-
localization, in 30-day neurons derived from WT and PD lines. Data represent mean ± 
























































































































We next performed functional studies to investigate the dopaminergic and 
electrophysiological properties of these neurons. First, dopamine released in the 
culture medium was assessed by ELISA and normalized with TH expression (Figure 
4.11 A.). Second, the spontaneous action potential of neurons was recorded by 256-
channel microelectrode array (MEA), indicating that the mDA neurons generated 
were electrically active (Figure 4.11 B.). Furthermore, channel properties of mDA 
neurons were validated by introducing exogenous pharmacological agents to 
determine their effects on firing patterns. As shown in Fig 4.11 C., DL-2-amino-5-
phosphonovaleric acid (APV), a selective NMDA receptor antagonist, significantly 
reduced the firing rates in mDA neuron cultures. The decreased firing activity induced 
by risperidone was also observed, indicating that the neurons generated possessed 
functional dopamine (DA)-D2 receptors. The results described so far show that the 
differentiated cultures of dopaminergic neurons are functional in terms of 
synthesizing and releasing dopamine. The neuronal cultures display spontaneous 







 Figure 4.11: Functional analysis of mDA neurons. A. Measurements of total level 
of dopamine release from iPSC-derived neurons normalized by TH expression. Data 
represent mean ± SD (n=3). B. Electrophysiological recordings of spontaneous action 
potentials from WT and PD mDA neuron cultures by microelectrode arrays (MEAs). 
Representative images were shown. C. Effects of neuromodulators applied to WT and 
PD mDA neurons. APV, an NMDA antagonist; Risperidone, dopamine D2 receptor 



















































































There have been several neural induction methods developed for inducing NPCs and 
neurons from hESCs or hiPSCs. Most of the protocols require EB aggregation, which 
is subsequently conditioned to neuroectoderm (Elkabetz et al., 2008; Pankratz et al., 
2007). However, the heterogeneity of EB significantly affects the purity of NPCs 
generated. The neural induction is usually inefficient due to the poor morphogen 
penetration inside 3-dimensional aggregates of EB. Furthermore, the attachment of 
EB on culture plates selectively affects the survival of certain neural lineages. 
Therefore, differentiation protocols adapted to monolayer culture with higher 
efficiency were chosen by most of the studies recently.  
During the formation of neural plate the organizer dorsal mesoderm gives rise to 
follistatin, chordin and noggin to antagonize BMP signaling to neuralize the ectoderm. 
Therefore, the inhibition of BMP pathway by defined molecules was employed for 
neural induction in hESCs and iPSCs, including Noggin and Dorsomorphin 
(Compound C) (Chambers et al., 2009; Zhou et al., 2010). Both of the molecules 
target BMP receptors, which inhibit the activation and further block the downstream 
phosphorylation of SMAD 1/5/8, thereby promoting the efficacy of neural fate 
acquisition. Another small molecule, SB431542, was used in combination with either 
of the BMP receptors mentioned above. SB431542 targets to TGFβ/activin/nodal 
signals, which subsequently inhibits SMAD signaling and suppresses the gene 
expression related with pluripotency (Morizane et al., 2011; Wattanapanitch et al., 
2014; Zhou et al., 2010). These dual SMAD inhibitors have been used for various 
neural differentiation strategies to derive NPCs. However, the NPCs derived could 
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only be maintained in culture for a few passages. The late-passage NPCs (at around 
passage 4) showed significant decrease in proliferation and neuronal differentiation 
efficiency. This phenomenon indicates that the dual inhibition of SMAD protocol 
fails to maintain the self-renewal property of NPCs. A further optimized condition for 
maintenance is required for the long-term culture and the storage of NPCs. 
In this study, a chemically defined protocol was optimized and employed to rapidly 
derive homogeneous NPCs from monolayer hiPSCs by using specific small molecule 
inhibitors (Li et al., 2011). Compared to the other protocols, the current protocol 
induces a rapid synergistic inhibition of GSK3, TGF-β/Activin and Notch signaling 
pathway, which significantly abolishes the expression of pluripotency-related genes. 
The rapid suppression of pluripotency-related transcription factors is essential for a 
uniform conversion of cell fate from pluripotent stem cells into NPCs. Therefore, the 
purity of NPCs generated is significantly higher than other neural induction protocols 
mediated by EB aggregates or dual SMAD inhibition. And small molecule inhibitors 
are more cost-effective than synthetic morphogen. Most importantly, the optimized 
maintenance condition in the current protocol enables the long-term expansion of 
NPCs in culture by introducing growth factors in combination with continuous 
blockage of GSK3. Recent studies in mouse showed that GSK3 signaling mediates 
the homeostasis in NPCs. Deletion of both GSK3α and GSK3β in mouse NPCs 
resulted in hyperproliferation (Kim et al., 2009b). Therefore, in the current protocol, 
CHIR99021 and SB431542 are continuously applied in NPC maintenance with a 
reduced dosage compared with neural induction, which steadily facilitate the self-
renewal of NPCs for expansion and long-term passaging. And the NPCs could be 
frozen down, providing a homogenous stock for further experiments. On the other 
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hand, Wnt/β-catenin signaling is known to be critical for neurogenesis in midbrain 
floor plate (Castelo-Branco et al., 2003; Joksimovic and Awatramani, 2014). 
Therefore, the continuous exposure of CHIR99021 activates Wnt/β-catenin signaling 
in NPCs, acting as pre-patterning for mDA precursors. 
For further mDA neuronal differentiation, an optimized protocol was developed based 
on the previous reports (Doi et al., 2014; Kriks et al., 2011; Li et al., 2011). As 
mentioned in the last paragraph, NPCs have been obtained and maintained with 
activation of Wnt/β-catenin signaling by CHIR99021. The NPCs were further 
ventralized into mDA precursors with FGF8 and purmorphamine. The mDA 
precursors were validated with the expression of CORIN, which was recently 
identified as a cell surface marker for floor plate mDA progenitor cells (Doi et al., 
2014; Ono et al., 2007). Previous reports showed that the conditional medium derived 
from PA6 stromal cells could efficiently induce dopaminergic differentiation in 
hESCs (Swistowska et al., 2010). The efficient induction is due to the SHH secreted 
by PA6 stromal cells. However, the conditional medium is not defined from batch to 
batch, resulting in variable differentiation efficiency. Therefore, protein factors FGF8 
and SHH were used as substitution in most of the recent reports. In the current project, 
we replaced SHH with purmorphamine a more cost-effective small molecule that 




In summary, efficient differentiation protocols were developed to generate nearly 
homogenous population of NPCs and also enriched populations of functional mDA 
neurons for further examination in vitro. Neural induction of hiPSC by small 
molecules produced a high yield of NPCs, which could be long-term cultured and 
cryopreserved as stock cells. The further patterning and maturation of NPCs gave rise 
to functional mDA neurons, were characterized by the expression of mDA markers 
and electrophysiological assessment. The mDA neurons generated were capable of 
producing and releasing dopamine. Furthermore, co-expression of Tuj1 and TH as 
determined by immunostaining indicated that the majority of cells in the population of 
differentiation cultures were mDA neurons. The neuronal differentiation protocol was 
highly reproducible in both WT and PD iPS cell lines with no significant difference 
regarding to the differentiation efficiency.  Ultimately, the NPCs and mDA neuron 
cultures obtained were subjected to phenotypic assays and expression profiling to 







Chapter V –Effects Of Prolonged Passaging of NPCs For PD Modeling In Vitro 
5.1 Introduction 
As it was presented in the Chapter IV, PD patient-derived iPSCs can be expanded in 
culture and directed to differentiate into mDA neurons, which served as disease 
modeling to study the progression and manifestation of PD in vitro. However, there 
was no obvious disease-related phenotype observed in NPCs and mDA neuron 
cultures directly derived from iPSCs in this study. 
It is a widely accepted notion that PD is a chronic progressive neurological disease 
that emerges with ageing, implying that phenotype in vitro might only occur in the 
neurons with extensive culture conditions. However, it is technically difficult to 
culture neurons long enough to recapitulate the lifespan of PD patients before disease 
onset. Therefore, alternative methods should be applied to mimic cellular ageing in 
vitro. Interestingly, it has been shown that serial passaging of iPSC-derived NPCs 
resembled the “ageing” progression, resulting in nuclear aberrations and progressive 
degeneration in P14 neural stem cells derived from LRRK2 G2019S iPS cell line (Liu 
et al., 2012). Such later-passage stem cells showed deficiency in proliferation and 
ability to be differentiated into mature neurons. The report indicated that the serial 
passaging of NPCs could artificially induce a decline in stem cell functions, which 
recapitulated ageing-associated molecular processes in vivo. And the accumulation of 
deteriorated events could be passed from stem cells to their differentiated daughters. 
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In vivo, tissues undergo age-related degenerative changes in the respective stem cell 
pool. These stem cells are capable of division to preserve the population or 
differentiation into specific subtypes to replenish the damaged region. During the 
ageing process, the balance between quiescence and proliferation of stem cells is 
progressively lost such that aged stem cells fail to respond to the regenerative signals 
and subsequently disturb the tissue homeostasis, which also reflects the overall ageing 
process of the human body. During the overall life span, accumulation of disrupted 
molecular processes including cell cycle dysregulation, DNA damage, mitochondrial 
dysfunction and aggregation of damaged proteins in stem cells gradually cause 
functional decline (Ito et al., 2004; Sahin and Depinho, 2010). In aged NPCs, 
proteomic studies indicated a metabolic dysregulation phenotype accompanied with 
decreased mitochondrial content compared with young adult NPCs (Stoll et al., 2011), 
which could be due to the accumulation of cell stress factors mentioned above. The 
incurred perturbation would strongly affect the function of differentiated neurons 
derived from the aged NPCs, which might mimic the primary aged neurons. 
Therefore, the ability to mimic aspects of ageing of NPCs in vitro could be an 
alternative method to induce neurons with predeposited ageing factors, providing an 
accelerated experimental design to study neurodegenerative pathogenesis. 
In vitro, stem cells, such as hematopoietic stem cells (HSCs) and mesenchymal 
stromal cells (MSCs) in culture usually experience replicative senescence after a few 
cycles of passaging. And such replicative senescence shares a similar spectrum of 
age-related gene expression changes with the aged somatic stem cells in vivo (Bonab 
et al., 2006; Wagner et al., 2009). Therefore, in order to study the age-associated 
pathology, NPCs were kept in culture for prolonged passaging. The effect of long-
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term culture on the NPCs was evaluated by transcriptome profiling. We explored the 
key molecular pathways perturbed during the serial passaging, which provided the 
experimental evidence of the ageing modeling of NPCs in vitro. 
In order to interrogate the age-associated pathology, the later passage NPCs and 
neurons derived were assayed, evaluating for survival, morphology and defects in 
neurogenesis of later NPCs and survival, morphological changes and 
electrophysiological function of later NPC-derived neurons. Furthermore, abnormal 
protein aggregation, selective cell death and cell stress response were tested. 
5.2 Results 
5.2.1 Ageing model of PD pathology in NPCs  
To recapitulate the ageing process in vitro, iPSC-derived NPCs were continuously 
passaged. Immunocytochemistry demonstrated that P10 NPCs derived from both WT 
and PD cell lines expressed NPC markers NESTIN and PAX6 (Figure 5.1 A). 
Notably, the growth rates of P10 NPCs slightly decreased after multiple passaging as 
determined in an EdU proliferation assay (Figure 5.1 B). The PD and WT NPC 
cultures gave rise to similar proliferation rates at P10 stage. Remarkably, the long-




Figure 5.1: Characterization of late-passage NPCs after serial passaging. A. 
Expression of NPC markers: NESTIN, PAX6 in passage 10 NPCs. Scale bar = 200µm. 
B. Proliferation rate of P1 and P10 NPCs. Compared to P1, the proliferation rates of 







5.2.2 Expression profiling of NPCs with serial passaging 
To understand the effects of in vitro passaging on transcriptional regulation in NPCs, 
we analyzed the transcriptome of NPCs across different passages. NPCs derived from 
4 individual iPSCs (including 2 WT cell lines GM23280, GM23279 and 2 PD cell 
lines ND35367, ND34391) and from different passages (P1, P10, P19) were harvested 
to determine the changes in the gene expression induced by serial passaging. Gene 
expression profiling was performed with Illumina beadchip microarrays. 
Microarray analysis of total RNA extracted from the NPCs in each passage revealed a 
statistically significant group of genes that were differentially expressed during the 
long-term passaging. One-way analysis of variance was used to determine the 
differential expressed genes across passaging with Benjamini-Hochberg p-value 
correction. Differential expression of genes at p < 0.05 were considered as statistically 
significant. Compared to P1, there were 567 genes down-regulated and 511 gene up-
regulated (Figure 5.2). These differentially expressed genes were further analyzed by 
gene ontology analysis, which seeks to determine if genes in common molecular or 
biological were similarly altered in expression. Consistent with the decreased cell 
proliferation identified by EdU assay (Figure 5.1 B), many of the under-expressed 
genes in late-passage NPCs were involved in cell cycle regulation, DNA replication, 
as evidenced by enrichment analysis of Gene Ontology biological processes (GOBP) 
terms (Table 5.1). This finding further provided molecular evidence of a decreased 
proliferation in NPCs along with prolonged passaging in vitro, resembling the 
proliferative senescence of stem cells. Additionally, the decreased expression of DNA 
repair machinery might result in DNA damage accumulation. For up-regulated genes, 
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the gene ontology analysis failed to identify significant enriched clustering of specific 
pathways. However, the enhanced expression of genes involved in Golgi apparatus 
and protein transport, which might be related with accumulation of damaged and 
misfolded proteins. 
Figure 5.2: Passaging-induced gene expression changes in NPCs derived from 
iPSCs. Global gene expression profiles of NPCs derived from 4 different iPSC lines 
and 3 different passages were analyzed by microarray. One-way ANOVA analysis 
revealed that 567 genes were significantly down-regulated and 511 gene were 











































































































Table 5.13Enrichment in gene ontology analysis of down-regulated genes across 
passaging in NPCs 





GO:0006260~DNA replication 4.47E-29 8.09E-26 




GO:0006281~DNA repair 1.18E-12 2.14E-09 
GO:0007049~cell cycle 6.51E-13 1.18E-09 






Table 5.24Enrichment in gene ontology analysis of up-regulated genes across 
passaging in NPCs 
GO Term p-value Bonferroni corrected 
p-value 


















To validate the microarray data, 18 genes with top relative expression fold changes 
were selected for verification by qRT-PCR (Figure 5.3 A and B). NPCs from 2 WT 
cell lines (GM23280 and GM23279) and 5 PD cell lines (ND38477, ND34367, 
ND35391, ND38369 and ND40597) were induced from iPSCs and individual 
passaging was performed for each cell line from P1 to P10. Overall, the changes in 
gene expression measured by qPCR strongly supported the microarray results, 
indicating a highly reproducible effect of serial passaging in both WT and PD cell 
lines.  
Interestingly, a few of the genes that were further verified have been previously 
shown to be involved in ageing process. By meta-analysis of age-related gene 
expression that involved 27 datasets from different organs and species, apolipoprotein 
D (ApoD) has been shown to be remarkably age-dependent up-regulated gene (de 
Magalhaes et al., 2009). Especially in ageing brain tissue, a number of studies have 
showed the dynamic changes of ApoD expression (Kim et al., 2009a; Ordonez et al., 
2006a; Ordonez et al., 2012). During ageing process, it was known that ApoD protein 
functions as an antioxidant mediating lipid peroxidation and stress response 
(Ganfornina et al., 2008). And ApoD has also been shown in various 
neuropathological disorders, including stroke, Alzheimer disease and Parkinson's 
disease (Bhatia et al., 2012; Ordonez et al., 2006b; Ordonez et al., 2012). In 
accordance with these reports, a significant up-regulation of ApoD was also detected 
in late-passage NPCs, indicating a consistent ageing progression through serial 
passaging (Fig. 5.3 C).  
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Similarly, EFEMP1 has also been implicated in ageing. EFEMP1 encodes an 
extracellular matrix protein called fibulin-3. EFEMP1-/- mice exhibited early signs of 
ageing, including reduced lifespan, decreased body mass, lordokyphosis, reduced hair 
growth, and generalized fat, muscle and organ atrophy (McLaughlin et al., 2007). A 
single mutation in this gene was associated with age-related macular degeneration 
(Stone et al., 1999). Consistent with the previous findings, the expression of EFEMP1 
decreased along with the serial passaging of NPCs (Fig. 5.3 C). 
 
Figure 5.3: Validation of selected genes from the microarray data set by qRT–
PCR. A, B. Expression is normalized to GAPDH. Error bars are presented as standard 
deviation from 3 biological replicates of 7 individual cell lines. C. Quantitative RT–




Another strong evidence for in vitro modeling of ageing in NPCs is the significant 
decrease of NPC proliferation markers (Table 5.3). It has been shown that ageing 
resulted in a decline in cell proliferation of NSCs in subventricular zone (SVZ) based 
on the labeling for the G1-phase cell cycle marker MCM2 and nucleoside analog 
double labeling in vivo (Maslov et al., 2004; Pruitt et al., 2007). In the expression 
profiling generated from serial passaged NPCs, a consistent decline of proliferation 
signature was detected, including MCM family of DNA licensing factors, Cyclin D2 
and Cyclin E1, indicating an overall decreased in G1-phase of cell replication. 
Table 5.3 List of the down-regulated genes related with cell cycle in late-passage 
NPCs identified by microarray. 
Symbol p (Corr) p-value FC ([P10] vs [P1]) FC ([P19] vs [P1]) 
CCND2 2.80E-02 6.11E-04 -1.42 -1.69 
CCNE1 1.21E-02 6.99E-05 -1.43 -3.01 
CDC123 2.55E-02 4.67E-04 -1.04 -1.48 
CDC25A 3.70E-03 2.00E-06 -1.43 -2.28 
CDC45L 1.81E-02 2.14E-04 -1.06 -2.33 
CDC6 1.08E-02 4.77E-05 -1.40 -2.30 
CDCA5 2.93E-02 6.75E-04 -1.01 -1.55 
CDCA7 8.59E-03 2.43E-05 -1.28 -2.58 
MCM2 3.14E-02 8.19E-04 -1.48 -2.04 
MCM3 1.57E-02 1.19E-04 -1.30 -2.48 
MCM3APAS 1.63E-02 1.38E-04 -1.77 -3.10 
MCM4 6.12E-03 9.15E-06 -1.48 -2.96 
MCM5 1.74E-02 1.86E-04 -1.16 -1.89 
MCM6 2.03E-02 2.78E-04 -1.27 -2.21 
MCM7 2.41E-02 4.06E-04 -1.24 -2.16 
MCM8 7.21E-03 1.65E-05 -1.14 -2.11 
MCM10 7.21E-03 1.56E-05 -1.25 -2.45 
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5.2.2 Abnormal nuclear structure in late-passage NPCs 
From the microarray results it was evident that NPCs underwent similar transcriptome 
changes resembling ageing progression. We further explored the morphological 
phenotypes of late-passage NPCs derived from PD cell lines. Consistent with the 
previous report (Liu et al., 2012), nuclear envelope malformations were identified and 
quantified in late-passage PD NPCs (Figure 5.4 A and B). Nuclear shrinkage with 
abnormal folding and protrusion on the envelope of P10 NPCs was quantified based 
on nuclear circularity index by using ImageJ. Defective nuclear morphology was 
defined by the nuclear circularity index < 0.6 (Liu et al., 2012; Schochlin et al., 2014) 
(WT-GM23280: 3.83±0.70%; WT-GM23279: 2.02±1.20%; WT-IR1.7: 2.59±0.68%; 
PD-ND38477: 9.87±2.91%; PD-ND35367: 11.15±3.01%; PD-ND34391: 
8.00±3.75%). It can be seen that, in PD late-passage NPCs (P10), there is an increased 
frequency of nuclear shrinkage (< 0.6) and a decreased frequency of round nuclear 
morphology (> 0.8) than WT NPCs. This morphological feature has already been 
identified in various cell types including neural lineages under cell stress condition 
and disease condition (Bonde et al., 2002; Nagaoka, 2003; Shinzawa and Tsujimoto, 
2003). Nuclear shrinkage has also been identified as a proceeding morphological 
change for apoptosis, followed by effector caspases and chromatin condensation. The 
identification of abnormal nuclear structures in late-passage PD NPCs indicated that 
cells might have experienced intrinsic cell stress due to prolonged passaging, and such 




 Figure 5.4: Deformed nuclear architecture in late-passage PD NPCs. A. 
Immunofluorescence analysis of the nuclear envelop marker LaminB and neural 
progenitor marker NESTIN in both wild type and PD iPSC-derived P20 NPCs, Nuclei 
were stained with DAPI. Scale bar = 200µm. B. Representative images of abnormal 
nuclear envelop in ND38477 (PARK2 255delA), ND35367 (LRRK2 G2019S) and 
ND34391 (SNCA triplication) cell lines. Arrows indicate noticeable nuclear shrinkage. 
Scale bar = 100µm. Nuclear envelope circularity calculated using LaminB staining by 
Image J shows decreased number of cells with nuclear circuitry index >0.8 in PD cell 
lines. Data represent mean ± SD (n=3). WT samples were pooled for statistical 
analysis. Comparisons are by one-way analysis of variance (ANOVA) followed by 


























5.2.2 Enhanced susceptibility to proteasomal stress-induced apoptosis in PD late-
passage NPCs 
 To further determine if NPCs generated from late-passage PD were more sensitive to 
exogenous cell stress, neurotoxin sensitivity assays were performed to test the cell 
stress susceptibility in late-passage NPCs. The experimental procedure is summarized 
in Figure 5.5 A. Prior to neurotoxin exposure, late-passage NPCs (P16) were 
subjected to antioxidant treatment by changing the original culture supplement to one 
without antioxidants (see method for details). After 16h treatment, a cell-permeable 
proteasome inhibitor, MG-132, was added to the fresh culture medium without 
antioxidant and applied to NPC cultures for incubation with a final concentration of 
10µM. MG-132 targets the proteasome activity, leading to increased protein 
aggregation and impairment of mitochondrial function (Maharjan et al., 2014). 
Therefore, cytosolic ROS could be evaluated as an indicator for cell sensitivity 
towards stress. After 12hrs, mitochondrial O2·− production was detected by site-
specific fluorogenic probes MitoSOX (Figure 5.5 B). While subtle increase of 
fluorescence was observed in WT cell lines after MG-132 treatment, significant 
enhancement of cytoplasmic fluorescence intensity was noticed in PD cell lines, 
especially evident in ND35367 (LRRK2 G2019S) cell line, which indicated a 
increased production of mitochondrial superoxide anion. These results demonstrated 
that late-passage PD lines were more sensitive to the proteasomal inhibition-induced 
mitochondrial dysfunction. Noticeably, in the DMSO control, there is a slight increase 
of fluorescence intensity in PD compared WT, indicating a potential intrinsic ROS 
production in PD late-passage NPCs at basal level. 
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Figure 5.5: Late-passage PD NPCs showed enhanced susceptibility to 
proteasomal stress featured by ROS production. A. Schematic representation of 
neurotoxin assay in late-passage NPCs. B. Mitochondrial ROS was detected using the 
MitoSOX Red probe 12 h after treatment with MG132 or DMSO control. Scale bar = 
100µm. Corrected total cell fluorescence calculated by Image J shows enhanced 
MitoSOX intensity in PD cell lines after MG-132 treatment. Data represent mean ± 
SD (n=3). WT samples were pooled for statistical analysis. Comparisons are by one-
way analysis of variance (ANOVA) followed by Dunnett’s Test. ns, non significant; * 














Next, it was determined whether the enhanced stress susceptibility in late-passage PD 
NPCs would subsequently lead to increased apoptosis. To further directly assess the 
apoptotic populations in response to proteasome inhibition, NPCs after 16hrs 
treatment were co-stained with NESTIN and cleaved caspase-3. The expression of 
NPC marker NESTIN indicated that most of the culture population still carried the 
progenitor identity. Most importantly, compared to WT NPC cultures, more cells 
were immunopositive for cleaved caspase-3, an apoptotic marker, in PD NPC cultures, 
featured by the formation of apoptotic bodies (Figure 5.6 A and B). And these results 
were further quantitatively validated by western blot (Figure 5.6 C and D).  
Thus, the results demonstrated that late-passage PD NPCs in culture displayed 
degenerative morphology in nuclear envelope with relatively higher sensitivity 























































Figure 5.6: Late-passage PD NPCs showed enhanced susceptibility to 
proteasomal stress-induced apoptosis. A. Immunofluorescence analysis of late-
passage NPCs derived from WT and PD iPSCs with MG-132 treatment for 16hrs, co-
stained for NESTIN and cleaved caspase-3. Scale bar = 100µm. B. Cleaved caspase-3 
positive NPCs in culture were calculated by Image J shows enhanced apoptotic 
population in PD cell lines after MG-132 treatment. Data represent mean ± SD (n=3). 
Comparisons are by two-way ANOVA followed by Bonferroni post tests. ns, non 
significant; *** p<0.001. C. Expression of cleaved caspase-3 in both WT and PD 
NPCs with or without MG-132 treatment was determined by western blotting (2 
biological replicates shown). D. Further quantification is normalized to β-ACTIN 
expression. Data represent mean ± SD (n=2). Comparisons are by two-way ANOVA 




















































































Age is an important risk factor for PD and has a substantial impact on the disease 
penetrance. The underlying molecular details of ageing progression are complex. 
Moreover, the multi-dimensional nature of ageing makes it difficult to be 
recapitulated in vitro.  
During the reprogramming process, the age-related features in somatic cells have 
been shown to revert back to embryonic stage (Chin et al., 2009). This specific notion 
has been further addressed by 1) the removal of age-related epigenetic signatures 
(Koche et al., 2011; Papp and Plath, 2013); and 2) the elongation of telomeres in 
iPSCs derived from aged cells (Agarwal et al., 2010; Le et al., 2014; Marion et al., 
2009). Moreover, the same cell lineage again re-differentiated from the iPSCs 
obtained will remain rejuvenated with regard to age-related epigenetic modifications 
(Frobel et al., 2014). The rejuvenation ability is one of the reasons that iPSC 
technology holds great promise for regenerative medicine. However, it also becomes 
a key hurdle in modeling of age-related degeneration disease. Alternative 
methodology is required for iPSC modeling to shorten the time required for 
physiological manifestation of aging-related defects from years.  
Cellular ageing presents progressive functional decline. In stem cells, cellular 
senescence is considered as ageing progress with a complex mix of biological 
progressive events that involves defective self-renewal, excessive accumulation of 
cell stress and DNA damage. In this study, we utilized serial passaging of NPCs in 
vitro to induce proliferative senescence pattern, which resembled the ageing process 
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of NSCs and neural progenitor pools in vivo (Flach et al., 2014; Maslov et al., 2004). 
By transcriptome analysis, genes, functionally involved in DNA repair, DNA 
replication and cell cycle, were progressively suppressed along with prolonged 
passaging. And these changes were consistent across different cell lines, 
demonstrating a reproducible way to model ageing. Moreover, in late-passage NPCs, 
increased cell stress sensitivity was detected in PD cell lines in response to 
proteasomal inhibition, which was not apparent in early-passage NPCs. So far, the 
results indicate that serial passaging of NPCs mimics the aging process, accelerating 
the cellular age-related progression and is sufficient to detect the fundamental 
difference in late-passage PD NPCs compared with WT NPCs. However, a few 
questions need to be further explored in the next chapter. Is it possible that the 
“ageing” signature in late-passage NPCs could be passed on to the mDA neurons 
differentiated from them? Do the mDA neurons generated preserve the enhance cell 
stress susceptibility?  
Our findings were compared with previous research in late-passage NPCs generated 
from LRRK2 G2019S iPSCs (Liu et al., 2012). Although similar phenotypic patterns 
were observed, a noticeable difference was observed in the speed of phenotypic 
progression and the severity of nuclear malformation. In the previous report, the 
nuclear abnormality of P15 PD-NPCs was characterized by the protrusion of nuclear 
microdomains; the PD-NPCs from P16 showed significantly lower neuronal-
differentiation capability than their wild-type counterparts. However, in the current 
NPC passaging system, the most common deteriorated feature in PD late-passage 
NPCs is the nuclear shrinking and folding. Moreover, both WT and PD late-passage 
NPCs (until P20) could be differentiated into mDA neuron cultures without 
 75 
significant difference in efficacy. The cause for the differences observed might be due 
to the different components in the NPC maintenance medium. In the previous study, 
neural stem cells were cultured in the presence of 3 µM CHIR99021, 2 µM SB431542 
and 10ng/mL hLIF, while in our protocol, EGF and bFGF were used to substitute the 
hLIF from neural induction phase. It is known that, during the early embryonic neural 
development, primitive neural stem cells are responsive to bFGF for symmetric 
expansion. Subsequently, LIF and ciliary neurotrophic factor (CNTF), which signal 
through the leukemia inhibitory factor receptor (LIFR), were exposed to the primitive 
neural stem cells to establish the different layers of VZ and SVZ. Thereafter the SVZ 
furthered develops, establishing EGF-responsive neural stem cell population (Gregg 
and Weiss, 2005). Eventually, the adult neural stem cells are mostly a mix population 
of bFGF-responsive and EGF-responsive cells (Tropepe et al., 1999; Vescovi et al., 
1993). Although hLIF has been used in many protocols for long-term propagation of 
NPCs in vitro, it was always used as an additive to EGF- and bFGF2- stimulated 
expansion (Andersen et al., 2009; Bauer and Patterson, 2006; Carpenter et al., 1999; 
Majumder et al., 2012). Therefore, for the prolonged proliferation of NPCs in vitro, 
mitogens bFGF and EGF were chosen in the current study. However, hLIF itself 
might not be sufficient to sustain long-term propagation and multipotency. Therefore, 
in the previous report, NPCs at late passages exhibited more advanced phenotypic 
progression. Furthermore, in the current study, the ultimate goal of modeling ageing is 
to obtain a population of mDA neurons for further assessment. The destructive 
neuronal differentiation phenotype in PD NPCs as characterized from the previous 
report actually is not related to the PD scenario and fails to match the focus of the 
current study. 
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Another hot research topic in ageing is premature ageing disease, known as 
Hutchinson-Gilford progeria syndrome (HGPS). HGPS is caused by a mutation in 
nuclear lamina gene LMNA, which encodes a nuclear envelop protein Lamin A/C. 
This mutation resulted in alternative splicing of LMNA, producing a truncated form of 
Lamin A/C, called as progerin. The accumulation of progerin in the nuclear 
membrane interfered the normal scaffold function of full length Lamin A/C, leading 
to various age-related phenotypes in the cell including nuclear envelop abnormality, 
loss of heterochromatin marks, telomere dysruption and increased DNA damage. The 
overall clinical symptoms of HGPS patient shared similarity with a vast range of 
physiological ageing phenotypes in elderly people (Kudlow et al., 2007). In a recent 
report, researchers developed a method to produce ageing-related features by 
transiently overexpressing progerin in neurons derived from human iPSCs (Miller et 
al., 2013). By introducing progerin in iPSC-derived mDA neurons, ageing-related 
degenerative changes of the neuron morphology were detected, featured by the 
decreased dendrite length. Such changes were more significant in the mDA neuron 
cultures derived from PD iPSCs with homozygous mutations in PINK1 or PARK2. 
Moreover, PD mDA neurons with progerin expression were transplanted into the 
striatum of mice model, showing a dramatic reduction in TH+ cell numbers, which 
mimics the disease phenotype in vivo. Overall, this report took a step to develop 
artificial ageing progression in iPSC modeling by adopting the pathology of 
premature ageing disorder. A key advantage of this approach is the ability to induce 
age-related features by ectopically driving progerin expression in any disease 
backgrounds. However, it remains unanswered whether progerin-induced changes 
mimic the normal ageing process since progerin is a pathogenic protein product, 
which is not present in the PD scenario. Furthermore, the pathogenesis of premature 
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ageing disorder induced by progerin is still uncertain. Therefore, it remains unknown 
whether the introduction of progerin in a PD background would induce even more 
complicated crosstalks between the dysregulated signaling pathways. On the other 
hand, the serial passaging method has been widely used in fibroblast and human stem 
cells to study cellular ageing process (Geissler et al., 2012; Wagner et al., 2009). This 
has also been shown in NPCs (Liu et al., 2012). However, the identity of these late-
passage NPCs corresponding to which stage of NSCs in vivo is still debateble. 
Additionally, the subsequently effect of the passaging towards the differentiated 
neuron remains to be determined. Given these two methods, serial passaging method 
was adapted into our study to facilitate the further phenotypic characterization since it 
was published earlier when this project was started.  
5.4 Conclusion 
In summary, I described an in vitro method to accelerate cellular ageing progression 
by serial passaging NPCs derived from iPSCs. Molecular characterization of the 
transcriptome changes across passages revealed a global decrease of gene expression 
involved in cell cycle, DNA repair and nuclear lumen, which resembled the ageing 
signature in vivo. The phenotypic characterization by proteasome inhibitor exposure 
indicated the enhanced cell stress sensitivity in PD late-passage NPCs compared with 
WT NPCs. Such vulnerability of PD NPCs might be due to the potentially incurred 
stress response under basal level. Ultimately, mDA neurons derived from the late-
passage NPCs could be further assessed for the potentially preserved ageing 
phenotypes and incurred stress sensitivity. This will be presented and discussed in the 
next chapter. 
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Chapter VI – Phenotypic Characterization of mDA Neurons Derived from Late-
passaged PD NPCs 
6.1 Introduction 
6.1.1 Overcoming the obstacles for the phenotypic characterization in iPSC 
modeling of PD 
The complex etiology of PD has been previously described as a combination of 
ageing, genetic disposition and environmental factors. iPSC lines derived from 
patients provided  a human cell-based model, which captures the complete genetic 
background of individual. However, as mentioned in the last chapter, the 
reprogramming method resets genomic methylation of the ageing somatic cells from 
donor (Rando and Chang, 2012). Without the input of the ageing factor, although PD-
specific iPSCs have been generated, the mDA neurons directly differentiated from 
these iPSCs failed to present any PD-related phenotype (Soldner et al., 2009). 
Therefore, it is necessary to introduce ageing pathology and exogenous challenges to 
accelerate the disease progression for conspicuous phenotypes. A number of methods 
have been developed to assess the progressive degeneration of PD mDA neurons in 
vitro, including extended culture of mDA neurons (until Day 75 post differentiation), 
neurotoxin exposure (6-OHDA, H2O2 and MG-132) and progerin overexpression 
(Byers et al., 2011; Miller et al., 2013; Nguyen et al., 2011; Reinhardt et al., 2013; 
Sanchez-Danes et al., 2012). Interestingly, by these additional methodologies, 
spectrums of phenotypes in PD mDA neurons were captured such as decreased 
neurite outgrowth and increased vulnerability to oxidative stress, which partially 
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resembled some certain stages of the PD degenerative signs. Based on the results 
from previous researches, it is evident that iPSC modeling of PD provides a system 
that can be used to monitor the cellular pathological manifestation. 
6.1.2 Lessons from the neurotoxin animal models 
It has been described in epidemiological studies that a number of environmental 
factors may cause PD or increase the risk of developing it, including chemical 
exposure (Priyadarshi et al., 2001). Besides the ageing pathology, which was 
discussed in detail in the last chapter, the neurotoxin etiology of PD was widely 
studied in animal models and cell culture. Several neurotoxins are currently in use in 
primates, rodents, and human cell-based model (Bove and Perier, 2012). Such 
neurotoxins induced cell stress that was also implicated in ageing neurons in vivo. 
Due to their ability to reproduce most of the biochemical, neuropathological and 
clinical features of human Parkinsonism, these chemicals are widely used to model 
the PD progression and to understand the cellular responses towards the imposed 
toxicity.  
6-hydroxydopamine (6-OHDA), a hydroxylated analogue of dopamine, is a classic 
neurotoxin used in animal models of PD. Injection of 6-OHDA into the substantia 
nigra pars compacta (SNpc) of rodents leads to marked lesions of striatal 
dopaminergic terminals, more than 50% loss of nigral dopamine neurons, and a 
reduction of 60–80% of striatal dopamine within 2-3 days (Lee et al., 1996). 6-OHDA 
is transported into mDA neurons through dopamine transporter (DAT) and undergoes 
prompt auto-oxidization, hence generating an intracellular oxidative stress and the 
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subsequent destruction of mDA neurons. 6-OHDA can also accumulate in the 
mitochondria, where it inhibits complex I activity and induces ROS production. 
MPTP is another well-known chemical that induces neuropathological and clinical 
characteristics of PD in both human and non-human primates. MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahy-dropyridine) is a by-product of meperidine-analogue synthesis 
(Kopin and Markey, 1988; Langston et al., 1983; Vazquez-Claverie et al., 2009) and, 
as a lipophilic compound, it easily crosses the blood-brain barrier. MPTP is 
metabolized to MPP+ by the enzyme MAO-B of astrocytes. Subsequently, MPP+ is 
transported into the cytosol of mDA neurons by dopamine transporter (DAT) and 
targets the mitochondrial complex I, resulting in increased mitochondrial ROS 
production (Vila and Przedborski, 2003). Structurally similar to MPP+, the widely 
used herbicide paraquat (N,N -dimethyl-4,4 -bipyridinium dichloride) also 
induces PD-like lesions in the mouse by triggering oxidative stress through redox 
cycling (Berry et al., 2010; Bonneh-Barkay et al., 2005; Miller, 2007). Expression 
profiling has been reported in SK-N-MC human neuroblastoma cell line with 
rotenone treatment to provide an overview of genome-wide responses towards 
neurotoxicity (Cabeza-Arvelaiz and Schiestl, 2012). The transcriptome analysis based 
on this study indicated a disruption in microtubule system, blockage of voltage-
dependent anions channels (VDACs), leading to DNA damage response, promotion 
of differentiation and neuroprotection, and the activation of apoptotic pathways. Such 
categories did resemble the dysregulated pathways associated with ageing-related 
degeneration. Thus, this study supported the idea that cell stress did induce an ageing-
related transcriptome changes. 
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As it can be seen, the common pathway of the degenerative phenotypes in neurotoxin 
animal models is related with oxidative stress-induced cytotoxicity, which resembled 
the ageing pathology. The specificity of the mDA neuronal death is controlled by 
regional injection or the specific affinity between neurotoxin and DAT. Subsequently, 
the ultimate compromise in mitochondrial oxidative capacity after neurotoxin 
treatment plays an important role in cell death pathway decision. Therefore, to 
accelerate the PD progression in iPSC modeling with PD genetic backgrounds, a 
similar perturbed mitochondrial function could be achieved by challenging the mDA 
neurons generated with such neurotoxins. 
In the previous chapter, prolonged passaging in iPSC-derived NPCs has been 
described as an alternative method for mimicking ageing progression in vitro. In this 
chapter, by differentiating the late-passage NPCs into mDA neurons, a similar 
endogenous program of ageing pattern is identified in the neuron cultures. Multiple 
methods of phenotypic characterization are described to detect the vulnerability of PD 





6.2.1 Transcriptome profiling of mDA neurons derived from late-passage NPCs 
To gain insights into the endogenous pattern of the neurons derived from late-passage 
NPCs, mDA neuronal differentiation was performed in both P1 and P10 NPCs from 3 
WT cell lines and 3 PD cell lines, which carried different PD-related inherited gene 
mutation: ND 38477 (PARK2 c.255delA), ND35367 (LRKK2 G2019S) and ND34391 
(SNCA triplication). Using DNA microarrays, gene expression profiling was 
performed with the total RNA extracted from the mDA neuron cultures with various 
conditions to assess differences between P10 and P1 NPC-derived mDA neurons. 
By Welch's unequal variances t-test, comparing the P10 NPC-derived neurons to P1 
NPC-derived neurons, 287 up-regulated genes and 547 down-regulated were detected 
with corrected p-value < 0.05 and absolute fold change > 2.0 (Figure 6.1). 
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Figure 6.1: Passaging-induced gene expression changes in mDA neurons derived 
from late-passage NPCs compared with mDA neurons from early-passage NPCs. 
A. Global gene expression profiles of mDA neurons derived from 6 different iPSC 
lines and from 2 different NPC passages (P1 and P10) were analyzed by microarray. 
Welch's unequal variances t-test analysis revealed that 547 genes were significantly 
down-regulated and 287 genes were significantly up-regulated across passaging. p 



































































































































regulated across passaging between DA cultures and NPCs. P-value determined from 
hypergeometric distribution analysis indicates the significance of overlap. C. Venn 
diagram showing the overlap genes that are down-regulated across passaging between 
DA cultures and NPCs. P-value determined from hypergeometric distribution analysis 
indicates the significance of overlap. D. Venn diagram showing the overlap genes that 
are down-regulated between ageing brain (Loerch et al., 2008), late-passage NPC-
derived neurons from this study and progerin-induced ageing effect (Miller et al., 
2013). 
 
A gene ontology (GO) analysis of the transcripts that were up-regulated or down-
regulated in the late-passage NPC (P10) derived mDA neuron cultures compared to 
early-passage (P1) derived mDA neuron cultures (Table 6.1 and 6.2). Interestingly, a 
significant enrichment of gene with ontologies related to neuron differentiation, 
axongenesis, neuron projection and transmission was observed in the up-regulated 
gene population. Since the same differentiation protocol and duration was applied it 
was evident that, compared to the neuron cultures derived from P1 NPCs, that there is 
an overall enhancement of the neuronal maturity and functionality in P10 NPCs-
derived neurons in response to the prolonged passaging at NPC stage. Among the up-
regulated transcripts NR4A2 (Nurr1) was noticed since it is a marker for mature mDA 
neurons. It shows 4-fold up-regulation in P10 NPCs-derived mDA neuron cultures 
compared with the neuron cultures derived from P1 NPCs, suggesting that the 
neurons obtained with serial passaging might be more mature.  
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Table 6.1 Enrichment in gene ontology analysis of up-regulated genes in mDA 
neuron cultures derived from late-passage NPCs 
GO Term p-value Bonferroni corrected p-value 
GO:0030182~neuron differentiation 4.86E-08 5.33E-05 
GO:0021952~central nervous system projection 
neuron axonogenesis 1.61E-07 1.77E-04 
GO:0007409~axonogenesis 4.75E-07 5.21E-04 
GO:0021955~central nervous system neuron 
axonogenesis 5.93E-07 6.51E-04 
GO:0048667~cell morphogenesis involved in 
neuron differentiation 1.17E-06 1.29E-03 
GO:0048812~neuron projection morphogenesis 1.45E-06 1.59E-03 
GO:0030030~cell projection organization 1.68E-06 1.84E-03 
GO:0031175~neuron projection development 2.09E-06 2.29E-03 
GO:0048666~neuron development 2.62E-06 2.87E-03 
GO:0000904~cell morphogenesis involved in 
differentiation 6.51E-06 7.11E-03 
GO:0048858~cell projection morphogenesis 6.80E-06 7.44E-03 
GO:0019226~transmission of nerve impulse 9.30E-04 6.40E-01 
 
 
Table 6.27Enrichment in gene ontology analysis of down-regulated genes in 
mDA neuron cultures derived from late-passage NPCs 
GO Term p-value Bonferroni corrected p-value 
signal peptide 2.02E-10 2.64E-07 
GO:0044421~extracellular region part 2.52E-06 7.39E-04 
GO:0031982~vesicle 1.06E-06 3.12E-04 
GO:0031410~cytoplasmic vesicle 2.86E-06 8.41E-04 
GO:0031988~membrane-bounded vesicle 1.09E-05 3.21E-03 
GO:0016023~cytoplasmic membrane-bounded 





For the down-regulated genes, the highly enriched gene ontology terms are related to 
neuropeptide signals and cytoplasmic vesicles. The reduced neuropeptide signaling 
highlighted by functional clustering resembled the age-related trend in vivo (Chung et 
al., 2005). On the other hand, the genes enriched as “vesicle” mainly function in 
endoplasmic reticulum and synaptic vesicle (Supplementary table 5). It is interesting 
to observe an increased expression of mature neuronal markers in the late-passage 
NPC-derived neurons, which was also accompanied with the decreased expression of 
endoplasmic reticulum chaperones (Calnexin, PDIA6 and HSP90B1) and synaptic 
vesicle genes (SYN2 and SNAP23). A potential decline of the cytoplasmic vesicle 
transport was found, which could be a dysregulated event in the late-passage NPC-
derived neurons. 
Next, the up- and the down-regulated genes in P10 versus P1-derived mDA neuron 
cultures were respectively compared with the gene lists identified from passaging 
effects in NPCs. This comparison intended to isolate the differential expressed genes 
in late-passage versus early-passage at both NPC and neuron stages. The overlapping 
gene fractions are now presented in Venn diagram (Figure 6.1 B and C). The detailed 
gene lists with expression fold changes and corrected p-values are presented in 
Supplementary table 6 and 7. P-values determined by hypergeometric probability 
indicated the high significance of the overlapping genes. This statistical analysis 
demonstrated an impact of passaging in NPCs to the differentiated neurons, which 
could be presented by the consistent gene expression changes across NPCs and 
neurons, such as the up-regulation of FSTL5, MTUS1 and down-regulation of 
EFEMP1, WNT5A and SYN2. Overall, passaging induced an ageing-related 
transcriptome changes in the late-passage NPCs and the subsequent neuron progeny.  
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On the other hand, it is intriguing to know how these transcriptome changes resemble 
the ageing neurons in vivo. Moreover, considering the recent report in ageing 
modeling by progerin, it is interesting to find out whether both methods could 
introduce age-related transcriptome changes in neurons. Therefore, a collection of 
genes found to be down-regulated in human ageing brain were recruited for analysis 
(Loerch et al., 2008). This dataset, as a reference of in vivo ageing transcriptome 
changes, was compared with the down-regulated genes in late-passage NPC-derived 
neurons from this study and the down-regulated genes induced by progerin from the 
previous report (Miller et al., 2013). The overlapping gene fractions are presented in 
Venn diagram (Figure 6.1D). The result presented a significant overlapping of 45 
genes (p<7.223e-11) between in vivo ageing dataset and the passaging effect, which 
includes the genes identified at both NPC and neuron stage such as WNT5A and SYN2. 
The detailed gene lists with expression fold changes and corrected p-values are 
presented in Supplementary table 8. For the comparison between progerin-induced 
gene changes and down-regulated gene changes in late-passage NPC-derived neurons, 
it was shown that there was a moderate fraction: 19 genes commonly observed in both 
dataset (p<0.002). Thus, the above analysis strongly suggests that there is an ageing-
related decreased gene expression changes in late-passage NPC-derived neurons 
compared with early-passage NPC-derived neurons, which resembled the ageing 
brain transcriptome changes in vivo. This comparison also indicated that serial 
passaging and progerin shared a similarity of decreased gene changes that were 
induced in neuron cultures. For up-regulation genes, same analysis was performed. 
However, no significant gene overlapping could be identified in these three categories.  
 
 88 
Next, analysis was performed by 2-way ANOVA test to compare the passaging effect 
onto the DA neuron cultures and the PD versus WT group with a fold change cut-off > 
1.5 and corrected p-value cut off < 0.05 (Figure 6.2 A). The most abundant gene 
changes that could be found in PD versus WT are FOXA2 and FOXA1. These two 
genes showed significant down-regulation in PD neuron cultures compared to WT 
cultures, and such down-regulation was only present in late-passage NPC-derived 
neuron cultures (Figure 6.2 B). FOXA2 and FOXA1 are known to be the important 
transcription factors for mDA neuron differentiation (Ferri et al., 2007). They also 
have a strong implication in adult DA neurons maintenance (Domanskyi et al., 2014; 
Stott et al., 2013). This leads to an interesting argument that will be further discussed 
in the Section 6.3. GO analysis was performed in down-regulated genes, which 
demonstrated the gene clustering associated with cytoplasmic vesicle (p=5.94E-04, 
p(corrected)=0.05) and lysosome (p=0.002, p(corrected)=0.06) (Figure 6.2 C). For 








Figure 6.2: Transcriptome analysis in PD late-passage NPC-derived mDA 
neuron cultures compared with WT. A. Global gene expression profiles of mDA 
neurons derived from P10 NPC-derived mDA neuron cultures in 3 PD cell lines were 
compared with 3 WT cell lines by two-way ANOVA analysis. p(Corrected)<0.05; 
FC>1.5. Analysis revealed that 230 genes were significantly down-regulated and 202 
genes were significantly up-regulated in PD P10 NPC-derived mDA neuron cultures 
compared to WT P10 NPC-derived mDA neuron cultures. B. Table showing the 
expression fold changes of FOXA2 and FOXA1 in the analysis. C. GO analysis of the 
down-regulated genes in PD P10 NPC-derived mDA neuron cultures compared to 




























































































FOXA2$ -16.42$ 1.03$ 9.01E-03$
FOXA1$ -5.32$ 1.00$ 2.93E-03$
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6.2.2 Morphological alterations of PD-iPSC-derived DA neurons 
To further characterize the mDA neurons from late-passage NPCs, 
immunocytochemistry was performed in the mDA neurons derived from late-passage 
NPCs (P12).  Cultures of differentiated mDA neurons derived from 3 WT cell lines 
and 3 PD cell lines (consistent with the microarray) were co-stained with TUJ1 and 
TH to visualize the neurite morphology (Figure 6.3 A). It was evident that PD mDA 
neurons exhibited morphological abnormalities in neurite length compared to WT. 
Quantification of TH-positive neurite length showed statistically significant (p<0.001) 
reduction in the extension of mDA neurites in ND35367 and ND34391 cell lines 
(GM23280: 167.8±17.29µm; GM23279: 197.6±25.13µm; IR1.7: 171.4±19.20µm 
ND38477 194.2±30.29µm; ND35367: 124.0±13.01µm; ND34391: 144.7±15.26µm) 
(Figure 6.3 B). Notably, mDA neurons derived from late-passage NPCs of ND35367 
(LRRK2 G2019S) cell line showed damaged neurites with hallmark blebbing in 
neuronal projections and axonal fragmentation, whereas it was not observed in WT 







Figure 6.3: Neurite shortening in mDA neurons derived from late-passage PD 
NPCs. A. Representative images of neurites double labeled with TUJ1 and TH at D35. 
Axonal degenerative morphology is obviously present in mDA neuron cultures 
derived from late-passage NPCs with LRRK2 G2019S mutation (ND35367). Scale bar 
= 100µm. B. Quantification TH+ neurites in mDA neuron cultures from 3 WT and 3 
PD cell lines. Data represent mean ± SEM (n=3). ns, non-significant; *** p<0.001. 
WT samples were pooled for statistical analysis. Comparisons are by one-way 
ANOVA followed by Dunnett’s Test. Comparisons within WT groups are by one-
way ANOVA followed by Tukey’s Multiple Test. C. Representative images of loss of 
neuronal projections particularly in LRRK2 G2019S. Arrows indicate noticeable 










































Next, it was determined whether the shorter neurites in PD cell lines were associated 
with apoptosis, eventually resulting in a degenerative phenotype. In chronic 
neurodegenerative diseases, progressive up-regulation of caspase-3 mRNA has been 
demonstrated in transgenic mouse models of amyotrophic lateral sclerosis (ALS) and 
Huntington disease (Chen et al., 2000; Li, 2000; Vukosavic et al., 2000). We 
investigated caspase-3 expression changes by RT-qPCR with the differentiation and 
further prolonged culture of mDA neurons. In this experiment, we recruited 2 WT cell 
lines (GM23280 and GM23279) and 5 PD cell lines (ND38477, ND34367, ND35391, 
ND38369 and ND40597). In PD mDA neuron cultures, subtle changes of caspase-3 
expression were detected in both WT and PD mDA neurons at day 28 compared with 
NPC stage (Figure 6.4 A). The enhancement of caspase-3 expression only showed 
statistical significance in ND34391 (SNCA triplication) at day 28 compared with WT 
cell lines. However, after further culture to day 49, expression of caspase-3 was 
elevated in all the PD cell lines assayed, showing a moderate statistical significance 
(Figure 6.4 B). These results suggest that the progressive induction of caspase-3 
expression in PD mDA neurons along with prolonged culture might contribute to the 
subsequent degeneration.  
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Figure 6.4: Increased apoptotic neuron population in mDA neurons derived 
from late-passage PD NPCs. A. Caspase-3 gene expression was detected by qRT-
PCR on mDA neuron cultures differentiated for 28 days and 49 days. Data represent 
mean ± SD (n=4). Comparisons are by two-way ANOVA followed by Bonferroni 
posttests. ns, non significant; * p<0.05, ** p<0.01, *** p<0.001. B. Summary of the 
expression change folds combining 2 WT lines and 5 PD lines. Data represent mean ± 






































analysis of mDA neurons differentiated from WT and PD iPSCs for 40 days, co-
stained for MAP2 and cleaved caspase-3. Scale bar = 100µm. D. Quantitative 
analyses of the percentage of neurons with positive staining for cleaved caspase-3. 
Data represent mean ± SEM (n=3). Comparisons are by one-way ANOVA followed 
by Dunnett’s Test.* p<0.05.  
 
To further directly assess the apoptotic populations in mDA neuron cultures, neurons 
at day 40 were co-stained for MAP2 and cleaved caspase-3. Compared to WT mDA 
neuron cultures, more cells were positive for cleaved caspase-3 in PD mDA neuron 
cultures, presenting by fragmented neuronal structure and the formation of apoptotic 
bodies (Figure 6.4 C). Quantification of the apoptotic populations further confirmed 
this finding (GM23280: 3.020±1.384%; GM23279 1.426±0.624%; ND38477: 
1.936±0.775%; ND35367: 10.66±3.206%; ND34391: 4.946±2.978%; ND39896: 
4.724±1.950%; ND40597: 6.048±4.142%), presenting enhanced apoptotic population 
in the PD cell lines except ND38477 (Parkin mutation). Thus, our results so far 
demonstrated that PD mDA neurons in culture displayed degenerative morphology 
with a relatively high percentage of cell populations undergoing apoptosis compared 






6.2.3 Protein aggregation and electrophysiological study in PD mDA neurons 
Emergence of PD-related phenotypes has been described in the previous section, 
indicating potential disease progression occurred at basal level. Another clinical 
feature strongly implicated in both familial and sporadic PD is the abnormal 
accumulation of α-synuclein in protein aggregates within Lewy bodies (Baba et al., 
1998; Chung et al., 2001; Farrer et al., 2001; Kalia et al., 2015). First, SNCA mRNA 
expression changes were determined by RT-qPCR with further prolonged culture of 
mDA neurons at Day 28, 35, 42 and 49 (Figure 6.5A). 2 WT cell lines and 5 cell lines, 
as previous section, were recruited. The selection of these 5 cell lines was due to their 
gene mutations that covered all the mutation types we had. Two-way ANOVA test 
were performed to show the effect of the prolong culture (p<0.0001), the variance 
between different cell liens (p<0.0001) and the interaction between prolong culture 
and cell lines (p<0.0001). 
Thus, the accumulation of α-synuclein was evaluated by detecting the phosphorylated 
form of α-synuclein (PS129α-synuclein), which was identified as the predominant type 
of α-synuclein (approximately 90%) in Lewy bodies (Fujiwara et al., 2002; Sato et al., 
2013; Sugeno et al., 2008). It was found by the western blot of mature mDA neuron 
cultures that PD mDA neurons robustly expressed PS129α-synuclein compared to WT 
mDA neurons, especially in ND34391 cell line carrying the SNCA triplication 
mutation (Figure 6.5 B and C). In the ND38477 cell line with PARK2 c.255delA 
mutation an enrichment of PS129α-synuclein was also observed, corresponding to the 
Lewy body pathology in PARK2-related early-onset Parkinsonism (Farrer et al., 
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2001), while a mild PS129α-synuclein phenotype was present in most of the LRRK2 
G2019S cell lines. 
Figure 6.5: Abnormal α-synuclein aggregation and defective electrical activity in 
PD mDA neuron cultures. A. SNCA gene expression was detected by qRT-PCR on 
mDA neuron cultures differentiated for 28, 35, 42 and 49 days. Data represent mean ± 
SD (n=4). Comparisons are by two-way ANOVA followed by Bonferroni posttests. * 
p<0.05, ** p<0.01, *** p<0.001. B. Representative western blot illustrating PS129α-
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synuclein protein abundance in WT and PD mDA neuron cultures with different 
genetic backgrounds. C. Quantification of PS129α-synuclein protein abundance in 2 
WT cell lines and 4 PD cell lines from 3 biological replicates. Data represent mean ± 
SEM (n=3). Comparisons are by one-way ANOVA followed by Dunnett’s Test.* 
p<0.05, ** p<0.01. D. Raster plot of spontaneous spiking activity by using 248-
channel MEAs. Synchronized networks in WT cultures are presented as vertical 
bands of spikes network; MEA recordings reveal less synchronized neuron networks 
in PD DA cultures. E. Quantitative analysis of the numbers of firing neurons and 
firing rates was calculated in one WT cell line (GM23279) and one PD cell line 
(ND35367) in two biological replicates. In each biological replicate, multiple field 
potentials were recorded indicated by N. Data represent mean ± SD. 
 
Besides morphological and neurochemical phenotypes described so far it is also 
intriguing to know whether there are any differences in neuronal activity between PD 
and WT mDA culture. Therefore, an electrophysiological study was performed using 
multielectrode arrays (MEAs). Field potentials from multiple areas within mDA 
neuron cultures were recorded. It was notable that the simultaneous recording in mDA 
neuron cultures revealed synchronized firing networks in WT cultures, while such 
synchronized firing was not identified in PD mDA neurons with LRRK2 G2019S 
mutation (Figure 6.5 D). Moreover, in comparison to WT cell lines, quantification of 
electrical activity within the mDA neuron cultures indicated that there was significant 
decrease in the active channels and firing rates in PD mDA neuron cultures with 
LRRK2 G2019S mutation (Figure 6.5 E). Based on the results presented, PD mDA 
neurons appeared to present native PD-related phenotypes involved in protein 
aggregation and electrophysiological impairment. 
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6.2.4 Increased susceptibility of PD-iPSC-derived mDA neurons towards 
neurotoxins and PD environmental factors 
As shown in the last chapter, in late-passage NPCs the PD cell lines displayed 
enhanced oxidative sensitivity compared to WT cell lines, thus demonstrating a 
phenotype acquired after serial passaging. In addition, the microarray experiments 
comparing P1-derived mDA neurons and P10-derived mDA neurons demonstrated a 
similar ageing pattern featured in the transcriptome that was carried over from late-
passage NPCs to the corresponding differentiated mDA neurons. Additionally, it has 
been illustrated in the previous reports that exposure to neurotoxins can cause 
mitochondrial functional impairment and the release of ROS, leading to a number of 
cellular responses including apoptosis and increased risk of developing PD. Therefore, 
it is intriguing to understand the vulnerability of mDA neurons towards oxidative 
stress by applying neurotoxins to the genetic iPSC-modeling of PD. This 
neurotoxicity challenge may resemble the stress situation in vivo and accelerates the 
detection iPSC-modeling of disease-related phenotypes. 
In order to explore the antioxidant capacity, we compared the susceptibility of mDA 
neurons derived from both WT and PD late-passage NPCs to multiple neurotoxins. 
The experimental procedure is summarized in Figure 6.6. Prior to neurotoxin 
exposure, the antioxidant components in the cell culture supplement of mDA neurons 
derived from late-passage NPCs (P10~P15) were removed. After 16h treatment, 
various neurotoxins were added individually to the fresh culture medium without 
antioxidant and applied to mDA neuron cultures for incubation for 20~24 hrs. 
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Figure 6.6: Schematic representation of neurotoxin assay in mDA neuron 
cultures derived from late-passage NPCs.  
 
First, 6-OHDA and MG-132 were used to challenge the mDA neuron cultures 
generated from P10 NPCs, with a final concentration of 10 M for 6-OHDA and 
2uM for MG-132 (Nguyen et al., 2011). At 24 h, cells were fixed and stained for 
TUJ1 and TH to visualize the neuron morphology and to quantify the neurite length 
(Figure 6.7). Based on the TH staining, it was observed that the morphology of mDA 
neurons from WT cell lines did not show much difference before or after neurotoxin 
treatment. However, in PD cell lines, mDA neurons exhibited morphological changes 
in neurite length compared after treatment. Quantification of TH-positive neurite 
length to compare the mDA neurite extensions after 6-OHDA treatments with the 
DMSO control indicated a statistically significant reduction in ND35367 (p < 0.001) 
and ND34391 (p < 0.001) cell lines, while the decreased reduction was not observed 
in WT cell lines (Figure 6.7 D). For MG-132 treatment, the decrease in neurite length 
in all PD cell lines were much more remarkable compared to WT cell lines (Figure 
6.7 D). Overall, it was shown by the TUJ1 and TH staining that PD mDA neurons 
presented progressively degenerated phenotypes after neurotoxin treatment based on 
the more significant decreased neurite length compared to WT mDA neurons by two-






























































Figure 6.7: Neurite degenerative effect of 6-OHDA and MG-132 on mDA 
neurons derived from late-passage NPCs. A. Representative images of neurites 
double labeled with TUJ1 and TH at D34 with DMSO control, B. 6-OHDA treatment 
or C. MG-132 treatment. Scale bar = 100µm. D. Quantification TH+ neurites in mDA 
neuron cultures from 3 WT cell lines and 3 PD cell lines with DMSO control, 6-
OHDA and MG-132 treatment. Data represent mean ± SD (n=3). Comparisons within 
the treatment are by one-way ANOVA followed by Dunnett’s Test. Comparisons 
across different treatments are by two-way ANOVA followed by Bonferroni posttests. 



























Next, to further measure the differential susceptibility of neurotoxin-induced cell 
death, neurons were fixed and stained for TUJ1 and cleaved caspase-3 after 
neurotoxin treatment (Figure 6.8). It could be observed from the immunostaining that 
WT mDA neuron cultures showed no significant increase in cell death after 6-OHDA 
treatment, while enhanced apoptotic population could be noticed in the mDA neuron 
cultures derived from ND35367 and ND34391 cell lines (Figure 6.8 A). In MG-132 
treated cells, such apoptotic population became more significant (Figure 6.8 C). The 
apoptotic neurons in the culture were quantified based upon the cleaved caspase-3, 
normalized by the total nuclei numbers in the field (Figure 6.8 D). Based on two-way 
ANOVA, the apparent increase in cell death showed a statistical significance in 
ND35367 and ND34391 cell lines compared with WT cell lines (p (genotype) < 0.001, 
p (treatment) < 0.001).  
In summary, these findings demonstrate that neurotoxin exposure towards mDA 
neurons derived from late-passage PD NPCs induce a degenerative progress in neurite 
extensions, leading to an enhancement of apoptotic populations, while the WT cell 
lines sustain the cytotoxicity and present minor degenerative phenotypes relative to 
PD cell lines. Overall, these observations suggest that the PD mDA neurons are more 



























































Figure 6.8: Differential susceptibility of PD and WT mDA neuron cultures to 
neurotoxin-induced cell apoptosis. A. Representative images of mDA neuron 
cultures double stained with TUJ1 and cleaved caspase-3 at D34 with DMSO control 
B. 6-OHDA treatment or C. MG-132 treatment. Scale bar = 100µm. C. Quantification 
cleaved caspase-3 + neurons in mDA neuron cultures from 3 WT cell lines and 3 PD 
cell lines with DMSO (control), 6-OHDA and MG-132 treatment. Comparisons 
within the treatment are by one-way ANOVA followed by Dunnett’s Test. 
Comparisons across different treatments are by two-way ANOVA followed by 




























Paraquat, a widely used herbicide, has been identified as an environmental factor for 
PD due to its structural similarity to the active metabolite of MPTP: MPP+. This toxin 
leads to destruction of mDA neurons in human (McCormack et al., 2002). To test and 
compare the effect of paraquat on WT and PD iPSC-derived mDA neurons, mDA 
neuron cultures derived from P12 NPCs were subjected to the removal of anti-
oxidants and treated with paraquat with a final concentration of 400µM for 20hrs 
(Peng et al., 2004; Song et al., 2011). Subsequently, neurons were fixed and stained 
for NURR1 and cleaved caspase-3 after neurotoxin treatment (Figure 6.9). NURR1 is 
a nuclear marker for mDA population. And the co-localization of NURR1 and 
cleaved caspase-3 indicated the apoptotic mDA cell neurons in culture. It could be 
observed from the immunostaining that WT mDA neuron cultures showed no 
significant increase in cell apoptosis after paraquat treatment, while a notable 
apoptotic population was apparent in the mDA neuron cultures derived from 
ND35367 (p<0.001) and ND34391 (p<0.05) cell lines. The apoptotic neurons in the 
culture were further quantified and showed a statistically significant enhancement in 
PD cultures based on two-way ANOVA (p (genotype) < 0.001, p (treatment) < 0.001) 
(Figure 6.9 C).  
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Figure 6.9: Differential susceptibility of PD and WT mDA neuron cultures to 
paraquat treatment. A. Representative images of mDA neuron cultures double 
stained with NURR1 and cleaved caspase-3 at D34 with DMSO control or paraquat 
treatment. Scale bar = 200µm. B. Quantification cleaved caspase-3+ neurons in mDA 
neuron cultures from 3 WT and PD cell lines. Data represent mean ± SD (n=3). 
Comparisons within the treatment are by one-way ANOVA followed by Dunnett’s 
Test. Comparisons across different treatments are by two-way ANOVA followed by 



















































To determine the effect of paraquat towards mDA neurites, neurons were co-stained 
with TUJ1 and TH (Figure 6.10 A and B). As shown in TH staining, the majority of 
mDA neurons derived from WT cell lines preserved the morphology of extended 
neurites with paraquat incubation, while in mDA neuron cultures derived from PD 
cell lines, impaired neurite fragments were observed in most of the cultures, 
especially evident in ND35367 cell lines (Figure 6.10 C). It was notable that there 
was no intact mDA neuron in the mDA neuron cultures generated from ND35367 cell 
line after paraquat treatment. Moreover, although PD mDA neurons derived from 
late-passage NPCs displayed a native neurite shortening phenotype indicated in the 
DMSO control, the defective neurite further deteriorated after paraquat treatment 
based on the quantification of the neurite length of TH+ neurons (Figure 6.10 D). 
Based on two-way ANOVA, the decreased neurite length showed a statistical 
significance in ND38477 and ND35367 cell lines compared with WT cell lines (p 
(genotype) < 0.001, p (treatment) < 0.001). Thus, the results so far suggested that, in 
overall, mDA neurons derived from PD late-passage NPCs were more susceptible to 



























































Figure 6.10: Paraquat-indiced defective neurites in mDA neurons derived from 
late-passage PD NPCs. A. Representative images of neurites double labeled with 
TUJ1 and TH at D34 with DMSO or B. paraquat treatments. Scale bar = 200µm. C. 
Left panel: representative images of loss of neuronal projections after paraquat 
incubation; Right panel: zoom-in images presenting local fields of mDA morphology. 
Scale bar = 100µm. D. Quantification of neurite length of TH+ neurons from 3 WT 
and 3 PD cell lines. Data represent mean ± SD (n=3). Comparisons within the 
treatment are by one-way ANOVA followed by Dunnett’s Test. Comparisons across 
different treatments are by two-way ANOVA followed by Bonferroni posttests. ** 
































To understand the development and progression of PD, an effective cell model that 
combines the genetic predispositions with other risk factors is required to generate a 
PD-related phenotypic readout. However, the difficult accessibility of aged human 
primary mDA neurons prior to disease progression has hindered the disease cellular 
characterization and study of the underlying molecular pathology. The derivation of 
mDA neurons from late-passage NPCs provided a novel method to model aged 
neurons, presenting native PD-related phenotypes. The long-term passaging induced 
gene expression changes in NPCs and the mDA neuron cultures generated from these 
NPCs. By transcriptome profiling analysis of early- and late-passage NPC-derived 
neurons, a consistent pattern of passaging induced gene changes were identified. 
These gene expression changes were also found to overlap with those observed in 
ageing brain in vivo. WNT5A is one of the down-regulated genes in both late-passage 
NPCs and neurons. It has been reported that WNT5A cooperates with WNT1 to 
maintain midbrain DA precursors in vivo (Andersson et al., 2008; Andersson et al., 
2013; Blakely et al., 2011). The down-regulation of WNT5A expression presents a 
potential gradual decline of mDA precursor capacity after serial passaging. On the 
other hand, in late-passage NPC derived mDA neuron cultures, specific genes related 
with neuron functions were shown to be down-regulated and shared a similarity with 
the ageing brain, such as neurotransmitter receptors and ion channels: GABRA2, 
DRD1 and GRIN2A. Overall, serial passaging methodology had been adapted into this 
study to recapitulate age-related cellular changes in both NPCs and NPC-derived 
neurons from various PD genetic backgrounds (Liu et al., 2012). NPC maintenance 
formula was further modified to produce late-passage NPCs and subsequent 
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differentiate these into mDA neuron cultures. By transcriptome analysis, I further 
confirmed the age-related changes in these cells. Since I was able to generate mDA 
neurons from late-passage NPCs, these “aged” neurons could be used to characterize 
late-onset PD phenotypes. 
On the other hand, two-way ANOVA analysis was performed to compare mDA 
neuron cultures of PD versus WT. Interestingly, the down-regulation of FOXA2 and 
FOXA1 was found specifically in PD late-passage NPC-derived neurons. Regarding 
to the potential heterogeneity of cell population, the down-regulation of FOXA2 and 
FOXA1 might be due to a decreased mDA population in PD cell lines versus WT cell 
lines at late-passage. However, no other mDA neuron markers could be identified 
with significant differential expression. This is intriguing. From previous report, 
conditional DA neurons-specific knockout of both genes in adult mice midbrain 
ultimately led to a reduction of DA neuron after 24 weeks (Domanskyi et al., 2014). 
Thus, the down-regulation of FOXA2 and FOXA1 might be a preceding event in PD 
mDA neuron cultures, which may be associated with the further apoptotic phenotypes 
observed in prolonged culture (Figure 6.4). The transcriptome data generated from 
iPSC disease modeling is always under debate that how similar they are with the 
disease tissue in vivo. Since PD brain data was mostly sampled from post-mortem 
tissue instead of preclinical samples, the transcriptome changes were more related 
with the late stage of the disease, such as programmed cell death and cell survival 
signaling (Simunovic et al., 2009). On the other hand, late-passage NPC derived 
neurons presented disease-related features based on our study. However, compared to 
post-mortem samples, these neurons are still at an early stage of disease progression. 
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The late-passage PD NPCs-derived neurons exhibited a degenerative phenotype 
indicated by the decreased neurite length and progressive up-regulation of caspase-3 
activity. Intriguingly, such native phenotypes presented at basal level may reflect the 
underlying cellular stress resulted by the interaction of disease mutations and ageing 
modeling. It is predictable that further deterioration and eventual cell death in the vast 
majority of PD mDA neurons could be observed with further prolonged culture. 
However, such phenotypic readout in different PD cell lines is not equivalently 
profound in one of the cell line (ND38477 Park2 c.255delA), which will be further 
discussed below. On the other hand, due to this, two-way ANOVA analysis shown 
above to compare PD datasets with WT datasets might not be able to capture the gene 
changes with variance within PD group, such as neurite axongenesis.  
Interestingly, a mild PS129α-synuclein phenotype was observed in LRRK2 G2019S cell 
lines in an inconsistent pattern (Figure 6.4 A).  In some of the LRRK2 G2019S cell 
lines, the expression of PS129α-synuclein was equivalent to WT cell lines. Actually, 
such variation in Lewy body inclusion among patients with LRRK2 G2019S mutation 
is commonly recognized in autopsy findings (Gaig et al., 2009; Poulopoulos et al., 
2012). First, it remains under debate that whether LRRK2 G2019S contributes to 
phospho-S129 of α-synuclein. Currently, there is only one paper that claims LRRK2 
G2019S can phosphorylate recombinant α-synuclein at serine 129 in vitro (Qing et al., 
2009). However, contradicted negative result was also reported in mice (Herzig et al., 
2012; Lin et al., 2009). A more recent paper on LRRK2 G2019S PD post-mortem 
material provided more insights into the heterogeneous pS129 α-synuclein 
phenotypes in human (Mamais et al., 2013). In this paper, researchers uncovered 
differential pS129 α-synuclein immunoreactivity in LRRK2 G2019S PD brains and 
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divergent solubility properties of α-synuclein species. Thus, it is expected that, even 
though the cell lines were bearing the same LRRK2 G2019S mutations, α-synuclein 
phenotypes could be divergent due to different genetic backgrounds. Second, the 
clinical data for our cell lines is available for ND35367 (LRRK2 G2019S/G2019S), 
ND40018 (LRRK2 G2019S/G2019S) and ND34391 (SNCA triplication). Both LRRK2 
G2019S patients did not present significant cognitive impairment or dementia. And 
ND34391 (SNCA triplication) patient presented apparent dementia with Lewy bodies. 
The clinical information did provide some clues that α-synuclein phenotypes do not 
have a full penetrance in PD patients harboring LRRK2 G2019S. Nevertheless, the 
limited clinical information for the other cell lines prevented us drawing any 
consolidated conclusion. The apparent pS129 α-synuclein phenotype in sporadic cell 
line was further supported by quantification. However, we do not have any clinical 
information to correlate this finding with the patient. One possible explanation for this 
phenotype is that the sporadic case may carry a genetic variance affecting the same 
molecular pathway(s) as did the SNCA mutation.  
On the other hand, heterogeneity in the phenotypic characterization of neurite length 
and cell apoptosis was described among different PD cell lines. ND38477 cell line, 
which carried Park2 c.255delA mutation, showed no significant or mild degenerative 
phenotypes compared to other cell lines. Such phenotypic diversity is understandable 
due to the complex nature of PD progression and the individual-to-individual 
variation. PD patients with distinct disease mutations have variable course and 
severity of mDA degeneration. Therefore, without further exogenous perturbation, 
mDA neurons, which carried Park2 c.255delA mutation, may not be able to present 
the distinguished neuronal death as other cell lines. However, we also cannot exclude 
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the possibility that, in Park2 c.255delA cell line, mDA neurons derived from even 
later passage of NPCs or mDA neurons being cultured much longer would express 
morphological signs of degeneration relative to WT cell lines. And it is noteworthy 
that a unifying vulnerability in different PD cell lines was quantified in response to 
different neurotoxins treatments, suggesting that exogenous perturbations might 
accelerate the disease progression of the basal level. Thus, the degenerative signs in 
mDA neurons with Park2 c.255delA mutation were finally triggered and exposed.  
Furthermore, as expected, the severity of stress response elicited by different 
neurotoxins was variable. It is known that each neurotoxin might initiate the cell 
stress through different signaling pathways. For example, 6-OHDA triggers oxidative 
stress inside neurons by the metabolite product hydrogen peroxide, while MG-132 
targeted the proteasome, thereby inducing ubiquitinated protein aggregation and 
subsequent cell stress response. Moreover, the dosage of each neurotoxin used had a 
significant impact on the ultimate cytotoxicity. Therefore, it is impractical to achieve 
equivalent cellular outcomes with the same neurotoxin dosage. On the other hand, a 
more stringent methodology could be applied in the neurotoxicity assay by building 
up dose-response curves for each neurotoxin in each cell line. By comparing the curve 
slopes or LD50 of each neurotoxin in difference cell lines, more accurate neurotoxin 
sensitivity could be determined. Overall, a spectrum of disease-related phenotypes 
was observed in PD cell lines, indicating cell stress vulnerability of PD mDA neurons 
compared to WT.  
Another question that should be mentioned is the selective neurotoxin susceptibility 
of mDA neuron. In this neurotoxicity assay, dopaminergic neuron specific 
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compounds such as 6-OHDA and paraquat were employed. The measurement of 
neurite length was based on TH staining, which only labeled the dopaminergic 
neurons in the cultures. However, in order to prove that mDA neurons from PD cell 
lines were more sensitive towards cell stress compared to other cell subtypes from the 
same culture or same cell line. Additional methodology could be applied to test this 
question. Non-dopaminergic neurons can be generated from iPSC lines by random 
differentiation or by direct differentiation towards cortical or motor neurons. It would 
be interesting to see different responses in these cultures compared to dopaminergic 
neuron cultures. 
6.4 Conclusion 
In this chapter, I presented a variety of methodologies in mDA neurons to model key 
aspects of PD in vitro, including ageing progression and environmental factors. By 
utilizing the serial passaging at NPC stage and neurotoxin treatment, the accumulation 
of ageing features and cell stress in relation to PD progression could be rapidly 
recapitulated in cell culture. With further characterizing the cell morphology, neurite 
extensions and apoptosis commitment, degenerative signs of PD mDA neurons were 
illustrated, reflecting the key PD-relative phenotype in vitro. Furthermore, evaluation 
of altered cell responses to neurotoxic substances highlighted the overall vulnerability 
of PD mDA neurons towards various kinds of cell stress, relative to WT mDA 
neurons. In short, these findings further validated iPSC-based modeling of PD with 
various genetic backgrounds. Unifying phenotypic profiling could be achieved by 
further optimization in neurotoxin dosage, and hence this methodology could be used 
as readouts for screening of potential therapeutic targets. 
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Chapter VII – Transcriptome Profiling of PD mDA neurons Identifies Molecular 
Modifiers at Early Stages of PD Progression 
7.1 Introduction 
The studies of the etiology and pathogenesis of PD at the cellular level provide many 
perspectives in diagnosis and treatment for this disease. A spectrum of hallmark 
symptoms has been described in clinical practice, based on which medical 
therapeutics were developed to restore dopamine levels in midbrain and to prevent the 
further deterioration of degenerative neurons. Despite the increasing knowledge on 
PD-associated dysregulated cellular processes, the early unifying gene/pathway 
dysregulation underlying the cause of PD from various genetic backgrounds has yet to 
be discovered, thereby inhibiting our understanding of the initial molecular 
mechanisms for PD progression. 
So far, most of the transcriptome information of PD stems from postmortem tissues 
that have exhibited loss of mDA neurons and/or Lewy bodies. Instead of extracting 
mRNAs from whole midbrain, mDA neurons were further isolated and assessed, 
facilitated by laser capture microdissection (LCM) (Elstner et al., 2009; Simunovic et 
al., 2009; Zheng et al., 2010). However, it remains ambiguous whether the laser-
captured mDA neurons remaining in advanced degenerative tissue are more resistant 
to the disease, or are surviving neurons at the endpoint of disease, or are progressing 
slowly compared to those degenerative neurons.  They might reflect features of nerve 
damage and signs of cell death rather than the original pathological changes. The 
pathogenic molecular features might be obscured by the crosstalk between various 
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signaling pathways in response to pro-inflammatory cytokines. Thus, the analyses of 
transcriptome derived from postmortem midbrain provide insights into the molecular 
alterations in late-stage PD mDA neurons, but fail to explore the early-phase in 
disease pathogenesis.  
Recent advances in human iPSC technology enable the generation of clinically 
relevant neuronal subtypes in vitro. Researchers are able to get access to viable 
patient-specific mDA neurons derived from iPSC lines. A number of recent studies 
have investigated the global transcriptome patterns of PD mDA neurons by RNA-
sequencing (RNA-seq) or microarray (Reinhardt et al., 2013; Woodard et al., 2014). 
The RNA-seq performed in mDA neuron cultures with mutation in GBA N370S 
demonstrated a list of differentially expressed genes associated with dopamine 
synthesis, metabolism, and receptors, in comparison with the mDA neurons derived 
from iPSCs of unaffected twin. However, the fold changes of such dysregulated genes 
were not significant (Woodard et al., 2014). Another interesting genome-wide 
expression profiling performed in PD iPSC modeling was generated in mDA neurons 
carrying heterozygous LRRK2 G2019S mutations (Reinhardt et al., 2013). Expression 
analysis of multiple pairs of isogenic cultures identified a group of candidate genes 
dysregulated by LRRK2 G2019S including CPNE8, CADPS2, MAP7 and UHRF2. In 
this study, the molecular pathways for these dysregulated transcripts were further 
speculated, but no detailed functional study was performed to elucidate the 
involvement of these genes in PD progression. In addition, the transcriptome studies 
in iPSC models so far focus merely on single unique gene mutation, which fails to 
exploit the shared alterations underlying different PD contexts. The fact that PD could 
arise from numerous genetic predispositions suggests that there might be a unifying 
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molecular pathology underlying the various genetic backgrounds. Therefore, the 
recruitment of cell lines from various PD genetic backgrounds could enable us to 
detect the concordant early molecular regulators. In order to address this hypothesis, 
in this chapter, I described the transcriptome profiling in PD iPSC model by RNA-
sequencing and microarray. The uniformed expression changes and alternative 
splicing events across different genetic backgrounds were detected (Figure 7.1). 
Shortlisted candidate genes were further prioritized and verified. Downstream 
pathways affected by the candidate genes were explored, uncovering the novel 
molecular events in early PD progression. 
Figure 7.1: Scheme of the experimental design for RNA-seq. NPCs and mDA 
neurons derived from WT iPSCs and PD iPSCs with various disease mutations were 
subjected to transcriptome profiling by RNA-seq. Reads were mapped to human 
genome and calculated for differential expression of protein-coding genes and long 
non-coding transcripts. Transcripts from spliced alignments were assembled to 






















7.2.1 RNA-sequencing reveals the uniformed transcriptome dysregulation in PD 
mDA neurons 
To explore the early molecular events that elucidate PD pathology, I examined the 
gene expression profiling in both NPCs and early-passage (P1) NPC derived mDA 
neurons from six iPSC lines, including three WT cell lines (GM23280, GM23279 and 
IR1.7) and three PD cell lines carrying different PD genetic mutations (ND38477 
PARK2 c.255delA, ND35367 LRRK2 G2019S, ND34391 SNCA triplication) (Figure 
7.2 A). Sequencing was performed on ribosome RNA (rRNA)-depleted total RNAs of 
two biological replicates for each condition at a depth of ~40 million reads per sample. 
Principal component analysis (PCA) was applied to RNA-seq data, showing 
clustering of cell types based on the first principal component (PC1) (Figure 7.2 B). 
NPCs derived from all iPSC lines clustered closely together, while the mDA neuron 
cultures clustered separately in PC2 (Figure 7.2 B), indicating that, compared to mDA 
neuron cultures, the transcriptomes of NPCs were homogenously similar across 
different cell lines.  Furthermore, the subtle variance between WT and PD samples 
across two cell stages was captured based on PC3 with an overlap between some 
samples (Figure 7.2 B). Since NPCs gave rise to more homogeneous population 
across PD and WT cell lines, such uniformed cell population largely affects PCA 
analysis done with both NPC and mDA samples in terms of isolating the difference 
between PD and WT. Therefore, NPCs samples were removed from the PCA analysis, 
a clear separation between PD and WT mDA neurons was observed in PC2 (Figure 
7.2 C), which characterized a phenotype in the context of global transcriptomic 
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landscape. Comparative analysis of RNA-seq data was performed by DESeq 
Bioconductor package. A total of 908 differentially expressed genes were discovered 
to be differentially regulated in PD mDA neurons with a p-value less than 0.01 and 
absolute fold change more than 2, of which 511 transcripts were protein-coding 




Figure 7.2: Global gene expression in NPCs and mDA neurons derived from WT 
and PD iPSCs by RNA-sequencing. A. Schematic diagram of RNA-seq 
experimental design and analysis workflow. Two biological replicates were 
sequenced in each condition. B. Principal component analysis (PCA) with percentage 
of variance illustrating clustering of cell types based on the first principal component 
(PC1) and the separation of PD and WT samples based on the PC3. C. After removing 
the NPCs samples, PCA shows the separation of PD and WT mDA samples in PC2, 
and a subtle batch effect of two biological replicates was observed in PC1. D. 
Transcriptome characterization by DESeq analysis identifies 908 differentially 



















































































































































































































Enrichment analysis based on Gene Ontology (GO) was conducted by using a web 
tool ConsensusPathDB (http://cpdb.molgen.mpg.de). Interestingly, the analysis of 
under-expressed protein-coding transcripts in PD mDA neurons revealed a decrease 
in expression of deubiquitinating enzymes and genes associated with proteolysis 
(Table 7.1). The ubiquitin signaling system has become a well-known regulator of 
neuronal functions (Ding and Shen, 2008; Tai and Schuman, 2008). A dysregulated 
deubiquitination system may result in proteolytic stress due to the accumulation of 
ubiquitin-labeled proteins. However, further experiments are required to address the 
functional implication of deubiquitination pathway in PD, which would be discussed 
in the next section. Functional implications of the unifying up-regulated protein-
coding genes in PD mDA neurons indicated an enriched clustering of gene functions 
involved in nervous system and synaptic signaling transmission, providing strong 
molecular evidence of a unifying dysregulated neuronal activity in PD mDA neurons 







Table 7.18Gene ontology analysis of down-regulated genes in mDA neuron 
cultures derived from PD iPSC lines compared with WT. 
Gene Ontology 
ID GO Term p-value 
FDR corrected 
p-value 
GO:0036459 ubiquitinyl hydrolase activity 3.33E-16 1.56E-14 
GO:0004843 ubiquitin-specific protease activity 2.35E-09 1.52E-07 
GO:0070011 
peptidase activity, acting on L-amino 
acid peptides 
2.23E-08 7.25E-07 
GO:0008233 peptidase activity 4.69E-08 1.10E-06 
GO:0042974 retinoic acid receptor binding 3.55E-06 7.70E-05 
GO:0038023 signaling receptor activity 8.93E-05 2.77E-03 
GO:0004888 transmembrane signaling receptor activity 2.33E-04 3.78E-03 
GO:0030163 protein catabolic process 3.33E-04 7.08E-02 
GO:0006508 proteolysis 3.66E-04 7.08E-02 
 
 
Table 7.29Gene ontology analysis of up-regulated genes in mDA neuron cultures 
derived from PD iPSC lines compared with WT. 
Gene Ontology 
ID GO Term p-value 
FDR corrected 
p-value 
GO:0007399 nervous system development 8.84E-08 3.00E-05 
GO:0007268 synaptic transmission 2.34E-07 1.61E-05 
GO:0097060 synaptic membrane 8.32E-06 3.14E-04 
GO:0051932 synaptic transmission, GABAergic 1.22E-05 2.06E-03 
GO:0007270 neuron-neuron synaptic transmission 1.56E-05 2.40E-03 
GO:0097458 neuron part 2.07E-05 3.14E-04 
GO:0007267 cell-cell signaling 2.19E-05 2.40E-03 
GO:0034702 ion channel complex 2.57E-05 3.14E-04 
GO:0048731 system development 2.72E-05 2.40E-03 
GO:0044459 plasma membrane part 2.73E-05 3.14E-04 
GO:0045211 postsynaptic membrane 5.18E-05 9.78E-04 
GO:0031226 
intrinsic component of plasma 
membrane 6.35E-05 9.78E-04 
GO:0008328 ionotropic glutamate receptor complex 6.38E-05 9.78E-04 
GO:1902495 transmembrane transporter complex 7.50E-05 6.90E-04 
GO:0005887 
integral component of plasma 
membrane 8.32E-05 2.41E-03 
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To verify the RNA-seq result, independent differentiation was performed with the 
original six cell lines and additional six PD cell lines, which either carried LRRK2 
G2019S mutation or subjected to sporadic case (Table 2.1). In total, 12 cell lines were 
employed and differentiated into mDA neurons. 38 protein-coding genes and 22 long 
non-coding RNAs identified from RNA-seq were selected for qRT-PCR analysis by 
Fluidigm BioMark™ real-time PCR system based on the ranking of p-value and fold 
change (Figure 7.3 A). The enrichment was confirmed as differentially expressed in a 
consistent pattern in most of the PD cell lines relative to WT cell lines. A selective 
collection of genes validated was presented with highly reproducible dysregulation 
pattern across multiple PD cell lines (Figure 7.3 B). As noticed, this collection of 
genes contained interesting protein-coding candidates involved in neuronal activity 
for further functional study, which will be discussed in detailed in Section 7.3. 
Additionally, a potential role of long non-coding RNAs in PD was described for the 
first time.  
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Figure 7.3: Validation of differentially expressed genes from RNA-seq analysis in 
mDA neurons from additional PD cell lines. A. Heat map depiction of qRT-PCR 
data for validation of short-listed candidates from RNA-seq analysis in additional PD 
cell lines and original samples. Housekeeping genes and mDA markers were included 
as control. NTC stands for no template control. Three biological replicates were 
included for each cell line. B. Selective list of genes showed consistent differential 
expression in PD cell lines. Results were plotted as fold differences of relative gene 
expression normalized to pooled WT controls from 3 WT cell lines. Data represent 
mean ± SD (n=3). Two-tail P value was calculated between WT group and PD group 
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7.2.2 RBFOX1 regulates alternative splicing events in PD mDA neurons 
I thus sought to determine how the dysregulated gene expression might affect PD 
mDA neurons. I initially focused on RBFOX1 (RNA-binding protein, fox-1 homolog) 
or A2BP1 (ataxin 2-binding protein 1), since it is a neuron-specific splicing factor 
with a consistent up-regulation of gene expression across PD cell lines. This gene was 
known to target to the binding motif (U)GCAUG, regulating exon inclusions (Jin et 
al., 2003; Shibata, 2000). In neurons, RBFOX1 regulates neuronal splicing networks 
and hence controls neuronal excitation. Knockout of RBFOX1 in mice altered the 
splicing of exons in multiple transcripts affecting neuronal excitation and calcium 
homeostasis (Fogel et al., 2012; Gehman et al., 2011).  In our data, the expression of 
RBFOX1 is robustly enriched in PD mDA neurons relative to WT mDA neurons 
(Figure 7.4 A). The overrepresentation of RBFOX1 was further confirmed in 
additional cell lines, indicating a more than 10-fold up-regulation in PD mDA neurons 
(Figure 7.3 B and Figure 7.4 B). To further explore the downstream splicing targets of 







Figure 7.4: Differential alternative splicing of NMDA receptor GRIN1 mediated 
by RBFOX1 in PD mDA neurons. A. Genome browser view of differential 
expression levels of RBFOX1 in 3 WT and 3 PD cell lines (n=2). Quantification by 
qRT-PCR verified the relative expression levels of RBFOX1 in RNA-seq WT and PD 
mDA neuron cultures. Data represent mean ± SD (n=2). Comparisons are by one-way 
ANOVA followed by Dunnett’s Test.*** p<0.001. B. qRT-PCR verified the relative 
expression levels of RBFOX1 in independent experiments in 2 WT and 2 PD mDA 
neuron cultures. Data represent mean ± SD (n=3). Two-tail P value was calculated 
between WT group and PD group by unpaired t-test with Welch’s correction. *** 




















































































































































and exon 21. Hatched box below indicated the exon 5. Yellow boxes represent 
(U)GCAUG motifs. D. Relative expression levels of various GRIN1 isoforms in WT 
and PD mDA neurons. Data represent mean ± SD (n=3). Two-tail P value was 
calculated between WT group and PD group by unpaired t-test with Welch’s 
correction. **p<0.01. E. qRT-PCR verified the relative expression levels of GRIN1 
isoform (exon 5-6) in independent experiments with 3 WT and 9 PD mDA neuron 
cultures. Data represent mean ± SD (n=3). Data represent mean ± SD (n=3). 
Comparisons are by one-way analysis of variance (ANOVA) followed by Dunnett’s 
Test. ** p<0.01; *** p<0.001. 
 
GluN1 is N-methyl-D-aspartate (NMDA) receptor subtype, encoded by GRIN1. It 
belongs to glutamate receptor channel superfamily that forms functional 
heterotetramers with other NMDA receptor gene families. Two (U)GCAUG motifs lie 
downstream of the exon 5 of this gene, inducing exon 5 inclusion mediated by 
RBFOX1 (Figure 7.4 C). To evaluate the alternative splicing events in GluN1, three 
pairs of primers were designed to detect the expression of different isoforms (Figure 
7.4 D). The overall transcripts of GluN1 were detected by the primers spanning exon 
3 and 4, both of which were included in all splice variants. As shown in the qRT-PCR, 
the expression of total transcripts of GluN1 did not vary between PD and WT mDA 
neurons.  The other isoform with exon 21 inclusion also did not show much difference, 
and thus serves as a useful endogenous control. However, the expression of specific 
isoform with exon 5 inclusion showed significant increase in PD mDA neurons, 
implying that differential splicing events in PD mDA neurons are regulated by 
RBFOX1. This result was further validated in independent experiments with 3 WT 
and 9 PD mDA neuron cultures (Figure 7.4 E). 
Another gene known to be an RBFOX1 target, SNAP-25, was also verified. SNAP-25 
(synaptosomal-associated protein of 25 kD) is a component of the SNARE (Soluble 
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NSF Attachment protein REceptor) complex, interacting with syntaxin and 
synaptobrevin (vesicle-associated membrane protein) to facilitate vesicle fusion. Thus, 
it is a critical regulator for the exocytosis of neurotransmitter in mDA neurons. SNAP 
-25 contains two homologous 5th exon, but with a difference in nine amino acid 
residues. Alternative splicing of these two exons results in two isoforms, SNAP-25a 
and b (Figure 7.5 A). Disturbed balance between SNAP-25a and SNAP-25b might 
lead to nervous system dysfunction. It was notable that RBFOX1 binding motifs have 
been spotted in this mutually exclusive exon pair. From our RNA-seq data, a 
differential distribution of reads in exon 5a and b was observed in WT and PD mDA 




Figure 7.5: Differential alternative splicing of SNAP-25 mediated by RBFOX1 in 
PD mDA neurons. A. SNAP-25 gene structure: hatched boxes indicate the open 
reading frame of Snap-25. Yellow boxes represent (U)GCAUG motifs. B. Left: 
Genome browser view of differential expression levels of exon 5a and 5b of SNAP-25 
in 3 WT and 3 PD cell lines (n=2). Right: qRT-PCR verifies the relative expression 
fold change of SNAP25b versus SNAP25a in 3 WT and 3 PD cell lines. WT samples 
(6 values) and PD samples (6 values) were pooled for statistical analysis by unpaired 





























Further verification was performed in additional PD cell lines and independent 
differentiation experiments, indicating a consistent dysregulation of SNAP-25 
alternative splicing in PD mDA neurons (Figure 7.6A). To further prove that 
RBFOX1 is the regulator of such alternative splicing events, lentiviral-mediated short 
hairpin RNA (shRNA) knockdown of RBFOX1 was performed in mDA neurons from 
3 WT cell lines and 3 PD cell lines (ND35367, ND41181 and ND34391). The 
efficiency of RBFOX1 knockdown was determined by qRT-PCR, showing around 70% 
reduction of mRNA expression in both WT and PD mDA neuron cultures (Figure 7.6 
B). Subsequently, the splicing events of Snap-25 with either scramble shRNAs or 
RBFOX1 shRNAs transduction were measured. The expression profiling of SNAP-25 
isoforms in PD mDA neurons with RBFOX1 knockdown indicated the splicing 
distribution of SNAP-25b and Snap-25a was perturbed (Figure 7.6 C). Two-way 
ANOVA analysis indicated that in scramble shRNAs control, there is a significant 
difference in splicing distribution of SNAP-25 between WT and PD. And after 
knockdown, the significance is removed. A further discussion regarding to the 
knockdown experiment is presented in the next section. Overall, I was able to validate 
the dysregulated RBFOX1-depenent splicing events in PD mDA neurons. 
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Figure 7.6: Knockdown of RBFOX1 alters the alternative splicing pattern of 
SNAP-25 in PD mDA neurons. A. qRT-PCR verified the relative expression levels 
of SNAP-25a and SNAP-25b in WT and PD mDA neurons normalized to total 
transcripts of SNAP-25. Locations of primers for detection of different isoforms are 
indicated by arrows. Data represent mean ± SD (n=3). B. Knock-down efficiency of 
RBFOX1 shRNAs was determined by qPCR in WT and PD mDA neurons relative to 
scramble shRNA controls. Data represent mean ± SD (n=3). C. Relative expression 
levels of SNAP-25a and SNAP-25b after RBFOX1 knock-down in WT (3 
independent cell lines) and PD (3 independent cell lines) mDA neurons normalized to 
total Snap-25 transcripts. Data represent mean ± SD (n=3). Comparisons between 
groups are by two-way ANOVA with Bonferroni posttest. Comparison between 










































































































































7.2.3 Genome-wide profiling identifies dysregulated splicing events in PD mDA 
neurons. 
To globally measure differential alternative splicing events in PD mDA neurons, 
RNA-seq was performed on two WT cell lines (GM23280 and IR1.7) and two PD cell 
lines (ND35367 and ND40018) (Figure 7.7 A). RNAs were collected from two 
biological replicates of each cell lines. RNA-Seq libraries were prepared from total 
RNA using poly(A) enrichment of the mRNA. Subsequently, reads mapped to splice 
junctions were quantified to reveal the alternative splicing events in both WT and PD 
mDA neuron cultures. By comparing the splicing events between PD and WT mDA 
neurons, 645 events of splicing differences were identified in 439 protein-coding 
genes with absolute fold change cutoff of 2 and adjusted p-value  0.05. Gene 
ontology analysis revealed that genes showing significant differential splicing in PD 
mDA neurons are robustly associated with mitochondrial function, cell apoptosis and 
cellular redox metabolism (Figure 7.7 B).   To identify the differentially spliced genes 
specifically mediated by RBFOX1, I overlapped the 439 gene candidates with the 
predicted RBFOX1 targets from the most recent RBFOX1 target gene list (Gehman et 
al., 2011; Weyn-Vanhentenryck et al., 2014), which generated a short list of 41 genes 
(Figure 7.7 C and Supplementary table 9). From this set of genes, both GRIN1 and 
SNAP-25 were identified, revealing a consistent pattern of dysregulated splicing 
pathway by RBFOX1 in PD mDA neurons. Gene functions are strongly involved in 
neuron synaptic activity (Figure 7.7 D). In summary, the genome-wide identification 
of alternative splicing events in mDA neuron cultures by RNA-seq enabled us to 
isolate the over and underrepresentation of splicing variants in PD mDA neurons. 
Consistent with the phenotypic characterization and what we validated in RBFOX1 
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functional study, a splicing-regulatory network for controlling oxidative stress 
response and neuronal activity was prioritized, implying substantial importance of 
dysregulated splicing events in PD progression. 
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Figure 7.7: RNA sequencing identified global alternative splicing dysregulation 
of oxidative stress-responsive genes. A. Scheme of RNA-seq analysis for detecting 
alternative splicing variants. B. Gene ontology analysis of genes with differentially 
alternative splicing in PD mDA neurons relative to WT mDA neurons. C. Venn 
diagram showing the overlap of alternative splicing events in PD versus WT with the 
predicted RBFOX1 targets. P-value determined from hypergeometric distribution 
analysis indicates the significance of overlap. D. Gene ontology analysis of the 
overlap genes mediated by RBFOX1 revealed an enrichment of genes involved in 






































7.2.4 Microarray reveals LRRK2 G2019S-associated transcripts 
As introduced in Section 1.4.1, LRRK2 G2019S, the most prevalent dominant 
missense mutation, has previously been implicated in both familial and sporadic PD 
with high lifetime penetrance, suggesting a strong susceptibility factor in PD 
progression. Moreover, from our phenotypic characterization experiments, it is 
notable that PD cell lines carrying LRRK2 G2019S mutation presented more severe 
PD-related defects than other cell lines. Thus, it is interesting to know whether mDA 
neurons with LRRK2 G2019S display more profound disease-associated molecular 
signatures. Therefore, to illustrate the above question and to provide support for the 
previous RNA-seq analysis, the molecular features of LRRK2 G2019S-specific PD 
mDA was further examined by microarray. 
mDA neurons were derived from three WT iPSC cell lines and five PD cell lines with 
either homozygous or heterozygous LRRK2 G2019S mutations, as described 
previously ( ND35367: LRRK2GS/GS, ND40018: LRRK2GS/GS, ND41181: LRRK2GS/+, 
ND41180: ND41181: LRRK2GS/+ and ND40599: ND41181: LRRK2GS/+). Three 
biological replicates of each cell line were used for microarray expression analysis, 
which provided sufficient statistical confidence to detect the differentially expressed 
genes in PD compared with WT. For data analysis, one-way ANOVA analysis was 
performed to test for the differentially expressed genes between WT individuals and 
individuals with heterozygous and homozygous LRRK2 mutations, and the FDR-
adjusted p-values  0.05. The analysis revealed a list of 1630 entities. In order to 
investigate the affected signaling pathways and to gain an overview of dysregulated 
biological processes in PD neurons, gene ontology analysis and functional annotation 
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clustering were performed using the up-regulated and down-regulated genes (Figure 
7.8 A). Gene ontology analysis of the up-regulated genes revealed an enrichment of 
transcripts involved in ion binding, cation channel, synaptic transmission, 
neurotransmitter degradation and regulation of cell apoptosis; categories shared with 
previous RNA-seq results. On the other hand, genes which were significantly down-
regulated appeared to be related with ribosome, mitochondrial function, negative 
regulation of apoptosis, oxidoreductase activity and lysosome function. These results 
further support the notion that mDA neurons derived from PD iPSCs possess 
dysregulated neuronal activity and increased susceptibility to oxidative stress due to 
the impairment of mitochondrial and lysosomal functions, which could be the 
universal early events during disease progression and result in neuronal degeneration 
(Krebiehl et al., 2010; Schneider and Zhang, 2010).  
To prioritize the candidate genes, a set of unpaired t-test of unequal variance was 
performed on WT versus homozygous LRRK2 mutations as well as on WT versus 
heterozygous LRRK2 mutations, with a p-value  0.05 and a fold change cut-off  2. 
The 114 overlapping genes from these three sets of comparisons are presented in the 
Venn diagram, which indicates the similar dysregulated expression between 
homozygous and heterozygous mutations (Figure 7.8 B). Hierarchical clustering as 
well as heat-map analysis for the differentially expressed genes in homozygous 
LRRK2 G2019S was performed (Figure 7.8 B and Supplementary list 1). Furthermore, 
the differential gene expression was compared with previous RNA-seq analysis from 
multiple PD genetic backgrounds, revealing a consistent pattern of gene dysregulation 
(Supplementary list 2). Not surprisingly, RBFOX1 was also found in the list, further 
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supporting that this splicing factor is a consensus regulatory element in PD early 
progression across different genetic mutations. 
 
Figure 7.8: Gene microarray analysis of LRRK2 G2019S mutation in iPSC model. 
A. Gene ontology analysis of up-regulated and down-regulated genes in the mDA 
neurons with LRRK2 G2019S mutation. B. Proportional Venn diagram presentation of 
microarray data. C. Hierarchical clustering and heat-map of genes differentially 
expressed in microarray analysis performed on mDA neurons from WT, LRRK2GS/GS 
and LRRK2GS/+. Gene expression is represented as a color, normalized across each 
row, with brighter red for lower values and brighter green for higher values. FDR 
adjusted p-value0.05; FC (Abs)2.  
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7.3 Discussion 
7.3.1 Identification of Novel Genes Dysregulated in PD mDA neurons 
Having established the iPSC model of PD presented in the previous chapters, 
genome-wide transcriptome profiling of this model was further investigated to 
identify novel molecular regulators that could be potentially important for early 
events in PD progression. To date, there are only a few studies on the transcriptome 
profiling iPSC-derived neurons in the context of neurodegenerative diseases. Among 
these studies, researchers intended to interrogate the potential alterations only in 
monogenic PD (Reinhardt et al., 2013; Woodard et al., 2014). However, as stated in 
the hypothesis, the phenotypic similarity across PD genetic mutations firmly implies 
the sharing of common downstream signaling pathways. Towards this end, multiple 
iPSC lines with distinct familial PD mutations were recruited for gene expression 
profiling. Intriguingly, I observed a consistent pattern of gene dysregulation in PD 
mDA neurons across different cell lines. Gene ontology analysis of the gene lists 
revealed the overall affected signaling networks involved in protein ubiquitination 
system and neuronal activity. The down-regulation in deubiquitination pathways was 
concentrated in a novel deubiquitinating enzyme family, USP17. This gene family 
was consistently down-regulated in PD cell lines with a moderate fold change. It has 
been shown to be associated with apoptosis and cell mobility (de la Vega et al., 2011; 
Shin et al., 2006). However, the interacting substrates of these genes in neurons are 
not known. Therefore, a potential experiment could be performed to identify its 
binding targets by immunoprecipitation. Thus, the potential targets could be further 
validated in PD mDA neuron cultures for differential ubiquitination levels. Overall, 
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protein ubiquitination, as a central pathway identified accompanying the extensive 
loss of mDA neurons, could be the early events associated with the further 
phenotypes presented in Chapter 6. Regarding to the correlation between the 
dysregulated gene expression and the phenotypic characterization, an interesting 
opinion is presented here that the minor phenotypes observed in the cell line with E3 
ligase PARK2 mutation could be due to the compromising deubiquitination activity. 
Ubiquitin ligase has the opposing catalytic activity with deubiquitinating enzymes to 
allow balance of the ubiquitylation status of a protein substrate. Thus, although the 
truncated E3 ligase PARK2 might result in the defective ubiquitination of a certain 
substrates, the overall reductions in deubiquitination system in PD mDA neurons 
could minimize the effects. However, due to the lack of knowledge of USP17 and 
PARK2 substrates, it still remains difficult to assess the validity of the above 
speculation. After all, transcriptome analysis in PD mDA neurons further supports the 
important role of fine-tuned ubiquitination system in PD progression. 
On the other hand, so far, only a few transcriptome profiling have been reported in 
iPSC-based PD models, and none of which have shown any GO clustering (Reinhardt 
et al., 2013; Woodard et al., 2014). Therefore, it is essential to compare our findings 
with the current available resource derived from the relevant context, which is the 
meta-analysis of gene expression in PD neurons. It is interesting to see that our 
research is in line with previous reports on the dysregulated pathways in PD neurons 
regarding to the deubiquitination pathway and neuron activity (Lewis and Cookson, 
2012), which is novel in the field of iPSC-based PD modeling and consistent with the 
general area of transcriptome analysis of PD. 
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Furthermore, the expression profiling also led to the identification of specific genes 
with altered expression in PD mDA neurons. The further validation of their 
expression in additional PD cell lines increases confidence that such dysregulation 
could be the unifying regulators for pronounced disease phenotypes. PADI3 or PAD3 
belongs to peptidylarginine deiminases family, which mediates protein post-
translational citrullination (deamination) in a calcium-dependent way. Such 
peptidylarginine deiminase modulates the physiological activity of the target proteins 
via citrullination in nervous system, suggesting a potential role in neurological 
disorders (Jang et al., 2013; Jang et al., 2012). It was reported in human neural stem 
cells that PAD3 levels/activity plays a role in fine-tuning AIF-dependent cell death (U 
et al., 2014). So far, although there is no direct information on the direct association 
of PADI3 and neurodegeneration, abnormal protein citrullination has been observed 
in AD and PD (Ishigami et al., 2005; Nicholas, 2011), suggesting a potential pathway 
in neurodegenerative pathogenesis.  
To gain information about the expression levels of long non-coding transcripts, RNA-
seq was performed with total RNA (ribosomal RNA-removed) to preserve the long 
non-coding RNAs without poly (A) tail. A2M-AS1 is a novel, antisense, long non-
coding RNA identified specifically down-regulated in PD mDA neurons. It encodes a 
tail-to-tail overlapping transcript of α-2-Macroglobulin (A2M) gene. A2M, encoding a 
protease inhibitor, is genetically associated with AD and both early- and late- onset 
PD based on GWAS (Blacker et al., 1998; Tang et al., 2002). In AD pathology, A2M 
protein binds soluble beta-amyloid (Aβ), of which it mediates the endocytosis and 
degradation (Borth, 1996; Narita et al., 2002). However, the function of A2M-AS1 
RNA has not been studied. Based on the known functions of tail-to-tail long non-
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coding RNAs, such as BACE1-AS and NKX2.2-AS1(Faghihi et al., 2008; Tochitani 
and Hayashizaki, 2008), A2M-AS1 may also have a similar role in stabilizing the 
transcripts of its overlapping protein-coding gene. In PD mDA neurons, we observed 
a decrease of A2M-AS1 expression, which may result in decreased A2M translation. It 
requires future mechanistic examination to determine whether A2M protein levels are 
disrupted in PD mDA neurons. In this study, we described long non-coding RNAs 
differentially expressed in PD mDA neurons in vitro, which provides important 
insights to the potential function of long non-coding RNA transcripts in PD 
pathogenesis. 
For the up-regulated genes, RBFOX1 was further explored due to its special role in 
neuronal splicing network, which will be discussed in the next section. Overall, the 
intriguing differential gene expression patterns identified sheds light on the unifying 
molecular alterations underlying PD mDA neurons.   
7.3.2 Dysregulated alternative splicing networks in PD mDA neurons 
By considering the findings observed in the differential expression profiling, a key 
neuron-specific splicing factor RBFOX1 was found highly over-represented in PD 
mDAs, which could consequently result in the alterations of the splicing events in its 
target genes. Thus, RBFOX1 splicing targets were subsequently evaluated in PD 
mDAs, revealing an emerging role of the downstream splicing dysregulation triggered 
by RBFOX1 in PD progression. 
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GluN receptors function as di-heteromeric or tri-heteromeric assemblies that typically 
associate GluN1 subunits with GluN 2 and/or GluN 3 subunits (Paoletti et al., 2013). 
Such heterogeneity of GluN receptors contributes to the diverse electrophysiological 
characteristics and neuronal homeostasis. Since GluN1 is the major component in all 
the GluN receptors, the ratio of GluN1 splice variants is expected to have a major 
impact on receptor location and channel properties. The alternative splicing of exon 5 
substantially contributes to the GluN receptors activity. Exon 5, encoding a 21 amino 
acid region, localizes in the aminoterminal domain (ATD) that controls allosteric 
modulation. The functional properties of GluN1 with/without exon 5 have been 
characterized (Paoletti et al., 2013; Rumbaugh et al., 2000; Vance et al., 2012). GluN 
receptors consisted of exon 5-containing GluN1 possess a lower potency of NMDA 
receptor agonists and displays faster deactivation phrase than GluN1 without exon 5, 
leading to reduced neuronal excitability. Thus, the increase expression of exon 5-
containing GluN1 due to overrepresentation of RBFOX1 in PD mDA neurons could 
provide a potential explanation of the decreased neuronal firing rates that we observed 
by MEA (Figure 6.4 C). Moreover, such splicing modulation by RBFOX1 could be 
induced by depolarization (Lee et al., 2009). The enrichment of specific GluN1 splice 
variant with exon 5 in PD mDA neurons could be gradually achieved along with 
advancing neurons, which corresponds well to the age-dependence of 
neurodegenerative processes.  
Another gene identified as an RBFOX1 regulatory target in PD mDA neurons is 
SNAP-25. SNAP-25 is one of the presynaptic plasma membrane-anchored proteins, 
known as t-SNAREs. It forms a complex with another t-SNARE: Syntaxin-1, and the 
synaptic vesicular membrane protein Synaptobrevin (VAMP-1/2) to facilitate 
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membrane fusion and subsequent neurotransmitter release (Xu et al., 2013). 
Alternative splicing of exon 5a or 5b introduces 9 amino acid substitutions in the C-
terminal end of the first SNARE motif and the first part of the cysteine-containing 
linker (Nagy et al., 2005). This region is subject to posttranslational palmitoylation 
and implicated in membrane anchoring of SNAP-25 (Lane and Liu, 2002). The 
characteristics of exocytosis with different SNAP-25 isoforms have been evaluated, 
varying in their ability to stabilize vesicles in the releasable vesicle pools (Sørensen et 
al., 2003). A certain balanced expression of the two isoforms is required for 
maintaining an operational neuronal network homeostasis. The overrepresentation of 
RBFOX1 in PD mDA neurons results in aberrant expression of the two isoforms, 
which could be involved in regulating SNARE complex assembly and the further 
physiological changes in neurite circuits. On the other hand, both RBFOX1 and 
RBFOX2 have a binding site on SNAP-25 (Lovci et al., 2013), suggesting that the 
splicing alterations in knockdown study of RBFOX1 might be compensated by 
RBFOX2. Thus, alternatively, an overexpression of RBFOX1 in WT cell lines could 
be performed to investigate the splicing redistribution. 
Considering these potential explanations raises the possibility for an important role of 
alternative splicing events in regulating the homeostasis of neuronal function. Thus, 
the overall transcriptome splicing events in PD mDAs was further evaluated by RNA-
seq. The study showed that substantial differential alternative splicing occurred in PD 
mDAs with a significant enrichment of differentially spliced genes involved in 
mitochondrial and neuronal activity. From previous literature reports and the 
phenotypic characterization in our study, there is strong evidence of oxidative stress 
implicated in PD mDA neurons. Increased vulnerability in PD mDA neurons towards 
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oxidative stress-induced apoptosis triggered by neurotoxins has also been described in 
Section 6.2.4, indicating that the dysregulated antioxidant network by alternative 
splicing possibly affects the threshold of neuronal degeneration triggered by external 
stimuli. A candidate gene that may be associated with this hypothesis is VDAC3, a 
gene encoding voltage dependent anion selective channels in the outer mitochondria 
membrane. Based on our analysis, VDAC3 mRNA was found to be differentially 
spliced in PD mDA neurons relative to WT, and it was also previously recognized as 
a target of RBFOX1 (Weyn-Vanhentenryck et al., 2014; Zhang et al., 2008). VDAC3 
recruits PARK2 to defective mitochondria, facilitating the elimination of impaired 
mitochondria by mitophagy (Sun et al., 2012b). Alternative splicing in VDAC3 may 
cause a change in the protein conformation, channel permeability and protein 
interaction (Sampson et al., 1998). Thus, the alteration in the splicing abundance of 
different VDAC3 isoforms may play a role in the mitochondrial dysfunction in PD 
mDA neurons, resulting in the oxidative stress-related phenotypes observed. It could 
be further explored by determining the binding affinity of different VDAC3 isoforms 
with PARK2. And the subsequent mitochondria turnover could be determined by 
measuring autophagosomes. Overall, alternative splicing is an essential and 
complicated post-transcriptional process that has a broad physiological impact on the 
neuronal homeostasis (Li et al., 2007; Mills and Janitz, 2012; Tollervey et al., 2011). 
The complexity of the alternative splicing landscape in the context of PD is described 
in this study for the first time in vitro, which may lead to  further thoughts on splicing 
regulation studies in individual candidates. The further direction of the splicing 
regulation studies is presented in Chapter 8.3. 
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7.3.3 Identification of LRRK2 G2019S specific dysregulated transcripts in mDAs 
To gain further insight into the mechanistic regulation specific in the presence of 
LRRK2 G2019S, differential gene expression profiling was performed by microarray. 
Given the fact that genetic backgrounds might have a substantial impact on the gene 
expression pattern, the recruitment of multiple patients cell lines, with either 
homozygous or heterozygous mutations, and sufficient biological replicates enabled 
us to diminish the impact of genetic variability in the comparison . From this analysis, 
a number of pathways were shown to be dysregulated in LRRK2 G2019S mDA 
neuron cultures. The most significant underrepresented gene clustering belongs to 
ribosome, regulating translational elongation. Informatively, it has recently been 
reported that LRRK2 G2019S increases bulk translation by phosphorylation of 
ribosomal protein s15 (RBS15), contributing to the neuronal toxicity (Martin et al., 
2014). By comparing our differential gene list with the LRRK2 kinase screening 
results, we find that a number of down-regulated ribosomal proteins are potential 
LRRK2 phosphorylation substrates. It is possible that a potential negative feedback in 
PD mDAs compensate the aberrant protein production and to maintain protein 
homeostasis at basal level. In short, the finding of down-regulated translation-related 
genes in the current study further supports the novel role of LRRK2-mediated protein 
synthesis in the pathogenesis of PD. 
Unsurprisingly, another significantly down-regulated gene cluster observed in our 
study is involved in mitochondrial pathway. The perturbation in mitochondrial genes 
has been described in both animal models and postmortem tissue. Transcriptome 
analysis in human PD-affected substantia nigra also revealed an overall decrease in 
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gene expression involved in mitochondrial genes (Duke et al., 2006). Such concordant 
findings between postmortem tissue and human cell-based model further validate our 
disease modeling in vitro. Notably, mitochondria-related genes were also found 
differentially spliced in PD mDA neurons relative to WT, indicating the common or 
overlapping pathogenic outputs by transcriptome dysregulation. 
PDE7B, encoding a cyclic nucleotide 3 , 5 -phosphodiesterase (PDE), is 
substantially up-regulated across homozygous and heterozygous LRRK2 G2019S cell 
lines. PDE7B was found to be highly enriched in striatum, degrading intracellular 
cyclic AMP (cAMP) to mediate neuroprotection and neuroinflammation (Reyes-
Irisarri et al., 2005). In neurons, cAMP-dependent protein kinase cascade modulates 
the neuronal survival signaling (Bok et al., 2003; Li et al., 2000). Interestingly, PDE7 
inhibitors were shown to protect human dopaminergic neuronal SH-SY5Y cells from 
6-OHDA-induced cell death and also prevent drug-induced dopaminergic injury in 
vivo (Morales-Garcia et al., 2011). Thus, based on the gene expression changes in 
LRRK2 G2019S neurons, it is possible that the inhibitor administration for PDE7 
present a neuroprotective effect by restoring cAMP in DA neurons when exposed to 
neurotoxins.  
MAP7, which encodes the microtubule-binding protein ensconsin, was found to be 
significant overrepresented in both homozygous and heterozygous LRRK2 G2019S 
mDA neurons. MAP7 is known to promote microtubule polymerization and facilitate 
organelle transport by interacting with microtubule motor kinesin-1 in nervous system 
(Barlan et al., 2013; Gallaud et al., 2014). Overexpression of MAP7 has been shown 
to induce a decrease in mitochondria motility due to saturation of kinesin-1 binding 
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sites on the microtubule lattice in Drosophila neurons (Barlan et al., 2013). Although 
the association between LRRK2 mutations and microtubule has been reported in both 
postmortem tissues and cell cultures (Kett et al., 2012), there is no clear indication of 
the underlying mechanism. Our study provides an insight that LRRK2 G2019S might 
affect the microtubule homeostasis and mitochondrial functions through up-regulation 
of MAP7. Recently, MAP7 has also been found up-regulated in iPSC-derived mDAs 
from LRRK2 G2019S mutants relative to the respective isogenic controls (Reinhardt 
et al., 2013). This indicates one example of consistent gene expression change 
between gene expression profiling from multiple LRRK2 G2019S cell lines and from 
isogenic pairs. However, this study only presented 5 differentially expressed genes 
with moderate changes (0.5-1.5). Thus, we are not able to conclude further 
consistency between these two studies. 
7.4 Conclusion 
The main objective of this chapter is to unravel novel gene expression signatures in 
PD mDA neurons. Transcriptome profiling in mDA neurons by RNA-seq provided 
important implications for our understanding of the early molecular changes 
consistently underlying different PD genetic mutations.  
Gene expression profoundly altered in PD mDA neurons revealed the unifying 
dysregulated signaling networks involved in ubiquitin-proteasome system and 
neuronal activity. In addition, the expression profiling identified novel regulatory 
molecules with PD-related functional implication, highlighting the important input of 
transcriptional dysregulation in PD pathogenesis. Functional studies of the strong 
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candidate gene RBFOX1 revealed abnormal alternative splicing events in PD mDA 
neurons, thus suggesting a potential molecular understanding of the phenotypic 
characterization. To expand our interpretation of alternative splicing events, 
transcriptome-wide splicing changes in PD mDA neurons was explored. Many of 
these alterations reflected differences in mitochondrial functions that were associated 
with oxidative stress vulnerability observed in the phenotypic characterization. This 
finding highlights an important role of post-transcriptional regulation in PD pathology. 
In short, the results provided more insights into the common pathogenesis of PD and 
the crosstalk between multiple signaling pathways.  
Gene expression analyses that focused on LRRK2 G2019S mutation were also 
described in this chapter. The identification of common PD LRRK2 G2019S-
associated transcripts provides an initial attempt to study the pathogenic contribution 
of these genes in PD progression. By comparing the gene list that we generated with 
the previous PD pharmacological approaches and the recent transcriptome profiling in 
LRRK2 G2019S iPSC model, we are able to provide plausible biological explanations 
for a few genes and to narrow down the potential disease regulators with consistent 
PD relevance. In addition, the major findings in LRRK2 G2019S mutation provide 
supportive information for the previous RNA-seq results, successfully demonstrating 
a concordance of dysregulated gene expression across various disease mutation 
backgrounds. 
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Chapter VIII –Conclusions and Perspectives 
8.1 Overall conclusions 
Recently, it becomes increasingly apparent that iPSCs provide relevant human cell-
based models for neurodegenerative diseases. In the context of PD, since the disease 
affected neuronal subtype has been accurately defined, generation of patient-specific 
mDA neurons demonstrates greatest utility and effectiveness in understanding disease 
progression in vitro. Several reports in PD iPSC modeling have been described and 
discussed in Chapter I, which exploited different cell types to discuss PD 
pathophysiology. Subsequently, research efforts also continued to focus on 
identifying key factors that might serve as the early, unifying events in PD 
pathogenesis. In this thesis, genome-wide molecular alterations were examined in PD 
iPSC-based model by transcriptome profiling, which identified unifying dysregulated 
patterns of gene expression and alternative splicing events in PD mDA neurons, 
illuminating the potential molecular regulators and mechanisms in PD progression. 
8.1.1 Establishment of an in vitro human cell-based model for PD modeling 
In the first part of this study, step-wise protocols for robustly and reproducibly 
inducing patient-specific NPCs and mDAs for further examination were developed. 
The quality of the differentiation products from various genetic backgrounds was 
further evaluated by marker expressions and functional assays, indicating a consistent 
high yield of targeted cell subtypes with equivalent physiological properties. Such 
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protocols could generate an unlimited source of mDA neurons for further assessment, 
which established the fundamental methodology for PD modeling in vitro. 
Next, by serial passaging NPCs, an alternative methodology was developed to 
recapitulate ageing signatures in cells, resembling the ageing pathology of PD 
development. Such manipulation carried out on cell cultures has proved to model 
ageing at the transcriptome level, executing basic ageing cellular processes such as 
declined cellular replicative potential and progressively decreased DNA repair 
machinery. The physiological effects of prolonged-passaged NPCs ameliorated the 
disease-related phenotypes, showing increased vulnerability to cell stress in PD NPCs. 
Furthermore, such ageing signatures was passed down and validated in the respective 
differentiated cultures by transcriptome analysis. Thereby, the above methodology 
described in this study provides a feasible way in cell culture to overcome the late-
onset nature of PD progression, accelerating disease development in culture 
conditions. 
8.1.2 Pronounced disease phenotypes in mutant PD iPSC-derived mDA neurons  
A number of PD-related phenotypes in mDA neurons derived from PD late-passage 
NPCs were characterized, demonstrating neuronal degenerative signs, α-synuclein 
accumulation and defective neuronal network activity in PD mDA neuron cultures. 
Upon exposure to a number of neurotoxins known to induce cytotoxicity, PD mDAs 
exhibited enhanced sensitivity to apoptotic commitment. Collectively, these results 
described a spectrum of disease-related features in our iPSC-based models of PD by 
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incorporating aspects of ageing and assessing neurotoxicity, which strongly validated 
the reliability of this in vitro PD model with various genetic backgrounds. 
8.1.3 Identification of unifying molecular alterations in PD mDAs 
Comprehensive transcriptome analysis in PD mDA neurons revealed a consistent 
pattern of global transcriptome dysregulation across different PD backgrounds. 
Concordant downstream signaling pathways involved in ubiquitination homeostasis 
and neuronal activity were identified underlying divergent PD genetic predispositions. 
Moreover, differential expression of lncRNAs is also recognized as potential 
candidate involved in PD progression for the first time. A further validation was 
performed in the additional PD cell lines, from which a few transcripts were 
shortlisted for functional study. Subsequently, the critical downstream targets of the 
dysregulated transcripts were determined, revealing significant alterations in global 
alternative splicing events specifically enriched in mitochondrial functions and 
neuronal activity. 
The results from the expression profiling support the hypothesis that a unifying 
pattern of molecular changes has already occurred in the target PD mDA neurons as 
early events in disease progression. The differential gene expression and defective 
splicing regulation in PD mDA neurons provide apparently important clues to 




Although the reprogramming procedures of iPSC generation has become more 
efficient and standard in recent years, it has been observed and characterized that 
iPSCs generated from different sources or even same starting cell population yield 
variable epigenetic signatures (Bar-Nur et al., 2011; Lister et al., 2011). Such so-
called somatic memory including aberrant DNA methylation and histone modification, 
in principle, would affect the following lineage commitment and differentiation 
efficacy. Moreover, this variability could be transmitted and maintained in the 
differentiated populations, inducing different heterogeneity of cell population. Thus, a 
certain part of disease-related molecular evidence, such as subtle gene expression 
changes, might be masked due to the inequivalent cell population in two-group 
comparison. Thus, this concern also raises an important question of the appropriate 
controls for iPSC-based modeling. 
In order to minimize the impact of inconsistent iPSC identities and neuronal 
differentiation efficacy, a few strategies could be adopted to optimize the 
experimental designs. For the RNA-seq studies on common molecular alterations 
underlying various PD backgrounds, larger numbers of iPSC donor individuals for 
each type of genetic mutations and healthy individuals could be recruited, especially 
including multiple colonies from the same patient. However, generation of mDA 
neuronal cultures from large-scale iPSC cohorts of PD patients is laborious. On the 
other hand, for the expression profiling focused on monogenic PD mutation, iPSC 
lines generated from monozygotic twins discordant for PD have been reported 
(Woodard et al., 2014). Compared to control cell lines from independent individual, 
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monozygotic unaffected twin provides a more relevant genetic background. 
Nevertheless, such monozygotic pair is rare. And it is difficult to determine how 
similar they are in terms of epigenetic signatures. Recently, by using genome-editing 
tools, researchers have managed to generate more rigorous controls for iPSC 
modeling with monogenic mutations, which are the isogenic control cell lines from 
the same original disease iPSC lines. (Kiskinis et al., 2014; Reinhardt et al., 2013). 
Genome editing technology by the clustered regularly interspaced short palindromic 
repeat (CRISPR)-associated nuclease Cas9 is adapted from bacterial immune systems, 
which enables researchers to target the precise genome sequence by guide RNAs 
(gRNAs), inducing DNA double-strand breaks (DSBs) and the subsequent DNA 
repair (Cho et al., 2013; Mali et al., 2013). By introducing pre-designed repair 
template, homology-directed repair (HDR) machinery could rejoin two DSB ends 
with the incorporation of the desirable sequences. This technology could be applied 
either to correcting disease-related mutation in the patient cell cultures or to 
introducing the mutation into cell cultures from healthy individual. Moreover, 
subsequent transcriptome analysis could reveal the global gene expression changes 
that attributed to that single genetic factor. Besides single disease mutation, 
introduction of different PD genetic mutations into the same iPSCs derived from 
healthy individual also facilitates the study on the impact of different PD genetic 
contribution to the equivalent genetic background. Overall, such strategy of 
constructing ideal control cell lines could narrow down the experimental variance to 
the single genetic point mutation.  
Another limitation involved in most of the iPSC-based disease modeling is the 
variable homology of target cell subtype among the total differentiated cell population. 
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The differentiated neuronal cultures derived from different iPSC cell lines and 
different experimental batches might have different proportions of unwanted cell 
types, regardless of the enriched mDA neuron differentiation introduced in this study 
Thus, to reduce the side populations from differentiated neuronal cultures, alternative 
methodology has been applied to purify mDA neurons. To rule out the possibility of 
biased sampling in transcriptome analysis, mDA neurons can be isolated as a pure 
population by cell sorting using recently identified mDA neuron surface marker 
CORIN and a certain combination of CD (cluster of differentiation) molecules (Doi et 
al., 2014; Woodard et al., 2014). These cell surface markers provide a decent yield of 
mDA neurons after sorting. But the challenging FACS process and the further 
recovery may create a potential cell stress in the neurons or neuron precursors, thus 
resulting a biased selection in the survived population. On the other hand, mDA 
neuron reporters have been constructed for mouse PD model and recently for human 
ESCs (Ganat et al., 2012; Watmuff et al., 2015). However, reporter constructs require 
stable genomic integration that is not favorable for disease modeling. In spite of live 
cell sorting depending on specific cell surface markers or fluorescent reporters driven 
by cell type specific promoters, a method for analyzing RNA following intracellular 
sorting (MARIS) was recently introduced (Hrvatin et al., 2014; Ng et al., 2015). This 
methodology took advantage of the intracellular protein labeling to isolate subtype 
neurons by specific protein markers followed by RNA isolation and transcriptome 
analysis. It could be further adapted to PD iPSC modeling by utilizing mDA specific 
markers such as FOXA2, NURR1 and PITX3.  
Single-cell technology, which also becomes a hot topic in recent years, could isolate 
the cell identity and the transcriptome variance at the same time within a mix of cell 
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population (Tang et al., 2010). The further incorporation of microfluidics technology 
and oligonucleotide sequencing barcodes facilitates the high-throughput application 
of single cell transcriptome analysis (Macosko et al., 2015; Rotem et al., 2015). By 
single-cell RNA-sequencing, the mixed neuronal population could be isolated and 
classified into different neuronal category by marker signature (Usoskin et al., 2015). 
This methodology could be further applied into iPSC disease modeling. Thus, 
researchers could identify the precise differential transcriptome landscape within the 
single PD mDA neuron compared to WT mDA neuron. Thus, compared to bulk 
RNA-seq, single-cell RNA-seq could be a more advanced way to exclude the effect of 
heterogeneous population without any pre-selection. 
In this study, we recruited 3 WT cell lines as control cell lines. Although significant 
diverse cell population was not observed based on marker detection and transcriptome 
analysis, an ideal control system for this study would be the isogenic lines for each 
mutation. And the differentiated culture could be subjected to purification of mDA 
neurons for further gene expression analysis.  
Like any other research in neuronal cell culture, iPSC-derived mDA neuron cultures 
provide limited information on the complex affected brain circuits in the context of 
PD. Based on postmortem examination, the gradient loss of mDA neurons is usually 
accompanied with glial response such as activated microglial cells and reactive 
astrocytes (Barcia, 2013; Teismann et al., 2003; Wu et al., 2002). Glial cells mediate a 
variety of deleterious events such as releasing inflammatory cytokines and ROS 
production, which may contribute to the deterioration of neuronal degeneration. In 
this study, the main focus is the early molecular events in PD primarily affected 
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neuronal subtype, which fails to address the pathogenic role of glial cells. To 
elucidate the complex interactions between different cell types in the context of 
disease, a sophisticated co-culture system needs to be established, which should be 
feasible to isolate the crosstalk between different cell types. Another methodology, 
which could mimic the in vivo microenvironment of disease progression, could be 
obtained by 3D cell culture system. The prime advantage of 3D cell culture is that it 
exhibits the complex multi-dimensional cellular interaction in vivo. The long-term 
culture of neuronal cells by using collagen tissue constructs has been reported (Bercu 
et al., 2013). In the context of neurodegenerative disease, 3D cell culture system has 
been employed for Alzheimer's disease in vitro modeling, revealing AD-related 
taupathy phenotypic changes and cellular redistribution of p21-activated kinase  
(Seidel et al., 2012; Zhang et al., 2014). Thus, the 3D cell culture could be further 
adapted to the PD iPSC modeling combined with the mixed culture with glial cells, 
resembling brain local environment. By powerful confocal laser scanning and 3D 
image analysis, the interaction between multiple cell subtypes could be elucidated, 
which serves a valid alternative model in vitro compared to 2D cell culture and 
complex animal models. 
8.3 Future Directions and Practical Applications 
Based on the PD iPSC-based modeling established in this study, a number of feasible 
methods have been inaugurated and optimized to manifest the pathologic 
development of PD in culture, which could be applied to the research for other late-
onset degenerative disease modeling, such as Alzheimer’s disease, Huntington’s 
disease and amyotrophic lateral sclerosis.  
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Prolonged passaging in iPSC-derived NPCs has been adapted into this study to 
generate mDA neurons, which preserves a similar program of ageing-related pattern. 
This methodology could be useful to accelerate the disease progression for 
conspicuous phenotypes in other neuronal subtypes for neurodegenerative disease 
modeling. Phenotypic characterization of the PD mDAs by neurotoxin treatment 
enabled us to detect PD-related degenerative signs in vitro, thereby providing a 
platform to validate the contribution of dysregulated transcripts to the disease 
progression by phenotypic rescue. Conversely, in the WT mDAs, the introduction of 
dysregulated transcripts might also induce PD-related phenotypes. For example, the 
ectopic expression of RBFOX1 in mDA neurons derived from WT cell lines could be 
studied for its downstream splicing alterations and the phenotypic responses towards 
neurotoxicity.  
The transcriptome study in this project also suggests possible therapeutic targets for 
PD progression, including the differentially expressed genes and the alternative 
spliced forms of certain genes. Thus, a further question that we need to explore is to 
isolate the causal correspondence between the genes identified and the phenotypes 
characterized. A stringent differential expression list containing 55 genes, isolated by 
RNA-seq and microarray, was selected for in vitro screening to identify potential 
pharmacological targets for PD treatment. Compared to unbiased genome-wide 
screening platform that contains more than 15,000 short interfering RNA (siRNA), 
our study bring the candidate gene list to manageable levels. However, manipulation 
of a single dysregulated gene might not have an overall causal impact on the 
phenotypes observed in culture. Therefore, based on the functional hypotheses of the 
candidate transcripts, targeting of the specific gene cluster could be achieved by 
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siRNA pools (Parsons et al., 2009). Such reverse genetic studies in large scale could 
produce more pronounced phenotypic readout for identifying key causal factors for 
PD progression. The recent advance in genome editing technology based on CRISPR 
system has been introduced in the above section. gRNAs could mediate sequence-
specific DSBs, leading to a frame shift indel mutations and potential loss-of-function 
allele. This gene specific targeting feature has facilitated the gene knockout screening 
by using single gRNA (sgRNA) pools (Sanjana et al., 2014; Shalem et al., 2014; 
Wang et al., 2014; Zhou et al., 2014). The sgRNA screening could provide complete 
loss of gene function at DNA level with less off-target effects compared to the 
traditional siRNA libraries. Thus, gRNA pools could be designed for the candidate 
genes that showed up-regulation in PD mDA neuron cultures, such as RBFOX1. By 
using lentiviral delivery, gRNA pools could be introduced into PD mDA neurons with 
Cas9 protein for further neurotoxicity assay. The neuron cultures with phenotypic 
rescue, typically with more surviving neurons than control, could be furthered 
sequenced to determine the types and frequency of the knockout targets. Reversely, 
the genes that showed down-regulation in PD mDA neuron cultures could be targeted 
in WT, with the phenotypic deterioration as a positive readout. 
On the other hand, RBFOX1, as a strong candidate gene, could be further studied. 
First, a genome-wide splicing regulation in PD mDA neurons by RBFOX1 could be 
investigated by performing RBFOX1 CLIP-Seq or transcriptome profiling in PD 
mDA neurons with RBFOX1 knockdown.  There is also great interest in exploring the 
effect of other alternative splicing events identified in PD mDA neuron cultures, since 
RBFOX1 interact with various splicing factors to coordinate splicing events (Sun et 
al., 2012a; Zhang et al., 2010). First, more sophisticated analysis can be performed in 
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the alternative splicing gene list. As previously indicated, RBFOX1 accounts for 9.3% 
of the total splicing genes in PD mDA cultures. Therefore, it is intriguing to know 
what are the regulators for the other splicing events. Motif analysis of the sequence 
around the exon/intron junction could also be introduced. By identifying the splicing 
motifs, we will be able to cluster and assign the splicing events to the specific 
regulators.  
Given the apparent importance of iPSC-based disease modeling in drug discovery, 
experimental progress has been made to apply the neuronal cultures to 
pharmacological screening (Heilker et al., 2014; Watmuff et al., 2015). Towards this 
end, based on the neurotoxicity assays described in this study, a high-throughput drug 
screening approach for PD therapeutic compound could be established. Together with 
high-content imaging, surviving mDA neurons or apoptotic neuronal populations 
could be quantified in response to neurotoxins with/without the presence of the 
selective compounds. The pharmacological agents that have a neuroprotective effect 
or revert the specific splicing dysregulation could serve as potential therapeutic 
interventions in PD treatment. 
On the other hand, towards more sophisticated analysis of gene regulatory mechanism, 
the transcriptome dataset in this study is applied with co-expression network analysis 
(Langfelder and Horvath, 2008). This analysis could identify the correlated gene 
modules, providing us a system view of the dysregulated pathways in PD versus WT 
and also the network connectivity between these pathways. Moreover, the 
transcription factor that targets the gene sets prioritized based on transcriptional 
network could be determined. Thus, the potential upstream dysregulated 
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transcriptional activation could be further investigated. On the other hand, the 
interaction network between the dysregulated genes could be analyzed. The gene sets 
based on neighborhood in the functional interaction network are isolated for its 
potential role in dysregulated pathway (Kamburov et al., 2011). For example, the up-
regulated genes in PD mDA neuron cultures showed high clustering with central gene 
NOS-1 (p-value=8.03E-05). This gene has been implicated in various 
neurodegeneration processes due to its ability to synthesize neurotransmitter nitric 
oxide. Such neighborhood-based functional clustering focuses more the biochemical 
interaction than GO analysis, which would improve our interpretation of the 
functional subset within the dysregulation gene lists. 
A general practical application for the mDA neurons generated, apart from disease 
modeling, is the cell replacement therapy. Successful engraftment has been observed 
in mouse and non-human primate models of PD, demonstrating increased motor 
activity (Doi et al., 2014; Hallett et al., 2015). Furthermore, the transplantation of fetal 
mDA neurons generated from patient-specific iPSCs could avoid the immune 
rejection. The next step in this direction requires consistent production of mDAs with 
corrected PD genetic mutation by genome editing. However, for sporadic cases, 
patients without known genetic mutation might have risk in transplanting the neurons 
from their own genetic background. Thus, manipulation of gene expression levels or 
alternative splicing events serves an opportunity to diminish disease progression risk. 
The recent CRISPR-mediated transcription repression or activation enables the stable 
gene expression modulation, which could further facilitate this application (Gilbert et 
al., 2013).  
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8.4 Concluding remarks 
In this thesis, I have described the successful establishment of iPSC-based model of 
PD for phenotypic characterization and transcriptome analysis. By serial passaging 
NPCs derived from iPSCs, transcriptome changes were induced in both NPCs and the 
NPC-derived mDA neuron cultures, which resembled cellular ageing progression. 
mDA neurons derived from late-passage NPCs elicited key PD-related phenotypes 
and served as the basis for further investigating the poptential regulators in PD. The 
unifying molecular dysregulations across various PD genetic mutations were 
identified by transcriptome profiling in mDA neuron cultures, revealing the early 
events associated with gene expression and splicing regulation. Downstream targets 
of a strong candidate gene, RBFOX1, were studied for their dysregulated splicing 
pattern in PD, which provided a potential moelecular explanation of the disease-
related phenotypes. In sum, this study provides valuable molecular evidence and 
biological implications for the proposed hypothesis of the unifying molecular events 
underlying divergent PD genetic backgrounds, which lends further support to develop 
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Supplementary Table 1: List of primers for genomic DNA fragment 
amplification for sequencing. 
 Forward Reverse 
SNCA 
exon 1 AAAGGCCAAGGAGGGAGTT ATCCTAACCCATCACTCATGAAC 
HBB  TTGGACCCAGAGGTTCTTTG GAGCCAGGCCATCACTAAAG 








Exon2  ACACCAGCATCTTCCAGCTC CACCTGCACAGTCCAGTCAT 
 
Supplementary Table 2: List of antibody used in this study 
Primary antibody Provider Dilution 
rabbit anti-PITX3 Millipore 1/500 
rabbit anti-TH Millipore 1/500 
rabbit anti-TH Pel-Freez 1/800 
rabbit anti-PAX6 Covance 1/500 
mouse anti-NESTIN Abcam 1/500 
rabbit anti-NANOG Santa Cruz 1/500 
mouse anti-SSEA4 Millipore 1/500 
mouse anti-TRA-1-60 Santa Cruz 1/1000 
rabbit anti-OCT4 Santa Cruz 1/500 
mouse anti-TUJ1 Covance 1/500 
mouse anti-MAP2 Abcam 1/500 
mouse anti-VIM BD Pharmingen 1/500 
rabbit anti-MSI1 Abcam 1/500 
rabbit anti-VMAT2 Santa Cruz 1/500 
rabbit anti-NURR1 Santa Cruz 1/200 
mouse anti-NURR1 Abcam 1/500 
rat anti-DAT Millipore 1/200 
goat anti-KIR3.2 Santa Cruz 1/200 
rabbit anti-VMAT2 Millipore 1/500 
mouse anti-SYP Abcam 1/500 
rabbit anti-PSD95 Abcam 1/1000 
rat anti-CORIN R&D System 1/200 
goat anti-LaminB Santa Cruz 1/100 
rabbit anti-cleaved caspase-3 Cell Signaling 1/800 
rabbit anti-PS129 SNCA Abcam 1/2000 
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Supplementary Table 3: Primers of gene analyzed by qRT-PCR 
Gene name Forward (5' to 3') Reverse (5' to 3') 
EN1 GCACACGTTATTCGGATCG GCTTGTCCTCCTTCTCGTTC 
FOXA2 GGAGCAGCTACTATGCAGAGC CGTGTTCATGCCGTTCATCC 




MSI1 GGGAGGTGAAGGAGTGTCTG CTGGTCCATGAAAGTGACGAA 
NANOG ATGCCTCACACGGAGACTGT AAGTGGGTTGTTTGCCTTTG 
NESTIN TTGCCTGCTACCCTTGAGAC GGGCTCTGATCTCTGCATCTAC 




PITX3 GTGGGTGGAGAGGAGAACAA TTCCTCCCTCAGGAAACAATG 
POU5F1/OCT4 GTGGAGAGCAACTCCGATG TCTGCAGAGCTTTGATGTCC 






TH GCCGTGCTAAACCTGCTCT GGATTTTGGCTTCAAACGTC 








PRAME CAGGACTTCTGGACTGTATGGT CTACGAGCACCTCTACTGGAA 

























GRIN1Exon 3-4 ACCCGCATGTCCATCTACTC CTGACCAGCAGGATGATGTG 
GRIN1Exon 5-6 AAAACCTCGACCAACTGTCC TGGCAGAAAGGATGATGACC 
SNAP-25a TCGAAGAAGGCATGAACCAT CATATGAAAAGGCCACAGCA 





Supplementary Table 4: ShRNA oligo sequences 










Supplementary Table 5: Genes enriched as “vesicle” GO term that are down-
regulated in late-passage NPC-derived mDA neuron cultures 
 DA P10vsP1 




FC (abs) DA P10vsP1 
APOA1 3.40E-04 5.01E-05 9.80 
SERPINF1 5.52E-04 1.42E-04 7.80 
ANXA2 1.51E-04 9.48E-06 7.08 
ANXA2P3 9.57E-05 3.38E-06 6.55 
ANXA2P1 9.57E-05 3.22E-06 6.08 
SPAG8 4.33E-03 3.05E-03 5.26 
SERPINA1 5.10E-04 1.16E-04 4.48 
LRRK2 3.47E-04 5.24E-05 4.44 
ECE1 7.18E-05 1.79E-06 4.44 
CANX 5.20E-05 6.25E-07 4.26 
STXBP2 7.99E-04 2.63E-04 4.02 
GABRA2 1.79E-04 1.33E-05 3.82 
SPARC 1.24E-03 5.32E-04 3.73 
GJA1 2.29E-03 1.37E-03 3.67 
CANX 2.45E-05 1.47E-07 3.67 
FSTL3 2.60E-04 2.87E-05 3.48 
RAB11FIP1 1.82E-04 1.53E-05 3.26 
SLC40A1 1.20E-03 5.07E-04 3.25 
SYN2 3.40E-04 5.00E-05 3.18 
GOLIM4 6.18E-04 1.75E-04 3.10 
SYPL1 7.70E-04 2.47E-04 2.56 
CAMK2D 2.37E-04 2.52E-05 2.48 
CALU 5.82E-04 1.53E-04 2.42 
HSP90B1 2.79E-04 3.35E-05 2.38 
SDCBP 3.39E-04 4.81E-05 2.35 
PCSK5 5.27E-04 1.29E-04 2.31 
PDIA6 3.76E-04 6.08E-05 2.24 
SNAP23 4.43E-04 8.64E-05 2.16 
SLC30A5 2.63E-04 3.01E-05 2.06 
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Supplementary Table 6: Up-regulated expressed genes in late-passage versus 
early-passage at both NPC and neuron stages 






FC (abs)  
NPC 
P10vsP1 








MTUS1 9.19E-03 3.02E-05 7.10 2.32E-04 2.39E-05 6.73 
FSTL5 9.38E-03 3.30E-05 11.19 3.67E-03 2.48E-03 5.81 
NR4A2 3.03E-02 7.54E-04 2.67 1.24E-02 1.02E-02 4.87 
PCDH17 2.09E-02 2.90E-04 5.13 1.93E-03 1.06E-03 4.42 
TRIM48 3.17E-02 8.28E-04 45.29 1.54E-02 1.30E-02 4.19 
NAV3 4.28E-02 1.52E-03 1.32 1.51E-03 7.31E-04 4.10 
PAX6 2.53E-02 4.57E-04 26.20 4.02E-02 3.56E-02 3.97 
STMN1 4.97E-02 2.05E-03 2.11 5.27E-04 1.29E-04 3.45 
KLHL35 1.39E-02 8.97E-05 1.48 9.16E-04 3.31E-04 3.42 
POU3F2 2.41E-02 4.09E-04 2.64 1.88E-04 1.66E-05 3.18 
XPR1 3.29E-02 9.05E-04 1.19 1.55E-03 7.54E-04 3.03 
BLCAP 4.00E-02 1.28E-03 1.03 8.87E-04 3.11E-04 2.84 
MLLT10 4.12E-02 1.40E-03 1.14 2.65E-03 1.65E-03 2.83 
C12orf68 3.92E-02 1.23E-03 1.43 3.73E-03 2.53E-03 2.79 
TBC1D24 3.06E-02 7.65E-04 1.26 2.22E-03 1.29E-03 2.72 
SYTL2 4.90E-02 1.99E-03 2.34 1.47E-02 1.24E-02 2.70 
SORBS2 4.11E-02 1.39E-03 1.26 1.11E-03 4.37E-04 2.61 
NLGN1 4.67E-02 1.82E-03 1.79 9.98E-03 8.03E-03 2.59 
CTNND2 1.95E-02 2.47E-04 2.90 2.29E-02 1.97E-02 2.55 
TP53INP2 2.71E-02 5.53E-04 1.71 2.32E-03 1.40E-03 2.54 
EPHB2 2.99E-02 7.25E-04 2.04 1.10E-03 4.33E-04 2.51 
SPAG16 2.71E-02 5.46E-04 6.58 9.75E-03 7.82E-03 2.46 
EPB41 4.20E-02 1.46E-03 1.05 3.60E-04 5.61E-05 2.44 
RASSF2 3.92E-02 1.24E-03 1.80 4.04E-04 7.02E-05 2.37 
C3orf34 3.01E-02 7.36E-04 1.36 1.29E-03 5.74E-04 2.37 
SCLT1 4.06E-02 1.37E-03 1.08 1.92E-04 1.76E-05 2.35 
C2orf80 3.69E-02 1.10E-03 2.91 3.22E-02 2.84E-02 2.35 
NOX4 7.21E-03 1.65E-05 2.46 1.18E-03 4.84E-04 2.33 
TAOK3 2.93E-02 6.68E-04 2.12 9.57E-05 3.17E-06 2.29 
ZMYND8 1.76E-02 1.91E-04 1.11 1.74E-04 1.24E-05 2.24 
TNRC4 1.83E-02 2.23E-04 2.60 7.36E-03 5.68E-03 2.15 
C17orf85 2.26E-02 3.61E-04 1.08 4.04E-04 7.10E-05 2.09 
WDR47 2.49E-02 4.33E-04 1.86 1.69E-03 8.55E-04 2.09 
NDRG3 3.17E-02 8.33E-04 1.33 1.46E-03 6.90E-04 2.06 
ABCC4 2.86E-02 6.44E-04 1.51 6.60E-03 5.04E-03 2.06 
RADIL 1.98E-02 2.57E-04 1.34 1.38E-03 6.40E-04 2.05 
STARD13 3.08E-02 7.83E-04 3.24 8.52E-03 6.70E-03 2.03 
UFD1L 1.58E-02 1.23E-04 1.30 6.72E-03 5.15E-03 2.00 
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Supplementary Table 7: Down-regulated expressed genes in late-passage versus 
early-passage at both NPC and neuron stages 






FC (abs)  
NPC 
P10vsP1 









SERP2 3.05E-03 8.65E-07 3.72 1.81E-04 1.40E-05 15.25 
COL23A1 4.60E-02 1.73E-03 1.88 3.53E-04 5.40E-05 10.78 
EFEMP1 2.54E-03 3.38E-07 10.93 2.80E-03 1.77E-03 9.19 
NME3 1.18E-02 6.57E-05 2.86 1.81E-04 1.43E-05 8.30 
MAP1LC
3A 
2.30E-02 3.76E-04 6.48 2.40E-02 2.08E-02 8.21 
ZNF671 4.20E-02 1.45E-03 2.91 6.30E-03 4.78E-03 7.45 
HES1 4.34E-02 1.56E-03 1.30 2.71E-03 1.69E-03 7.25 
NEDD9 2.82E-02 6.27E-04 3.79 2.03E-03 1.14E-03 6.89 
CSMD2 9.38E-03 3.39E-05 8.81 7.38E-04 2.33E-04 5.99 
GPBAR1 5.00E-03 5.31E-06 1.46 3.92E-03 2.70E-03 5.45 
HOXC6 1.12E-02 5.44E-05 12.66 4.21E-02 3.74E-02 5.19 
RHBDF2 2.33E-02 3.83E-04 1.49 1.76E-04 1.27E-05 4.94 
AR 1.81E-02 2.15E-04 1.30 1.91E-03 1.04E-03 4.92 
MEIS3P1 1.06E-02 4.57E-05 3.46 4.81E-03 3.47E-03 4.79 
DUSP23 2.62E-02 4.91E-04 3.76 4.35E-03 3.08E-03 4.72 
CLIC6 4.35E-02 1.57E-03 4.19 9.04E-03 7.13E-03 4.32 
LXN 5.00E-03 5.79E-06 3.69 2.05E-03 1.16E-03 4.18 
FAM114A
1 
2.63E-02 4.95E-04 1.02 4.73E-04 9.62E-05 4.09 
MIR564 1.53E-02 1.12E-04 3.97 6.94E-04 2.11E-04 4.09 
C7orf63 2.60E-02 4.84E-04 2.87 3.94E-03 2.72E-03 3.56 
WNT5A 3.86E-02 1.19E-03 2.99 7.27E-03 5.61E-03 3.30 
PRKCDB
P 
1.64E-02 1.43E-04 2.75 9.49E-03 7.55E-03 3.29 
RORA 1.96E-02 2.50E-04 3.23 2.02E-03 1.13E-03 3.21 
SYN2 9.62E-03 3.99E-05 2.76 3.40E-04 5.00E-05 3.18 
REXO2 1.93E-02 2.43E-04 1.15 1.23E-04 5.76E-06 2.90 
WDR63 1.87E-02 2.32E-04 2.59 5.02E-04 1.10E-04 2.88 
EFCAB1 3.70E-03 1.78E-06 6.59 2.60E-03 1.61E-03 2.79 
TST 3.75E-02 1.13E-03 1.22 1.81E-03 9.63E-04 2.77 
LEPR 4.31E-02 1.54E-03 1.67 5.02E-04 1.11E-04 2.54 
CDH6 3.70E-03 2.38E-06 3.53 4.13E-03 2.88E-03 2.27 
SPINT2 4.82E-02 1.93E-03 3.42 1.32E-02 1.10E-02 2.09 
CTDSP1 2.55E-02 4.67E-04 1.10 2.88E-04 3.51E-05 2.04 
ARL1 4.88E-02 1.98E-03 1.02 3.35E-04 4.68E-05 2.01 
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Supplementary Table 8: Passaging-induced down-regulated gene expression 
changes in late-passage NPC-derived neurons consistent with ageing brain 
 Significant age-related expression 



















PVRL3 2.55 -5.122 1.92E-04 6.18E-04 1.74E-04 2.84 
SYN2 2.53 -5.733 4.00E-06 3.40E-04 5.00E-05 3.18 
LOC400120 2.27 -7.408 0.00E+00 2.45E-05 1.49E-07 13.35 
KCTD16 2.13 -5.883 8.00E-06 9.47E-04 3.54E-04 3.16 
KCNIP4 2.10 -5.164 2.00E-05 1.85E-03 1.00E-03 7.05 
TOM1L1 1.79 -3.591 1.41E-03 1.26E-03 5.55E-04 2.17 
KIAA1244 1.77 -5.888 5.00E-06 6.60E-05 1.56E-06 3.91 
SLITRK4 1.76 -4.959 3.50E-05 1.74E-03 8.93E-04 6.22 
AK5 1.73 -5.495 1.10E-05 4.17E-04 7.62E-05 4.25 
SLIT2 1.71 -4.398 1.53E-04 1.20E-03 5.03E-04 2.65 
ZNF226 1.69 -3.946 8.21E-04 7.89E-04 2.56E-04 2.98 
ARL1 1.66 -5.46 9.00E-06 3.35E-04 4.68E-05 2.01 
LZTFL1 1.62 -5.751 5.00E-06 4.24E-04 7.89E-05 2.60 
DRD1 1.60 -3.194 3.58E-03 9.57E-05 3.10E-06 5.88 
ZMAT4 1.48 -4.108 3.54E-04 3.62E-03 2.44E-03 2.01 
PTGFRN 1.46 -3.645 1.14E-03 1.19E-03 4.96E-04 2.80 
SERPINF1 1.46 -4.723 7.30E-05 5.52E-04 1.42E-04 7.80 
MAP1LC3A 1.45 -3.413 2.06E-03 2.40E-02 2.08E-02 8.21 
KLF9 1.44 -3.847 7.90E-04 5.39E-04 1.37E-04 10.55 
PDIA6 1.44 -4.567 9.90E-05 3.76E-04 6.08E-05 2.24 
SHRM 1.41 -3.771 8.63E-04 1.56E-03 7.60E-04 2.67 
GRIN2A 1.40 -3.962 5.02E-04 1.51E-05 4.14E-08 5.05 
ZNF204 1.40 -3.375 2.43E-03 3.77E-04 6.24E-05 4.00 
CALU 1.39 -3.899 6.88E-04 5.82E-04 1.53E-04 2.42 
CFC1 1.37 -2.683 1.26E-02 3.57E-04 5.49E-05 8.82 
EPDR1 1.36 -3.211 3.68E-03 8.04E-04 2.66E-04 2.54 
GPRC5C 1.35 -2.32 2.84E-02 4.35E-03 3.08E-03 3.53 
OCIAD2 1.35 -3.611 1.60E-03 3.01E-03 1.94E-03 5.22 
GABRA2 1.33 -2.941 6.84E-03 1.79E-04 1.33E-05 3.82 
REXO2 1.33 -2.691 1.21E-02 1.23E-04 5.76E-06 2.90 
ZDHHC23 1.30 -2.654 1.37E-02 1.19E-03 4.92E-04 2.46 
RORA 1.28 -2.838 8.58E-03 2.02E-03 1.13E-03 3.21 
SLC6A1 1.28 -2.83 1.04E-02 1.62E-03 8.09E-04 3.63 
SLC30A5 1.27 -2.504 1.86E-02 2.63E-04 3.01E-05 2.06 
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DUSP14 1.26 -2.95 6.65E-03 9.51E-04 3.58E-04 2.37 
IRAK1 1.26 -2.466 2.04E-02 7.57E-03 5.87E-03 2.24 
MAPKAP1 1.26 -3.243 3.25E-03 2.34E-03 1.42E-03 2.01 
MGC42367 1.25 -2.568 1.64E-02 4.85E-03 3.52E-03 4.41 
MLF1 1.25 -2.566 1.62E-02 3.17E-04 4.15E-05 2.71 
TPK1 1.22 -2.04 5.13E-02 1.82E-03 9.68E-04 2.23 
ADSSL1 1.20 -1.76 9.18E-02 4.33E-03 3.05E-03 2.06 
C1orf115 1.20 -3.052 5.63E-03 3.22E-03 2.10E-03 2.32 
KCNMA1 1.19 -2.794 9.99E-03 7.82E-04 2.53E-04 2.11 
KITLG 1.18 -2.55 1.82E-02 1.64E-04 1.07E-05 5.63 
WNT5A 1.14 -2 5.62E-02 7.27E-03 5.61E-03 3.30 
 
Supplementary Table 9: Altered RBFOX1 splicing targets in PD mDA neurons 
 Exon-Exon Junction Location   
Gene Name Chromosome Start End log2 FoldChange P(adj) 
RPL35A chr3 197678183 197680358 8.95 2.33E-08 
VDAC3 chr8 42252652 42254195 5.95 1.46E-137 
USMG5 chr10 105154152 105155502 5.37 7.29E-04 
JUP chr17 39929179 39941198 4.88 1.04E-05 
DPYSL2 chr8 26492417 26500341 4.70 4.27E-12 
SYNGR1 chr22 39770559 39771940 4.18 3.67E-02 
DTD1 chr20 18608878 18611024 3.88 4.43E-02 
DGUOK chr2 74154180 74159724 3.81 4.06E-03 
RPL3 chr22 39710414 39710690 3.54 4.99E-03 
VAPB chr20 56965397 56993266 3.45 2.13E-02 
USMG5 chr10 105154152 105156165 2.47 6.91E-07 
STC1 chr8 23709898 23711558 1.99 1.15E-02 
USMG5 chr10 105152224 105153955 1.96 2.02E-08 
VAPB chr20 56993420 57015962 1.39 1.57E-02 
TMEM33 chr4 41937328 41937483 1.34 1.95E-02 
NBEAL1 chr2 204064171 204066265 1.31 6.90E-03 
TARBP2 chr12 53896997 53897513 1.23 4.75E-02 
NRXN3 chr14 80130293 80163972 1.23 1.14E-02 
CIT chr12 120307006 120313876 1.16 1.81E-02 
SNAP25 chr20 10265421 10273529 1.15 1.75E-18 
TBC1D1 chr4 38121730 38126582 1.13 1.57E-03 
TCF12 chr15 57511789 57523349 1.08 4.83E-14 
SLC12A5 chr20 44651711 44652007 1.06 4.73E-05 
RPS18 chr6 33240504 33243276 1.03 1.25E-02 
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RTN4 chr2 55200758 55209650 1.02 8.31E-08 
SORBS1 chr10 97111134 97114638 -1.08 1.12E-04 
SUN1 chr7 883158 891020 -1.16 1.35E-04 
SLC1A2 chr11 35308499 35313833 -1.21 3.13E-02 
SCN2A chr2 166165305 166165861 -1.30 2.17E-03 
JUP chr17 39928115 39942839 -1.31 6.52E-03 
SUN1 chr7 889671 891020 -1.34 1.50E-05 
UAP1 chr1 162562573 162567581 -1.36 6.90E-04 
SLC25A26 chr3 66271554 66286967 -1.42 2.38E-03 
NRXN3 chr14 78764204 79111462 -1.44 1.70E-02 
SNAP25 chr20 10265421 10273808 -1.49 7.48E-12 
NRXN3 chr14 78745006 78764173 -1.52 1.70E-02 
NRXN3 chr14 78710146 78744987 -1.52 1.70E-02 
FBXO8 chr4 175162370 175177177 -1.58 4.77E-02 
SLC24A2 chr9 19573468 19576921 -1.60 2.71E-02 
C17orf85 chr17 3725347 3727086 -1.63 3.59E-02 
UAP1 chr1 162560302 162562521 -1.67 2.54E-05 
SCN2A chr2 166165954 166166832 -1.68 2.09E-04 
NFIB chr9 14120624 14125630 -1.69 6.75E-03 
SNAP25 chr20 10273927 10277572 -1.80 1.18E-12 
DLGAP2 chr8 1617951 1624698 -1.80 3.66E-03 
ARFGAP3 chr22 43204897 43213147 -2.25 1.06E-12 
ABI1 chr10 27044671 27054146 -2.29 8.56E-04 
CAMTA1 chr1 7812594 7815697 -2.34 4.03E-12 
CAMTA1 chr1 7815729 7826518 -2.36 9.40E-11 
AKAP2 chr9 112918778 112924373 -5.02 4.64E-03 
LDHB chr12 21807612 21810401 -5.04 2.75E-03 
ARPC5L chr9 127624678 127626266 -5.12 2.12E-02 
AKAP2 chr9 112924413 112930678 -5.18 4.64E-03 
YWHAH chr22 32341665 32352125 -6.27 1.46E-03 
PRPF18 chr10 13639536 13639644 -6.65 1.71E-04 






Supplementary List 1: Gene with differential expression in LRRK2 GS/GS mDA 
neurons relative to WT described in Figure 7.8 C. 
ZNF248 OR51E1 TMEM191C PLD5 PMFBP1 
C8orf55 TAP2 LOC126235 SH2D4A LMO3 
GAPDHL6 ASIP LOC645146 CD36 MSRB3 
USMG5 LOC728832 LOC389895 ACCN1 FERD3L 
MAGEH1 GRIN3A IL17RA ERMAP SOBP 
CRYAB GRIA3 MT1A FAIM SULF1 
BIRC7 ZNF667 CCDC58 ARMC3 SAMD11 
GAL DIAPH2 TLN2 SDCBP2 WDR63 
KCNIP4 MID2 RNASE4 PCLO MAP7 
ZNF37A LOC286467 LOC100127983 RGS1 GPR177 
FOXD1 THBD IL12RB1 C20orf103 AVEN 
RPS6KA2 VAPA LOC286411 LY6G5C BEST4 
CAPN3 SOX3 CLDND2 SDCBP2 SPAG6 
GPR64 LOC388002 CNTFR XYLT1 C5orf49 
LOC401074 TNFSF9 HULC LOC645321 C10orf105 
LOR CHRNA1 PDLIM5 C7orf46 STAP2 
HOXD11 HLA-A29.1 LOC644366 C1R PCDHA2 
TCERG1L HOXC11 LMX1A ADCYAP1 TEKT1 
LY6H LOC729051 TXNRD2 NGB MATN3 
LOC645166 ACCS COMT SKAP1 FLJ16686 
MAGEH1 IGFBP6 A2BP1 PHF16 LOC440928 
HOXD9 MTP18 LOC202134 TTC29 NOTCH2 
PNOC CHRNA1 VSNL1 CACNA2D3 MSRB3 
LOC647322 LOC375295 NXPH2 DNAH7 TGFBR2 
PLP1 OR51E2 PCDHB5 SIDT1 WDR49 
LY6H ABL2 KCNIP4 HEPACAM2 FOXS1 
SPARCL1 PTGR1 VAV3 ZNF167 LOC90113 
SPARCL1 LOC644254 PDE7B EN1 TCTEX1D1 
ECE2 APOL2 VSNL1 TGFBR2 LOC653316 
FAM135B HOXD1 WARS2 HEPACAM2 C3orf25 
LOC646836 XK KCNIP4 MPPED2 C1orf192 
GPR64 NXT2 ZNF502 EFCAB1 EGLN3 
MT1X NHLH1 CD1D PLAT C7orf57 
HOXD10 SST LRRC3B CNTN3 PTPRO 
UPK1A CASP7 SDCBP2 C12orf26 ACCN4 
TFF1 CHRNA3 F13A1 PVALB SALL3 
NRP2 KCNAB1 LRRC3B BMP4 MAFB 
LOC642236 APOL2 SAMD3 C11orf70 TTC6 
ESPN PLP1 MGC27121 CNGB1 RND1 
CAPN3 C18orf56 FLJ10916 SKAP1 ADPRHL1 
LOC729985 PIGA C22orf42 CORIN RSHL3 
MEG3 ENO3 SLC35F4 LOC729780 ADAMTS9 
HLA-DPB1 LYN CRHBP ELMO1 TAC1 
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MMP26 HLA-DPB2 FAM46C GREM1 CUX2 
WFDC1 LTB4R C5orf40 CNTNAP2 IRAK1 
ABCB1 KLHL4 CD44 C13orf36 MORN5 
ATP2C2 PTGR1 COLEC12 ANGPT2 PNPO 
FLJ21986 LOC651894 SCGN TAC1 SLC12A5 
LOC643031 LOC654126 NEK11 ANKS1B PTPRO 
BHLHE22 LOC645863 FBN2 NXPH1 KLHL4 
KLK4 LOC440895 APOLD1 TAC1 ITIH5 
RHCE PIR CCDC65 PTPRT LMO3 
A2LD1 WNT5A SAMD3 MAP7 GDF10 
LOC642236 CCNB3 GAD2 RAB3B ADPRHL1 
FLJ22639 RPS6KA3 ZNF474 LPPR1 ANKS1B 
HLA-DRA ITM2A LOC642946 THSD7B EPHA8 
RBMS2 CENPM SLC6A17 RSHL3 TRAM2 
MMEL1 LOC653188 PALM2 C11orf9 ETS1 
CDX2 PRKCA SLC32A1 LOC441376 ACCN4 
PTPRR PDE4C C21orf63 CILP WDR16 
BIRC7 LOC255275 CHD5 USP41 LOC731954 
LOC100134393 LOC134466 C21orf62 PMP22 ACCN4 
NAPSA LOC654053 GATA3 C10orf41 SOX15 
DDR2 KLRC2 BCL11B CLUL1 EIF2AK1 
C8orf46 LOC440258 FAM19A5 CRLF1 LMO2 
KLRC3 C1orf115 ZNF474 C2orf62 LOC100129842 
MAP3K15 LOC442162 LOC134121 TMEM200A ASTE1 
ALOX5AP LCN15 TMEM107 WDR16 HBA2 
LOC100128688 LOC728653 KCTD8 MYT1L LOC400120 
RNF160 SLC9A7 WDR49 ZNF154  
MT1G ADA RALYL LRRC17  




Supplementary List 2: Genes overlapping between RNA-seq and microarray 
results. 
A2BP1/RBFOX1 CLUL1 MMEL1 PTPRT TCERG1L 
ABCB1 COMT MT1A SALL3 THSD7B 
ACCS CUX2 MT1G SCGN TNFSF9 
ALOX5AP FAM135B MT1X SLC12A5 ZNF667 
BIRC7 GDF10 NGB SLC6A17  
C8orf46 KLRC2 NHLH1 SOX3  
CHD5 KLRC3 PLP1 TAC1  
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